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Hypertension is a complex trait with approximately 20-50% heritability. Several 
genome-wide association studies (GWAS) have implicated hundreds of loci involved in 
blood pressure (BP) regulation, but these variants explain only a small proportion of the 
phenotypic variance, and the specific genes and variants at most of these loci have yet to 
be determined. Additionally, while 20 genes involved in renal salt homeostasis have been 
well-characterized in monogenic forms of hypertension or hypotension, the extent to 
which they contribute to primary or essential hypertension is unknown. 
 Hypertension is disproportionately prevalent in African Americans relative to 
other American populations, and yet African Americans are underrepresented in studies 
designed to advance genetic discoveries for this disease. The study described in Chapter 2 
addresses this issue by examining the genotypes of 15,914 African-ancestry individuals 
for rare and low-frequency variants, to further BP gene discovery and to explain more of 
the phenotypic variance of BP traits in African Americans. We identified rare variants in 
10 genes, with many supported by previous functional evidence of cardiovascular and 
related roles. 
 In Chapter 3, we examined the genes SLC12A3, SLC12A1, and KCNJ1 in an 
effort to replicate the BP-lowering effect of predicted loss-of-function variants as 
reported in a prior Framingham Heart Study (FHS) publication. While analysis of all 
variants meeting the FHS criteria in exome sequencing data from a second cohort, the 
Atherosclerosis Risk in Communities (ARIC) study, did not produce a BP-lowering 
effect, we did observe a similar reduction among carriers (~6 mmHg for SBP, ~3 mmHg 
	
	 iii	
for DBP) of a subset of 10 variants from the FHS study also appearing in the ARIC data, 
suggesting that variants at specific sites may be of interest within these genes. 
 We shifted the focus from exome studies to whole genome analysis of putative 
regulatory variation in Chapter 4, where we first identified tissues relevant to BP 
regulation and subsequently followed up with gene and variant discovery incorporating 
tissue-specific information in the analysis. We were able to identify several genes with 
strong expression support in the tissues of interest and for some genes, identify their 
tissue- or cell-type-specificity. 
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Chapter 1: Introduction 
 
What is hypertension? 
 Hypertension, or chronically elevated blood pressure, is defined as systolic blood 
pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg; clinically, 
the ideal blood pressure is defined as 115/75 (SBP/DBP) mmHg.1 Hypertension per se is 
not a disease but its is a major risk factor for cardiovascular disease, and associated 
diseases such as kidney disease and diabetes.1 The prevalence of hypertension in the 
United States is ~30%, frequently unrecognized, and is a condition with an incidence 
disproportionately elevated in African Americans as compared to other Americans.1  
Various forms of anti-hypertensive therapies have been developed to reduce the 
risk of hypertensive disease,2 but only 53% of such individuals have effective blood 
pressure (BP) control. The majority of these individuals is non-Hispanic white, with 
lower frequencies of controlled hypertension among ethnic minority groups, which may 
be due a combination of genetics and socioeconomic factors.3 The studies described in 
this thesis seek to advance our understanding of blood pressure genetics to improve our 
understanding of its’ disease mechanisms, and assist in informing therapies as well as 
public health approaches to address issues of high prevalence and insufficient treatment 
of hypertension (HTN). 
 
Genetics of blood pressure 
Primary hypertension is postulated to result from polygenic inheritance, with 
estimates of approximately 20-50% heritability.4–6 But, what about its mechanisms? 
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Approximately 20 genes with well-established roles in monogenic, syndromic forms of 
hypertension or hypotension involve renal salt homeostasis.7–11 This suggests its similar 
role in primary (aka, essential) hypertension, but this remains unproven. Consider that 
over two dozen large-scale genome-wide association studies (GWAS), in addition to 
several other studies, have identified common variants at hundreds of loci, residing 
mainly in non-protein-coding regions, that are associated with blood pressure (BP) 
traits,12–36 but that these contain just one of the monogenic blood pressure syndrome 
genes, CYP17A1.13,28 These studies do confirm the polygenic nature of BP control, 
however, genetic risk score analysis of 29 loci in one such large-scale study demonstrated 
association of these BP GWAS variants with cardiac damage and cardiovascular 
disease,12 but not with kidney disease or function. Further, most BP studies, of both 
monogenic genes and BP GWAS, have been conducted primarily in European-ancestry 
subjects, and just a small fraction of the BP phenotypic variance has been explained by 
the known genes and loci,33,37–39 emphasizing what we do not know of the “missing 
heritability.” 
At this time, the relative contributions of the monogenic genes and genes at BP 
GWAS loci to primary hypertension remain to be further examined; further, the specific 
causal genes and variants at the BP loci are yet to be determined. These open questions 
have motivated the primary aims of this dissertation, which are to identify the specific 
candidate genes and variants involved in BP regulation, both at novel and previously 
known loci, and to examine the contributions of these genes to blood pressure. The initial 
studies I conducted analyze the exome (Chapters 2 and 3), with the focus then shifting to 
analysis of regulatory variation across the genome (Chapter 4). Chapter 2 aims to further 
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BP gene discovery in African Americans, while Chapter 3 examines rare variants in 
known BP monogenic genes to assess their effects. The aim of Chapter 4 is to begin to 
dissect associated variants at BP GWAS loci as specific, but as yet putative, regulatory 
variation in tissues of interest given their primary location in the non-protein-coding 
genome.  
 
Identifying blood pressure genes in populations of interest 
As already stated, the hundreds of GWAS BP-associated loci have mostly been 
identified from European-ancestry populations, and, additionally, only explain a small 
(~3%) percentage of the phenotypic variance. 33,39 Further, the higher prevalence of 
hypertension and associated diseases in African Americans, coupled with the 
comparatively less successful treatment in this population, calls for further genetic 
discovery in this population. The study described in Chapter 2 was designed to serve two 
purposes: 1) to advance blood pressure genetics in a population highly affected by the 
condition yet underrepresented in such studies, and 2) to identify rare and low-frequency 
variants that may explain more of the BP phenotype. We addressed these questions by 
genotyping African-ancestry individuals on the Illumina HumanExome BeadChip.40 This 
exome array includes variants specifically selected for their putative functional 
significance and low frequency, and at a sample size of 15,914 individuals across eight 
studies, it is the second largest African-ancestry GWAS to date, and the largest to focus 
on exomic variants. We identified rare variants in 10 genes in this study, with supporting 




Expanding on studies of syndromic forms of blood pressure  
The BP literature identifies 20 genes containing rare variants with large effect 
sizes (>6 mmHg)7–11 involved in renal salt homeostasis and involved in monogenic forms 
of syndromic hypertension or hypotension. This has had great utility in identifying and 
establishing blood pressure drug targets, such as the multiple classes of diuretics to 
maintain renal salt and fluid balance.41 Nevertheless, as mentioned, the phenotypic 
variance explained by these rare variants is also small.37,38 While each of the main 
chapters includes some study of the monogenic genes, Chapter 3 outlines a study focused 
on replicating the previously observed effects of rare variants within the coding regions 
of three hypotension genes, SLC12A3, SLC12A1, and KNCJ1.10 The purpose of doing so 
was to examine the effect of variants meeting the same criteria to be considered as 
predicted loss-of-function from the prior study and to identify additional variants of 
interest, using exome sequencing data from the Atherosclerosis Risk in Communities 
(ARIC) European-ancestry population-based cohort. We discovered that analysis of all 
variants meeting the functional criteria to be considered damaging did not produce the 
expected BP-lowering effect, but that studying the subset of overlapping variants between 
their study and ours did. Consequently, variants at specific sites may be of interest for 
blood pressure regulation but we may have failed to observe the expected effect due to 
the presence of sequencing or other errors in our study. 
Additionally, as described in the next section, we aimed to identify putative 
regulatory variants specific to these monogenic genes. An expanded list of variants would 
allow a greater understanding of the various blood pressure pathways these genes are 




Mapping blood pressure loci in tissues of interest 
With an ever-growing list of well-replicated loci from BP GWAS, the main goal 
of Chapter 4 was to begin to elucidate specific causal genes and variants at these loci and 
to begin to dissect some of the unknown biology of BP regulation. The role of the kidney 
in BP regulation has long been acknowledged, but a systemic trait like blood pressure 
involves many other tissues.  In recent years, the growth of data in public genomics 
databases has now made it possible to use such functional information to assess the role 
of these ‘other’ (non-renal) tissues. 
The Genotype-Tissue Expression (GTEx) project (https://www.gtexportal.org/) 
includes genotype and expression data from 53 different tissues, with expression 
quantatitive trait loci (eQTL) available for 44 of them, all having sample size > 70 
individuals. These data allow us to examine sequence variant-gene expression 
correlation, on a tissue-by-tissue basis. The Roadmap Epigenomics project 
(http://www.roadmapepigenomics.org/) and the Encyclopedia of DNA Elements 
(ENCODE) project (https://www.encodeproject.org/) contain among other types of data, 
genotype, gene expression, chromatin accessibility and histone modification data from 
different tissues, time points, and organisms. The purpose of these projects is to integrate 
these different datasets to identify and determine context-specific functional genomic 
elements. 
 Standard analysis methods of genotype data involve testing variants at the variant 
level and at the gene-based level. Testing individual variants for BP association has been 
successful in large GWAS as described above, in which substantial sample sizes enable 
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identification of common variants with small effects. Gene-based tests, such as burden 
tests, such as T1 or T5, which analyze variants with minor allele frequencies < 1% or 
<5%, respectively,42 as well as non-burden tests like SKAT,43 which collapses and tests 
groups of variants, are usually used to detect the effects of a collection of low frequency 
and rare variants. Additionally, the development of functional scores for variants, such as 
CADD,44 GWAVA,45 PolyPhen,46 and SIFT47 scores, has allowed the selection of those 
at either the exome or genome levels that may be considered functionally damaging and 
to be prioritized for testing. However, these scores generally do not account for tissue or 
cell-type specificity. Therefore, analyses that incorporate or select on these scores in 
genome-wide analyses may identify genes of interest, but do not test genes in a tissue-
specific manner.  
 The primary source of BP heritability has previously been identified as DNaseI 
hypersensitivity sites (DHSs).6 In Chapter 4, we first focus on identifying tissues of 
interest for BP regulation by testing various tissues for enrichment of BP loci in eQTLs, 
using data from the GTEx project, revealing the aorta and tibial arteries as specific 
candidate tissues. We then focus on identifying the effects of putative cis-regulatory 
elements and on mapping BP loci in tissues of interest, incorporating deltaSVM scores,,48 
a new type of score that predicts the impact of variants on regulatory function tissue- or 
cell-type-specifically, into the analysis. We performed such analysis for the two arteries, 
as well as for data from several kidney cell types, using publicly available data from the 
ENCODE project and genome-wide genotypes from the Research Program on Genes, 
Environment and Health (RPGEH) Genetic Epidemiology Research on Adult Health and 
Aging (GERA) European-ancestry cohort. These analyses have revealed several genes 
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with strong expression support in the tissues of interest, and in multiple cases have also 
revealed tissue- or cell-type-specificity of these genes.  
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Chapter 2: Rare Coding Variants Associated with Blood Pressure Variation in 
15,914 Individuals of African Ancestry 
 
Introduction 
 Hypertension is a leading risk factor for cardiovascular disease. Several genome-
wide association studies (GWAS) have implicated common variants at approximately 
166 loci12–35 associated with systolic (SBP) and diastolic (DBP) blood pressure (BP) 
across multiple studies and populations, but the specific genes involved are unknown and 
are yet to be narrowed down within each locus. Further, these common variants 
collectively explain only a small fraction (<3%) of the total phenotypic variance of BP 
traits.39 There is an emerging consensus that low frequency and rare variants may account 
for a significant fraction of the remaining variance.49 If so, genotyping catalogs different 
from those that enable GWAS are required. The Illumina HumanExome Beadchip 
(“exome chip”) was designed as an array-based assay enriching for the lower frequency 
genetic variation that could be detected within exomes. The >240,000 variants on this 
chip were selected for their functional significance from ~12,000 human exome and 
genome sequences from individuals of varying ancestry (mainly European) and common 
disease states.40 These variants include primarily non-synonymous, splice-site, and 
nonsense variants, with an enrichment of low frequency variants down to a frequency of 
occurrence at a minimum of two or three times in at least two datasets.50 
 The present study focuses on identifying specific genes associated with SBP and 
DBP long-term average (LTA) residuals, similar to our previous efforts with common 
variants,18 adjusting for major BP confounders including body mass index (BMI), age, 
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and sex. We analyzed individuals of African ancestry within each study and then 
combined the results by meta-analysis across eight cohorts, including Africa America 
Diabetes Mellitus (AADM), Atherosclerosis Risk in Communities (ARIC) Study, 
Coronary Artery Risk Development in young Adults (CARDIA), Genetics Network 
(GenNet), Genetic Epidemiology Network of Arteriopathy (GENOA), Howard 
University Family Study (HUFS), Hypertension Genetic Epidemiology Network  
(HyperGEN), and Loyola University Chicago Cohort (LUC). The prevalence of 
hypertension is increased in African Americans as compared to other populations in the 
United States51 and, moreover, they are not highly represented in genetic epidemiological 
studies17,34,35,52; the only previous major GWAS with an exclusively African-ancestry 
discovery sample size larger than ours focused on common variant-level analyses.17,34 
Therefore, this study aims to expand the list of genes potentially involved in BP 
outcomes in these individuals, with a focus on single variants across the full frequency 
spectrum, as well as on the gene level. These analyses suggest several rare variant gene 
candidates for BP regulation, which are likely candidates based on published functional 
data. Additional analyses focusing on a subset of genes known to be involved in 
monogenic hypertension and hypotension syndromes, in which many rare variants of 




 Eight studies consisting of individuals (n=15,914 after quality control procedures) of 
African ancestry were analyzed in this study, including several individuals from the 
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family-based studies AADM,54,55 GenNet,56,57 GENOA,56,57 HyperGEN,56,57 and 
HUFS58,59 as well as from the population-based cohorts ARIC,60,61 LUC,62–65 and 
CARDIA.66,67 The AADM and LUC studies consist of native Africans with no European 
admixture; the participants from the remaining cohorts all consist of African Americans. 
The AADM cohort was designed to study the genetic epidemiology of diabetes and 
related traits including hypertension, and the HUFS cohort was designed to study 
multiple cardiometabolic traits including hypertension. The ARIC and CARDIA studies 
focus overall on cardiovascular traits and events, including blood pressure. The 
remaining studies were recruited specifically to study blood pressure and associated 
traits. Brief descriptions and additional data collection methods for each study are 
provided in the Supplemental Digital Content, Description of Cohorts. Genotyping 
information and phenotypic characteristics from the initial examination or phase of 
samples analyzed from each cohort are described in Table 1. An extended table 
describing phenotypic characteristics of all physical examinations/phases for all studies is 
presented as Supplemental Digital Content Table S1. All studies obtained written 
informed consent from the participants as well as approval from their institutional review 
boards. 
Exome Chip Genotyping 
 Samples were genotyped either at the Center for Inherited Disease Research 
(CIDR) at Johns Hopkins University on the Illumina HumanExome BeadChip v1.0 
(247,870 variants), or at the Human Genetics Center at the University of Texas Health 
Science Center at Houston (Houston) on either v1.0 or v1.1 (242,901 variants) 
(http://www.chargeconsortium.com/main/exomechip).68 Genotypes were called with 
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Illumina’s GenTrain 1.0 (CIDR) or Gentrain 2.0 (Houston) clustering algorithm from the 
Illumina GenomeStudio v2011.1 software. 
 
Quality control of Genotypes 
 Quality control (QC) of the samples and variants were carried out within each 
cohort, for this study, using the programs PLINK,69 R70 and KING.71 We began with 
17,940 total individuals and either 247,870 or 242,901 variants, depending on the version 
of the chip used. Technical failure variants were removed prior to sample and variant QC. 
Blind duplicates, identified by CIDR’s QC reports where available, and unexpected 
duplicates, identified by PLINK’s IBS distance metric, DST>0.98, were then removed 
from the samples, and those remaining were filtered on call rate (>95% retained), X-
chromosome heterozygosity and PLINK’s sex check F-statistic to identify sex 
discrepancies, as well as autosomal heterozygosity to identify individuals with 
unexpectedly high or low heterozygosity. Custom thresholds selected for the 
heterozygosity filters were a minimum of three standard deviations from the mean of 
each of the distributions. Finally, individuals with Mendelian errors, which may indicate 
genotyping errors or incorrect relationship assignment within their families, were 
excluded, as well as exhibiting too many first- or second- degree relationships within 
their cohort reflecting a data quality issue, as preliminary pedigree error correction; more 
extended pedigree error corrections were carried out after variant QC. 
 Quality control of variants include discarding those with >5% missing data, and 
those failing the Hardy-Weinberg Equilibrium (HWE) exact test in PLINK3571 (defined as 
p<1 x 10-6 on variants with minor allele frequency (MAF)>0.01 only, as HWE estimates 
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on variants with lower MAF become less reliable).34 Duplicate SNPs with discordant 
genotypes were removed within each cohort for downstream analyses. 
 Pedigree errors and sample switches were subsequently identified and 
correctd using KING and PLINK by identity-by-state (IBS) information. For the ARIC 
and LUC studies, only samples related as third degree or beyond were retained for 
analysis. These procedures left 15,914 individuals with ~233K variants in each cohort 
genotyped on the v1.0 chip and ~238K variants in each cohort genotyped on the v1.1 
chip. The vast majority of the variants removed were due to technical failure. The 




 Variants on the chip were annotated using ANNOVAR72 and phyloP73 scores. A 
subset of 42,018 variants was annotated as “deleterious”, defined as consensus intronic 
splice-site, nonsense-mediated decay (NMD)-compatible stop-gain, or conserved 
missense (phyloP > 4) variants. These variants were the ones considered in the Burden-
T1-del analyses (refer to Statistical Analyses section). 
 
Phenotypes 
 The traits SBP and DBP were analyzed in this study. For each sample, SBP and 
DBP measurements from all available visits were adjusted for medication use when 
applicable, by adding a fixed constant of 15 mmHg for SBP and 10 mmHg for DBP 
measurements.74 These corrected measurements were then further adjusted in a linear 
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regression using the known blood pressure measurement confounders age, age-squared, 
sex, BMI, the first 10 principal components of ancestry, and study center (where 
applicable for each cohort) per available visit per individual as covariates. Principal 
components were calculated for all cohorts using KING-mds, which accounts for 
pedigree structure, on a linkage disequilibrium (LD)-pruned set (r2<0.5 within 
window=50 SNPs, step=5 SNPs) of common variants (MAF>5%). The resulting adjusted 
BP values, or residuals, were then averaged across all available visits for each sample, 
and used as the phenotypes in the analyses described below. Selected individuals were 
dropped for issues including lower SBP than DBP, and implausible BMI values, but 
otherwise the full distribution was analyzed. The majority of individuals in some cohorts 
have data available for one examination only (AADM, GenNet, HUFS, HyperGEN, 
LUC), while in the others (ARIC, CARDIA, GENOA) the majority has data from more 
than one examination. The Pearson correlation coefficients for first examination residual 
versus average residual for individuals with multiple visits in each cohort are reported in 
Supplemental Digital Content Table S2.  
 
Statistical Analyses 
 Study-level analyses were conducted, followed by fixed-effects meta-analyses to 
combine the results with the seqMeta75 package in R, using SBP and DBP residuals as 
phenotypes. To account for correlations among relatives, a kinship matrix was used in 
seqMeta for family-based cohorts. For these meta-analyses, the union of non-
monomorphic SNPs passing QC in each of the cohorts was analyzed (170,540 variants). 
Analyses were restricted to autosomal and X-chromosomal variants.  
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 We performed both single-variant analyses assuming an additive model, as well 
as gene-based tests, using the included SNP information files in seqMeta for gene 
definitions. The gene-based tests are particularly useful for analysis of rare variants, 
which individually have low numbers of carriers in the population, by aggregating 
variants into functional units (genes) and testing for cumulative effects. The single 
variant analyses were grouped into three frequency classes (common: MAF≥0.05, low 
frequency: 0.01≤MAF<0.05 and rare: MAF<0.01). For gene-based analyses, we 
considered sequence-kernel association test (SKAT),43 the T1 burden test42 including all 
variants with MAF<0.01 (Burden-T1-all), and the T1 burden test including only those 
variants predicted to be deleterious (Burden-T1-del), which are defined as intronic splice, 
NMD-compatible stop-gain, or conserved missense (phyloP>4). The SKAT test is 
expected to be more powerful when the region contains variants that are largely neutral or 
have opposing directional effects, while burden tests are expected to be more powerful 
when the region contains variants largely in the same direction.43,76 Statistical 
significance was defined by the Bonferroni method of multiple test correction, 
considering the number of associations computed within each analysis. There was no 
additional correction for number of phenotypes (two) due to the high correlation between 
the phenotypes (Supplemental Digital Content Table S3: Pearson’s r, 0.75-0.87).  
 
Power Calculations 
Assuming an additive model, power was calculated as described previously.38 
Under an additive model, a quantitative trait can be represented by a two-component 
normal mixture distribution. One component represents the reference allele, weighted by 
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its frequency, p, and the other the alternate allele, with a genetic effect shifted by s 
standard deviations with respect to the reference allele distribution, weighted by its 
frequency q (q=1-p). Both distributions are assumed to have variance of 1. Where n is 
sample size, Φ is the standard normal cumulative distribution function (CDF), and z1-α/2 is 
the standard normal distribution quantile at significance level α, the power to detect the 





















 We conducted single variant analyses by frequency class (common, low 
frequency and rare), as well as gene-based SKAT and T1 burden tests as defined above 
on 170,540 variants in 15,914 individuals of African ancestry. Singleton variants 
(n=18,217) were dropped in the single rare-variant analyses to prevent observing 
significance resulting from partiality due to phenotypic outliers. Further, in gene-based 
tests, genes with only a single variant (n=10,041) were excluded, as they were already 
included in single-variant analysis, allowing assessment of only those that may possibly 
reflect an aggregate effect of variants. Genomic inflation factors were calculated for all 
170,540 single variants analyzed as well as the gene-based test results, for each of the 
cohorts and for the meta-analyses. The inflation factors for all of the meta-analyses are 
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shown in Supplemental Digital Content Table , and quantile-quantile (QQ) plots for 
meta-analyses are displayed in Supplemental Digital Content Figures S1-S2. The 
inflation factors for these analyses for each cohort are provided in Supplemental Digital 
Content Table S5. The LUC cohort exhibits slight inflation for a number of the tests; 
however, no additional adjustment was made, as all inflation factors fall near or within 
the acceptable range for GWAS.77,78 Otherwise, minimal inflation was observed across 
most cohorts, even at the meta-analysis level, although the QQ plots for rare variants 
presents several variants deviated from the expected, despite well-controlled genomic 
inflation factors.79 The inflation factor uses the median, which is robust to outliers and so 
may not be aligned with the QQ plot when a specific set of outliers is present. 
 A brief summary of the number of tests conducted, the Bonferroni correction 
threshold, and significant results for each analysis are shown in Table 2. A total of 
152,323 (non-singleton) variants were used in the single variant analyses. Significant 
results from the single variant results are outlined in Table 3, and those from the gene-
based tests are outlined in Table 4. Although the seqMeta program does not use 
approximated effect sizes (betas) in its score test, it provides estimates of the (non-
standardized) betas and their standard errors. The beta estimates for all of these 
significant rare variants indicate a BP increasing effect. 
 Single-variant analyses of 105,487 variants in the rare variant class revealed 
several associations with SBP and DBP (Bonferroni threshold p=4.74 x 10-7), 
summarized in Table 3, with supporting power calculations in Supplemental Digital 
Content Table S6, and depicted in the Manhattan plots in Figure 1. The vast majority of 
these variants are non-synonymous (missense). Significant associations of rs150432347 
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in COL6A1 (p=1.19 x 10-7), with 19 copies in four cohorts, as well as rs138594727 in 
CRYBA2 (p=3.02 x 10-7), with 15 copies in six cohorts, were identified with SBP. The 
intronic splice-site SNP rs11568416 in the gene SLC28A3 is additionally associated with 
SBP (p=8.92 x 10-8), with six copies present across unrelated individuals in four cohorts. 
Other single-variant analysis results include similar associations of rare variants in 
KRBA1, SEL1L3, and YOD1 with SBP, each with two to four carriers. The variant 
rs148474705 in GAPDHS is associated with both SBP and DBP, also with two carriers, 
and the SNP rs142319329 in the gene AFF1 is associated with DBP (p=2.95 x 10-7), with 
eight copies present across unrelated individuals in four cohorts. These variants are all 
present in heterozygous carriers. The mean standardized effect sizes generally indicate 
that more copies of the variant correlate with smaller effects, but results in this study are 
too sparse for this conclusion to be well supported. 
 Table 4 contains the results for the two significant genes from the gene-based 
tests (Bonferroni threshold p=1.02 x 10-5), which are depicted in the Manhattan plots in 
Figure 2. The T1 test on deleterious variants identified significant associations of 
CCDC13 for SBP (p=3.54 x 10-7) and QSOX1 for DBP (p=3.86 x 10-6). The associations 
of CCDC13 with DBP (6.90 x 10-5) and QSOX1 with SBP (p=3.09 x 10-5) are also close 
to statistical significance. This analysis included two SNPs for CCDC13, each with one 
copy in different cohorts: rs182436192 (SBP single variant p=5.66 x 10-3) and 
rs143310118 (SBP single variant p=1.90 x 10-5). There were also two SNPs included in 
the analysis for QSOX1: rs202144688, with one copy (DBP single variant p=7.59 x 10-4), 




 The low frequency, the common single variant analyses, SKAT and Burden-T1-
all analyses produced no significant results for either phenotype. Manhattan plots for 
these analyses are shown in Supplemental Digital Content Figures S3 and S4. However, 
it may be noted that the top result from the low frequency analysis for DBP was 
rs73828047 from ULK4 (p = 1.79 x 10-5); further, the ULK4 gene is second on the list of 
top results for the SKAT analysis in DBP (p=4.54 x 10-5), with rs73828047, rs2272007 
(2.64 x 10-3), rs1052501 (p=2.75 x 10-3), rs1716975 (p=3.34 x 10-3), and rs192994614 
(p=6.34 x 10-3) as the top five SNPs. These results are particularly of interest, as 
rs2272007 (MAF=0.30) and rs1716975 (MAF=0.30) are among the common variants 
previously associated (or in high LD with those associated) with DBP in multiple 
ethnicities,17,26 including African Americans. We additionally examined a set of 212 
variants representative of the 166 BP GWAS loci, of which 80 were represented in our 
final cleaned set. While our SBP single variant results fail to support any of these 80 
variants, a few show evidence at p<0.01 in the DBP single variant results: rs6969780 in 
HOXA3 (p=5.37 x 10-4, MAF=0.32), rs6825911 in ENPEP (p=1.70 x 10-3, MAF=0.45), 
rs1925153 in COL21A1 (p=4.51 x 10-3, MAF=0.41), and rs926552 in SNORD32B (8.79 x 
10-3, MAF=0.13). These results, though not significant in these analyses, may lend 
additional credence to the possibility of roles of these loci in BP regulation.  
Assessment of gene-based test results for the known monogenic renal salt-
handling BP genes surprisingly provided little evidence of their roles in BP regulation. 
The SKAT test for DBP produced the lowest p-value for the potassium channel gene, 
KCNJ5 (p=1.12 x 10-3). Four SNPs were analyzed in the SKAT test, but single-variant p-
values suggest that this evidence is primarily driven by the rs115012103 SNP (p=9.95 x 
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10-4). The SBP SKAT test p-value (p=4.65 x 10-3) for this gene is similarly evidential. 
Results from variant-based tests for this gene are listed in Supplemental Digital Content 
Table S7. Overall, the lack of support for the monogenic genes may possibly be attributed 
to their explaining a small proportion of all essential hypertension cases. 
 
Discussion 
 This meta-analyses of eight cohorts with individuals of African ancestry have 
identified several statistically significant associations of rare variants with SBP and DBP 
(AFF1, GAPDHS, SLC28A3, COL6A1, CRYBA2, KRBA1, SEL1L3, YOD1, CCDC13, 
QSOX1), and, further, provided additional evidence for previously identified BP loci. 
Beyond these statistical results, prior biological experiments offer compelling support for 
the plausibility of these candidates for BP regulation, presented in Table 5.80–92 
 There were no significant results from either the common or low frequency single 
variant analyses, or from the SKAT and Burden-T1-all analyses. Given that the focus of 
the array is on rare, functional variants, the significant results are, as expected, from the 
rare single variant and Burden-T1-del analyses. Additionally, the majority of the 
significant rare variants have just two to three copies across the eight cohorts analyzed in 
this study; this is also expected as one criterion for variant selection, as stated before, is 
that the majority of these variants only be present in two to three copies in a minimum of 
two studies, across multiple populations. Supplemental Digital Content Table S8 details 
frequencies of these alleles in the African ancestry sample from the Exome 
Aggregation Consortium (ExAC), with similar numbers of copies and frequencies as in 
this study. Further, the consistency of measurements across multiple visits in a study 
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where applicable for carriers augments the verity of the associations. Additionally, the 
power calculations in Table S6 support that there is sufficient statistical power (~55-
80%+) to detect the majority of variants of these effects and frequencies in this sample 
size. Despite this, it still must be considered that the few numbers of copies, especially 
those with only two copies, of these significant results strongly indicate that they require 
replication and further study for additional support. 
 Though there is some evidence for the ~166 GWAS replicated loci as well as the 
Mendelian syndromic blood pressure genes, their lack of significance in this study is 
surprising. It is likely that the dearth of common variants available on the chip 
contributed to inadequate tagging of causal variants within these loci. Despite this, it 
should be noted that recent BP exome array studies by Liu et al.31 and Surendran et al.32 
replicated several common, as well as low-frequency, variants. However, these studies 
consisted of mostly European ancestry participants, and as the sources of sequences that 
this chip was designed from were primarily European individuals, this likely made the 
array less informative for individuals of African and other ancestries. An ethnicity-
specific chip may therefore be more revelatory, as the familial hypertension variants 
might be different in African ancestry patients. Additionally, these studies consisted of 
over 300,000 individuals combined across the discovery and replication stages, while our 
study consisted of just ~16,000 individuals, at which power is much lower to detect 
common variants at their typical effect sizes. 
The Mendelian genes are contrastingly well known for containing rare causal 
variants with large effects, though we saw poor signal here as well. As stated above, an 
ethnicity-specific array may be more helpful here as well. Another possibility to explain 
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the absence of a signal in these genes is that their effect size might be somewhat smaller 
than the one observed in the rare variants of this experiment, and therefore the statistical 
experimental power is insufficient to show an association signal.   
Regardless, it is of interest that rare variants identified in this study may 
contribute to blood pressure variation as a polygenic trait. Studies of schizophrenia have 
identified rare variants from exome-based studies,93,94 demonstrating an enrichment of 
rare variants in genes containing common variants implicated in previous schizophrenia 
GWAS, aiding in fine-mapping of those loci. In our study, though the results did not 
reach statistical significance, the statistical support for low-frequency variants in ULK4 
provides evidence for this as the specific gene within its SBP/DBP GWAS locus. 
In summary, we identified several rare variants in 10 genes (AFF1, GAPDHS, 
SLC28A3, COL6A1, CRYBA2, KRBA1, SEL1L3, YOD1, CCDC13, and QSOX1) that are 
significantly associated with SBP and DBP traits in 15,914 individuals of African 
ancestry. In contrast to the previously identified common variants of most BP GWAS, 
and the rare variants in monogenic blood pressure syndromes, this study has identified 
rare variants that are potentially contributory to blood pressure as a polygenic trait, 
particularly in individuals of African-ancestry. The prior experimental evidence of the 
involvement of these genes with related traits in animal models suggests that these genes 
are viable candidates for BP regulation, and will benefit from additional investigation. 
Additionally, the results of this study suggest that future studies relying on genotype 
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Chapter 2 Figures 
 
 






Figure 2. Manhattan Plots for T1 analyses of deleterious variants at 5,024 genes for SBP 








Chapter 2 Tables  








BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation 
aAs this only illustrates the first visit or phase, there are many individuals in subsequent examinations that are included in these 
analyses but not in this table; the complete information may be found in Table S1. 
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Table 2. Summary of number of significant results and tests per analysis. 
 










Common 28,851 1.73 x 10-6 0 0 
Low frequency 17,985 2.78 x 10-6 0 0 
Rare 105,487 4.74 x 10-7 7 2 
Gene-based 15,554 3.21 x 10-6 0 0 
T1 (all variants) 14,465 3.46 x 10-6 0 0 
T1 (deleterious 
variants) 5,024 9.95 x 10
-6 1 1 
SBP, systolic blood pressure; DBP, diastolic blood pressure; # tests, number of variants 
or genes analyzed 
aThe significance threshold as determined by the Bonferroni method corrects for the 





Table 3. Rare Single Variant Hits for SBP and DBP (p<4.74 x 10-7). 
 
Variant Gene Site Type Trait MAF p-value # 
copies  β sm (SE)
a 
 β st 
(95%CI)b 
 
rs11568416 SLC28A3 intronic  splice SBP 1.89 x 10-4 8.92 x 10-8 6 39.44 (7.38) 
1.96 (1.16 
– 2.76) 
rs536397959 KRBA1 exonic synonymous SBP 6.28 x 10-5 2.35 x 10-8 2 73.65 (13.19) 
3.93 (2.55 
– 5.32) 
rs139989095 SEL1L3 exonic missense SBP 6.28 x 10-5 3.23 x 10-8 2 49.02 (8.87) 
3.91 (2.53 
– 5.30) 
rs147110080 YOD1 exonic missense SBP 6.28 x 10-5 1.18 x 10-9 2 64.41 (10.59) 
3.57 (2.18 
– 4.96) 
rs150432347 COL6A1 exonic missense SBP 6.05 x 10-4 1.19 x 10-7 19 22.14 (4.18) 
1.16 (0.71 
– 1.61) 
rs138594727 CRYBA2 exonic missense SBP 4.73 x 10-4 3.02 x 10-7 15 25.92 (5.06) 
1.27 (0.76 
– 1.78) 
rs148474705 GAPDHS exonic missense SBP 6.28 x 10-5 4.60 x 10-7 2 53.85 (10.68) 
3.51 (2.12 
– 4.89) 




rs142319329 AFF1 exonic missense DBP 2.51 x 10-4 2.95 x 10-7 8 21.10 (4.12) 
1.77 (1.07 
– 2.46) 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAF, minor allele frequency; β sm, seqMeta beta; β st, beta as 
standardized mean difference; SE, standard error; 95% CI, 95% confidence interval; # copies, allele count 
aThe β sm (SE) values are reported from seqMeta output, in units of the phenotype residuals.  
bThe β st (95% CI) values are calculated as the mean standardized difference between the LTA residuals for all carriers and all non-
carriers for each variant.   
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Table 4. Burden-T1-del significant genes for SBP and DBP (p<9.95 x 10-6). 
 
Gene Test Trait p-value # SNPs 
analyzed 
Cumulative 
Carrier Count  β sm (SE)a 
CCDC13 Burden-T1-del SBP 3.54 x 10
-7 2 2 54.38 (10.68) 
QSOX1 Burden-T1-del DBP 3.86 x 10
-6 2 3 32.93 (7.13) 
Burden-T1-del, T1 burden test on deleterious variants with minor allele frequency 
(MAF)<0.001; # SNPs analyzed, number of SNPs included in test for gene; Cumulative 
Carrier Count, number of carriers (same as allele count) across all analyzed variants; β sm, 
seqMeta beta; SE, standard error 










Gene Evidence of role in hypertension 
COL6A1 Encodes a collagen VI protein and provides structural support for a variety of tissues including the heart; 
has been shown previously, in addition to other VEGF-A pathway genes, to be associated with 
atrioventricular septal defect (AVSD) in patients with Down syndrome80 
SLC28A3 Encodes a sodium-dependent nucleoside transporter (NT); NTs have many physiological regulatory roles 
including that of mediating adenosine concentration, which in turn affects vascular tone81,82 
SEL1L3 Differentially expressed between male familial combined hyperlipidemia and coronary heart disease 
(FCHL-CHD) patients and non-FCHL-non-CHD controls in a microarray study.83 Also upregulated with a 
>6-fold expression change in a rabbit microarray study comparing simulating conditions before and after 
repair of coarctation of the aorta, a condition which may evolve into chronic hypertension84; as the authors 
stated, despite the surgically induced return to normal BP, the vasculature still retains its physical defects, 
and this gene may thus play a role in the continued residual effects. 
YOD1 A deubiquitinase, targeted by miR-21 in the distal small pulmonary arteries of mice with pulmonary 
arterial hypertension exposed to hypoxic conditions, as well as in human pulmonary artery smooth muscle 
cells with transfected miR-21.85  
CCDC13 Encodes a centriolar satellite protein involved in primary ciliogenesis64; this supports a potential role in 
hypertension present in individuals with autosomal dominant polycystic kidney disease, in which impaired 
primary cilia affects vascular tone87,88 
QSOX1 Recent experiments support cardiovascular function for QSOX1, encoding a sulfhydryl oxidase enzyme; 
one such function includes its induction of vascular smooth muscle cell migration and proliferation in 
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genomic inflation factors for statistical tests, statistical power for the tests, KCNJ5 single 
variant test results, and ExAC frequencies for rare variants; Supplementary Figures S1-S4 




Descriptions of Cohorts 
 
GenNet, GENOA and HyperGEN (FBPP) 
The GenNet, GENOA (Genetic Epidemiology Network of Arteriopathy) and HyperGEN 
(Hypertension Genetic Epidemiology Network) cohorts are family-based studies that are 
part of the Family Blood Pressure Program (FBPP),56,57 with visit dates from 1995 to 
2003.  For these studies, hypertension was defined as SBP ≥140 mmHg and/or DBP ≥90 
mmHg, and/or diagnosis and treatment with prescribed hypertension medication; severe 
hypertension was defined as SBP ≥160 mmHg and/or DBP ≥100 mmHg, or taking two or 
more hypertensive medications. 
 
The GenNet study consists of 1,101 African-Americans and 839 Hispanic-Americans 
from Maywood, IL, as well as 1,497 European-Americans from Tecumseh, MI, studied 
over two phases.  This study has exome chip data available from 962 African-Americans 
from 338 families in the final dataset.  Probands aged 18-50 years with measured blood 
pressure values in the top 20-25th percentiles, as well as their siblings and parents 
wherever possible, were recruited into the study.   
 
The GENOA study primarily focuses on siblings diagnosed with hypertension prior to 
age 60.  The study includes data on 1,606 European-Americans from Rochester, MN, 
1,857 African-Americans from Jackson, MS, and 1,803 Hispanic-Americans from Starr 
County, TX, studied across two phases.  In this analysis, exome chip data from 1,373 




The HyperGEN study includes 2,471 European-Americans and 2,300 African-Americans 
from Birmingham, AL, Forsyth County, NC, Framingham, MA, Minneapolis, MN, and 
Salt Lake City, UT.  The cohort consists preferentially of sibships containing at least two 
individuals with hypertension of which one individual had severe hypertension, as well as 
their parents wherever possible, and a minimum of one untreated adult offspring.  There 
are also ~800 random subjects age-matched with individuals in hypertensive sibships.  
Exome chip data from 2,059 African-Americans, comprising 902 families, are available 
in the final data for analysis.   
 
For both SBP and DBP, measurements were taken on an oscillometric automated BP 
device.  Either three measurements were taken on a Dinamap instrument, or two 
measurements were taken on an Omron instrument.  In GenNet individuals, 
measurements were taken on either a Dinamap or an Omron instrument; in GENOA and 
HyperGEN, all measurements were taken on a Dinamap instrument.  An average of up to 




Participants of the LUC (Loyola University Chicago) cohort were recruited from Yoruba-
speaking communities in southwest Nigeria, specifically Igbo-Ora and Ibadan, as part of 
a long-term study on the environmental and genetic factors underlying hypertension.62,63 
The study protocol was reviewed and approved by the Institutional Review Board at 
Loyola University Medical Center, and the Joint Ethical Committee of the University of 
	
	 33	
Ibadan/University College Hospital, Ibadan, Nigeria. All participants gave written 
informed consent administered in either English or Yoruba. Phenotype measurements 
were performed by trained research staff using a standardized protocol.64,65 Body weight 
was measured to the nearest 0.2 kg on calibrated electronic scales, whereas height was 
obtained using a stadiometer consisting of a steel tape attached to a straight wall and a 
wooden headboard. Systolic and diastolic blood pressures were measured using an 
Omron oscillometric device. Three measurements were taken three minutes apart and the 
average of the final two was used in the analysis. Participants with hypertension were 
offered treatment after detection at the screening examination. A total of 2,688 unrelated 
adults with quality controlled exome chip data were included in the present study.  
 
HUFS 
The HUFS (Howard University Family Study) is a multi-generational family-based study 
of African-American individuals enrolled from the Washington, DC metropolitan 
area.58,59  SBP and DBP were measured using an Omron oscillometric BP device.  Three 
measurements were taken in the sitting position, with ten minutes between each 
measurement, with the average of the last two measurements being used in this analysis.  
There are exome chip data from 1,784 individuals in 1,139 families available for analysis. 
 
AADM 
The AADM (Africa America Diabetes Mellitus) study enrolled both families and 
unrelated West African individuals focusing on Type 2 Diabetes from five study centers, 
including Accra and Kumasi in Ghana, and Enugu, Ibadan and Lagos in Nigeria. The first 
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and second phases of the study recruited affected sibling pairs and spouse controls and 
the third phase enrolled unrelated cases and controls. Information on several diabetes and 
cardiovascular-related traits54 were measure during clinic visit. Blood pressure was 
measured with 10 minutes between each measurement, with the average of the last two 
measurements being used in this analysis, as described for HUFS.55 There are 2,070 
individuals from 1,202 families present in the final dataset. 
 
ARIC 
The ARIC (Atherosclerosis Risk in Communities) study is a population-based, 
prospective study on 15,792 individuals, including 11,478 European-Americans and 
4,266 African-Americans from Forsyth County, NC, Jackson, MI, Minneapolis, MN and 
Washington County, MD.60,61  There have been five visits, with individuals in the first 
visit, in 1987-1989, being of ages between 45 and 64 years.  Subsequent visits occurred 
in 1990-1992, 1993-1995, 1996-1998, and 2011-2013.  The data from the first four visits 
were used in this analysis. SBP and DBP were measured thrice at each of the first three 
visits, and twice at the fourth visit, using a random zero sphygmomanometer; the average 
of the (final) two measurements were used for analysis.  In this study, exome chip data 
from 3,280 African-Americans are available in the final cleaned dataset. 
 
CARDIA  
The CARDIA (Coronary Artery Risk Development in young Adults) study is a 
population-based, prospective study of 5,115 young European-Americans and African-
Americans, with data collected on traits related to cardiovascular disease.66,67 These 
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individuals were selected from four study centers: Birmingham, AL, Chicago, IL, 
Minneapolis, MN, and Oakland, CA. The study began with the first examination in 1985-
1986 during which participants were 18-30 years old. Seven subsequent examinations 
were conducted in years 2, 5, 7, 10, 15, 20, and 25, with the most recent examination in 
2010-2011. The data from years 7, 10, 15 and 20 were used in this analysis, and 
additionally only individuals with at least two visits of data were included in this 
analysis. There are 1,698 African-American individuals analyzed in the final cleaned 




Table S1. Phenotypic characteristics for all examinations per cohort. 
 
















AADM 1 2070 57 45.55 (16.03) 25.96 (5.82) 132.69 (22.65) 
81.01 
(14.19) 28 
ARIC 1 3095 62 53.61 (5.80) 29.72 (6.26) 128.63 (21.00) 79.65 (12.15) 41 
ARIC 2 2706 63 56.41 (5.79) 30.05 (6.35) 127.17 (21.07) 75.45 (11.29) 45 
ARIC 3 2274 63 59.11 (5.70) 30.44 (6.50) 131.38 (21.16) 76.34 (11.05) 49 
ARIC 4 1989 63 61.88 (5.68) 30.67 (6.49) 134.15 (20.60) 75.94 (10.76) 55 
CARDIA 1 1534 58 31.45 (3.80) 28.24 (6.82) 111.33 (13.01) 70.92 (10.97) 3.2 
CARDIA 2 1567 58 34.39 (3.83) 29.11 (7.10) 112.96 (13.86) 74.76 (10.72) 5.8 
CARDIA 3 1439 59 39.56 (3.84) 30.56 (7.47) 117.38 (16.29) 77.19 (12.72) 13.1 
CARDIA 4 1341 61 44.54 (3.84) 31.43 (7.69) 120.78 (16.32) 76.68 (11.71) 25.7 
GenNet 1 782 60 40.42 (11.45) 30.25 (8.12) 127.09 (20.20) 77.70 (13.60) 100 
GenNet 2 182 60 32.13 (13.11) 29.86 (8.54) 116.76 (16.72) 67.58 (13.76) 13 
GENOA 1 1373 69 56.67 (10.66) 31.02 (6.57) 131.69 (23.51) 70.96 (11.53) 100 
GENOA 2 1082 71 61.45 (9.80) 31.79 (6.70) 134.10 (22.31) 73.35 (10.57) 67 
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N 2 261 60 32.81 (8.29) 31.69 (8.56) 119.02 (17.45) 
71.26 
(10.75) 6.1 
LUC 1 2688 71 48.66 (11.72) 26.12 (6.17) 146.09 (29.98) 91.92 (18.64) 39 







Table S2. Pearson correlations of first available visit with LTA (long-term average) 
residuals per cohorta 
 





AADM 0 NA NA 
ARIC 2806 0.85 0.85 
CARDIA 1698 0.73 0.70 
GenNet 2 NA NA 
GENOA 1079 0.86 0.87 
HUFS 0 NA NA 
HyperGEN 0 NA NA 
LUC 0 NA NA 
SBP, systolic blood pressure; DBP, diastolic blood pressure 
aPearson correlations between the first visit and LTA residuals for all individuals with 
data for multiple visits (# with multiple visits) are shown here. This comparison is largely 
meaningful for GENOA, ARIC, and CARDIA, for which for the majority of individuals 
















aEither one visit or LTA where available: (GENOA, ARIC, and CARDIA) residuals are 






Table S4. Genomic control inflation factors (λGC) for meta-analyses. 
 
Test λGC (SBP) λGC (DBP) 
Single Varianta 1.036 1.026 
SKAT 1.082 1.053 
Burden-T1-all 1.011 1.010 
Burden-T1-del 0.986 0.982 
λGC, genomic inflation factor; SBP, systolic blood pressure; DBP, diastolic blood 
pressure 
aThe overall inflation factor is shown here for all 170,540 single variants. Inflation factors 





Table S5. λGC for all analyses per cohort. 
 



















AADM 0.997 0.829 1.017 0.996 0.981 0.789 0.993 1.017 
ARIC 0.994 0.952 1.015 0.985 1.021 0.970 0.998 0.997 
CARDIA 0.989 0.888 0.941 0.901 0.986 0.874 0.985 0.963 
GenNet 0.911 0.747 0.960 0.883 0.945 0.777 0.971 0.899 
GENOA 0.997 0.853 1.041 0.929 0.965 0.838 1.007 0.940 
HUFS 0.966 0.865 0.985 0.969 0.953 0.824 0.966 0.956 
HyperGEN 0.989 0.875 1.009 1.001 0.960 0.858 0.994 0.954 
LUC 1.029 0.833 1.043 1.048 1.064 0.877 1.074 1.061 
SBP, systolic blood pressure; DBP, diastolic blood pressure; SS, single variant test; Burden-T1-del, T1 burden test on all variants with 





Table S6. Powera (%) for rare variants with mean standardized effect sizes 2, 3, and 4 in 15,914 individuals 
 
AFb/ESc Num copiesb 2 3 4 
 3.141 x 10-5 1 0.12 2.085 14.996 
6.283 x 10-5 2 1.361 21.358 73.241 
9.430 x 10-5 3 5.79 56.331 97.071 
1.257 x 10-4 4 14.991 83.224 99.848 
1.517 x 10-4 5 28.612 95.265 99.995 
AF, allele frequency; ES, effect size 
aPower (%) is shown in columns 3-5 as a function of allele frequency and effect size 
bAllele frequency is presented in each row (column 1), with the corresponding allele count (Num copies) the frequency represents 
(column 2) 




Table S7. KCNJ5 Single Variant results for SBP and DBP. 
 
rsID_dbSNP137 Trait p-value MAF  β sm (SE)a 
rs115012103 SBP 3.98 x10-3 0.011 3.166 (1.099) 
rs115012103 DBP 9.95 x 10-4 0.011 2.220 (0.674) 
rs139073333 SBP 0.844 0.001 0.826 (4.199) 
rs139073333 DBP 0.741 0.001 0.872 (2.640) 
rs138295501 SBP 0.809 0.000 4.887 (20.208) 
rs138295501 DBP 0.992 0.000 0.135 (12.948) 
rs148307402 SBP 0.482 0.001 2.997 (4.263) 
rs148307402 DBP 0.530 0.001 1.506 (2.397) 
SBP, systolic blood pressure; DBP, diastolic blood pressure; rsID_dbSNP137, rs number 
variant ID from dbSNP137; MAF, minor allele frequency; β sm, seqMeta beta 





Table S8. Allele frequencies for rare significant SNPs from the ExAC database on African Population. 
 











SLC28A3 rs11568416 SBP 1.89 x 10-4 6 3.91 x 10-4 4 
KRBA1 rs536397959 SBP 6.28 x 10-5 2 NA NA 
SEL1L3 rs139989095 SBP 6.28 x 10-5 2 1.02 x 10-4 1 
YOD1 rs147110080 SBP 6.28 x 10-5 2 9.64 x 10-5 1 
COL6A1 rs150432347 SBP 6.05 x 10-4 19 6.58 x 10-4 6 
CRYBA2 rs138594727 SBP 4.73 x 10-4 15 6.48 x 10-4 6 
GAPDHS rs148474705 SBP/DBP 6.28 x 10-5 2 1.95 x 10-4 2 
AFF1 rs142319329 DBP 2.51 x 10-4 8 3.20 x 10-4 3 
CCDC13 rs182436192 SBP 3.14 x 10
-5 1 NA NA 
rs143310118 3.14 x 10-5 1 NA NA 
QSOX1 rs202144688 DBP 3.14 x 10
-5 1 1.01 x 10-4 1 
rs201390473 6.28 x 10-5 2 NA NA 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAF, minor allele frequency; # copies, allele count in population 





Figure S1. QQ plots for all single variant analyses by frequency class for SBP ((a): 
common, (c): low frequency, (e): rare) and DBP ((b): common, (d): low frequency, (f): 
rare). Here, singletons are included in the rare variant plots and calculations, although 




Figure S2. QQ plots for all gene-based analyses (SKAT, Burden-T1-all, and Burden-T1-
del) for SBP ((a): SKAT, (c): Burden-T1-all, (e): Burden-T1-del), and DBP ((b): SKAT, 
(d): Burden-T1-all, (f): Burden-T1-del). All plots include genes containing just one 





Figure S3. Manhattan plots for common (28,851 SNPs) and low frequency (17,985 
SNPs) single variant analyses for SBP ((a): common, (c): low frequency) and DBP ((b): 







Figure S4. Manhattan plots for SKAT (15,554 genes) and Burden-T1-all (14,465 genes) 
analyses for SBP ((a): SKAT, (c): Burden-T1-all) and DBP ((b): SKAT, (d): Burden-T1-
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Chapter 3: Contributions of Rare Coding Variants in Hypotension Syndrome Genes 
to Population Blood Pressure Variation 
 
Introduction 
Hypertension (HTN) is a major risk factor for cardiovascular disease and affects 
~30% of adults worldwide.1,96 Recently, genome-wide association studies (GWAS) have 
identified common variants at ~166 loci associated with systolic blood pressure (SBP), 
diastolic blood pressure (DBP) and essential HTN, but these variants explain <5% of the 
phenotypic variance.12–36 In contrast, rare variants in ~20 genes involved in renal salt 
handling and water balance have been implicated in monogenic forms of either 
hypertension or hypotension with electrolyte abnormalities.10,53 However, the 
contribution of these genes to population level inter-individual variation in SBP and DBP 
is generally unknown. Since the existing GWAS loci do not include any of the 20 known 
hypertension or hypotension syndromic genes, it is reasonable to infer that common 
variation in these genes do not contribute greatly to inter-individual BP variation. The 
question is, why? 
In 2008, Ji and colleagues10 examined the effects of rare variants in SLC12A3, 
SLC12A1, and KCNJ1 on BP in the European ancestry Framingham Heart Study (FHS) 
subjects. The authors chose these ion channel genes because homozygotes for loss-of-
function (LOF) variants in these diuretics targets lead to recessive renal salt-wasting 
hypotension syndromes (Bartter (prevalence ~1/1,000,00010,97) and Gitelman (prevalence 
~1/40,00010,98)), so that, consequently, LOF heterozygotes in these genes could reduce 
BP substantially and be protective against hypertension. Ji and colleagues identified 18 
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not previously validated and potentially LOF missense variants in SLC12A3, SLC12A1, 
and KCNJ1 in the FHS offspring cohort and demonstrated a significant protective effect 
(-6.3 mmHg for SBP and -3.4 mmHg for DBP) in their carriers in all ages between 25-60 
years. 
We attempted to also investigate SLC12A3, SLC12A1, and KCNJ1 using identical 
methods but using whole exome sequence (WES) data on 7,810 European ancestry 
subjects from the population-based Atherosclerosis Risk in Communities (ARIC) cohort 
study. Like the FHS, ARIC is a longitudinal study with BP measurements over time and, 
therefore, allows for identical analyses as in the Ji et al. study. Success in such studies 




 The ARIC (Atherosclerosis Risk in Communities) study is a population-based, 
prospective study on 15,792 individuals, including 11,478 European and 4,266 African 
ancestry US subjects from Forsyth County, NC, Jackson, MI, Minneapolis, MN and 
Washington County, MD.60,61 There have been five visits, with individuals in the first 
visit (1987-1989) aged between 45 and 64 years.  Subsequent visits occurred in 1990-
1992, 1993-1995, 1996-1998, and 2011-2013.  The data from the first four visits were 
used in this analysis. SBP and DBP were measured thrice at each of the first three visits, 
and twice at the fourth visit, using a random zero sphygmomanometer; the average of the 
(final) two measurements at each visit were used for analysis.  In this study, exome 
sequence data from 7,444 European-Americans were analyzed (see below). All 
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participants provided written consent, and approval was obtained from the appropriate 
institutional review boards. 
 
Whole Exome Sequencing, Variant Calling, and Quality Control:  
 ARIC samples were sequenced at the Baylor College of Medicine Human 
Genome Sequencing Center (BCM-HGSC), as part of a larger set of CHARGE99 
samples. The exome sequencing protocol, variant calling, and quality control procedures 
are described elsewhere (Yu et al. Circ Cardiovasc Genet. 2015).100 Among 14,443 
CHARGE samples in the final cleaned set, which had mean depth of 78x coverage, there 
were 7,810 European American (EA) and 3,180 African American (AA) ARIC samples. 
Only the 7,810 EA samples were moved forward in our analysis at this point. 
We then applied additional stringent filters to the data from these 7,810 
individuals, and the following observations were culled: individuals with <90% call rate; 
variants with >10% missing genotype calls among samples; and variants failing Hardy 
Weinberg Equilibrium (P < 1 x 10-6).  Finally, we used the genotype data to estimate the 
genetic relationships among the remaining 7,767 individuals using KING,71 retaining 
only those individuals with the closest relationship being third degree. This provided a 
final dataset comprising 7,444 individuals. 
 
Whole Genome Sequencing, Variant Calling, and Quality Control: 
Genome sequencing was conducted, also as previously described in EA and AA 
ARIC study samples (Morrison et al. Nat Genet. 2013101; Morrison et al. Am J Hum 
Genet. 2017102). Briefly, individuals were sequenced on the HiSeq 2000 at 7.4x average 
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depth, and variants were called with goSNAP, which uses multiple variant callers 
including SNPTools, GATK, and GotCloud, in joint calling mode. Quality control 
procedures of the WGS data included the removal of variants failing Hardy-Weinberg 
Equilibrium (P < 1 x 10-14) per ancestry group, and those with site level inbreeding 
coefficient < -0.9, and principal components analysis to identify outliers in each ancestry 
group. The remaining 1,705 ARIC EA samples from these procedures102 were analyzed 
in the present study. 
 
Annotation to Identify Variants of Interest: 
 Annotation of variants in SLC12A3, SLC12A1 and KCNJ1, with respect to their 
deleterious effects, was carried out using ANNOVAR with refGene annotations to 
identify the putative LOF missense variants (“nonsynonymous”) in the selected 
transcripts used in the downstream analyses.  
 
Phenotypes: 
Longitudinal SBP and DBP phenotypes were calculated based on previously 
described methods,10,103 using the first four visits from the ARIC study. Briefly, SBP and 
DBP were adjusted in a cubic regression on age within each age group (<35, 35 to 44, 45 
to 54, 55 to 64, 65 to 74, and 75+ years) for the 7,444 individuals, and then used to adjust 
their measurements for those visits that were taken while on anti-hypertensive 
medications. While all SBP measurements were used, DBP measurements were restricted 
to those taken at age 55 years and below, as DBP is known to decline with increasing age 
beyond this point.104 Subsequently, these residuals were adjusted for mean age in a linear 
	
	 56	
regression, separately by sex; in our study, this was done with all individuals with at least 
one visit, and regardless of the time span between the first and last visits. This differs 
from previously described methods in Levy et al. where the authors state that at least 4 
examinations were required with a minimum time span of 10 years between the first and 
final examinations in the FHS study, and at least 3 examinations for FHS Offspring 
Cohort participants.103 The resulting standardized residuals were used as phenotypes for 
our studies, and the mean of the non-standardized residuals among carriers of analyzed 
variants is presented as the effect size in Figures 1 and 2. 
 
Transcripts, Orthologs and Paralogs Selection and Alignment: 
Methods for ortholog and paralog selection were as previously described10; they 
are briefly restated here emphasizing pertinent differences. In the original study, the 
representative transcripts NM_000339 (SLC12A3), NM_000338 (SLC12A1), and 
NM_000220/NM_153764-7 (KCNJ1) were analyzed; in our study, we analyzed the same 
transcripts for SLC12A3 and SLC12A1, and analyzed the transcript NM_153766 for 
KCNJ1. This KCNJ1 transcript encodes an identical protein sequence to those encoded 
by other transcript variants NM_153764 and NM_153767, and presented with maximum 
positional similarity through multiple alignment to variants listed as conserved in Ji et al., 
as compared to the canonical transcript, NM_000220. 
The orthologs analyzed in the Ji et al. study for SLC12A3 were from human, 
mouse, rat, rabbit, dog, cow, chicken, zebrafish and winter flounder. In our study, the 
obsolete record XP_871112 from cow was replaced with NP_001193107. The SLC12A1 
orthologs analyzed in their study were from human, mouse, rat, rabbit, dog, chicken, 
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zebrafish and Tetraodon. In our study, NP_062007 from rat was removed from Refseq 
records as it is a nonsense-mediated mRNA decay (NMD) candidate, and XP_850426 
from dog was removed from Refseq records as part of standard genome annotation 
processing (SGAP). These orthologs were dropped in our study. Finally, the orthologs 
studied for KCNJ1 in their study were from human, mouse, rat, dog, chicken, cow, frog, 
zebrafish, fugu, C. elegans, sea urchin and D. melanogaster. In our study, XP_546403 
from dog and XP_425795 from chicken were dropped due to their removal from Refseq 
records for SGAP, XP_684541 from zebrafish was replaced with the updated record 
NP_001092204, XP_585917 from cow was replaced with the updated record 
NP_0011179136, and NP_72245 from human was replaced with NP_722450 
(corresponding to the selected transcript for KCNJ1). 
The paralogs analyzed for SLC12A3 and SLC12A1 (SLC12A family) in both 
studies were from SLC12A1, SLC12A3, and additionally, to SLC12A2, SLC12A4, 
SLC12A5, SLC12A6, and SLC12A7. The paralogs analyzed for KCNJ1 (KCNJ family) in 
their study include KCNJ2, KCNJ3, KCNJ4, KCNJ5, KCNJ6, KCNJ8, KCNJ9, KCNJ10, 
KCNJ11, KCNJ12, KCNJ13, KCNJ14, KCNJ15, and KCNJ16. In our study, as for the 
orthologs, we used the human protein NP_72250 in accordance with the KCNJ1 
transcript analyzed, and additionally, NP_733838 from KCNJ14 was removed due to 
inadequate support for its transcript, NM_170720.1 
[http://www.ncbi.nlm.nih.gov/nuccore/]. 
Multiple alignments were performed with ClustalW v2.1105,106 (105,106) with 
default parameters for all orthologs per gene, and all paralogs per gene family (one for 
the KCNJ family and one for the SLC12A family), with five alignments in total. This 
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differs slightly from the original alignment procedure described in Ji et al., in which it 
was stated that pairwise alignments were used in addition to multiple alignments to 
determine conserved positions. While the multiple pairwise alignments may have some 
differences to a multiple alignment, this difference is not expected to lead to any 
significant change in our downstream assessment of overall conservation of residues. 
 
Selection Criteria and “Validation” Annotation: 
 The criteria used by Ji et al.10 to identify putative LOF missense variants included: 
1) allele frequency < 0.001, and 2) complete conservation across the selected orthologs. 
The exceptions to this were variants that were conserved in orthologs, but with the 
mutant residue present in paralogs, as these were thought to be sustainable within the 
species. Also, as in their study, we further annotated the analyzed variants from ARIC 
and the SNVs from FHS using PANTHER107 (v9.0), SIFT47 (with GRCh37/Ensembl 63) 
and PolyPhen-2108 to determine the deleterious effects of our selected variants. 
 
Statistical Analyses: 
 As all individuals in this study were unrelated, or related more remotely than third 
degree relatives. Standard one-tailed t-tests, under the assumption that the alternate 
alleles are BP-lowering, were carried out on standardized residuals as final phenotype 
values to compare carriers with non-carriers, assuming equal variance for both groups. 
Non-carriers were defined as those who have non-missing genotypes for all 65 variants; 





 Protein plots in Figures S1-S3 were created with the Protter software.109 
 
Results 
We examined rare missense variants in 7,444 EA ARIC subjects with WES data 
(no nonsense variants ultimately met the filtering criteria of frequency or conservation). 
The phenotypic (BP) and risk factor (age, sex, BMI) characteristics for these individuals 
are shown in Table 1. We identified a total of 216 missense variants (rate of 0.029 per 
individual) in the cleaned exome sequence data for SLC12A3, SLC12A1 and KCNJ1. To 
assess their properties, we aligned these genes to their orthologs and paralogs as 
described in the Methods section with ClustalW2, and discovered conservation (protein 
sequence identity) of 41.5%, 40.6%, and 18.3% of residues across orthologs of SLC12A3, 
SLC12A1 and KCNJ1, respectively, across all species considered in each of the multiple 
alignments. Of these, 65 variants (46, 17 and 2 for SLC12A3, SLC12A1 and KCNJ1, 
respectively) had minor allele frequencies (MAF) <0.001 in the 7,444 ARIC EA samples. 
These occurred at highly sequenced bases (in 7,810 ARIC EA individuals: median depth 
75X; range: 27-196X) demonstrating the high quality of the data. 
We annotated these 65 variants with SIFT, PANTHER and Poly-Phen2, which 
confirmed that the vast majority (57, or 86.2%) of these variants were predicted to be 
pathogenic by all three programs (Table S1).  We also used these versions of the software 
programs to obtain updated annotations for the 28 FHS SNVs, enabling comparisons 
between the two sets of variants (Table S2). All but three variants (89.3%) were predicted 
to be pathogenic by all three programs. Further, allele frequencies of these 65 variants in 
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non-Finnish Europeans from the Exome Aggregation Consortium (ExAC) are shown in 
Table S3, and those for the 28 FHS SNVs are presented in Table S4. There are 40 out of 
65 ARIC variants (~61.5%) and 17 out of 28 FHS SNVs (60.7%) with nonzero non-
Finnish ExAC allele frequencies, providing similar evidence for the existence of these 
genotype calls across the two studies. Further, examining the variant distributions across 
the three genes (Figures S1-S3) shows them to be evenly distributed across the domains 
in both studies. 
 Longitudinal SBP and DBP values were then analyzed by standard one-tailed t-
tests to test for differences between carriers and non-carriers of the variants. The 
standardized residual phenotype values of carriers, modeled after Figure 2 in Ji et al., are 
shown in Figures 1 and 2 for SBP and DBP, respectively. The mean effect was -0.745 
mmHg for SBP (t-test p=0.36) considering all 65 variants in 121 carriers and 6,750 non-
carriers, and 1.177 mmHg for DBP (t-test p=0.83) considering 39 variants in 62 carriers 
and 3,478 non-carriers. As only DBP measurements under the age of 55 were analyzed in 
this study (see Methods), there were fewer variants in fewer individuals analyzed. Thus, 
these results neither show a prominent direction of effect, nor are they statistically 
significant. 
 We had whole genome sequence data (WGS) available for a subset of these 
individuals and variants, enabling comparisons of the same genotypes at SLC12A3, 
SLC12A1 and KCNJ1. Genotype counts from the WES data were also present in the 
WGS data of 14 variants; seven variants were called in the same eight individuals in both 
sets concordantly. As this is too sparse to be truly informative, we compared the overall 
concordance of all genotype calls between the WES and WGS data for bi-allelic SNVs 
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from all 1,497 individuals. These comparisons had between 545,249 – 604,016 sites with 
a total concordance rate of 0.9995 (Table 2). As indicated in Table 2, there were many 
more variants, namely heterozygous variants, called in the exome sequence data than in 
the genome sequence data within this set.  
 We also examined a set of 10 variants from the 28 FHS SNVs that were also 
present in the ARIC exome sequencing dataset. Of these, 9 met the conservation and 
MAF criteria within ARIC, while 1 did not meet the conservation criterion (the proline at 
position 348 in SLC12A1 has an alanine substitution in Danio rerio). Standardized 
residuals for carriers of all 10 variants are shown for SBP, and for carriers of the subset of 
8 variants with DBP measurements available under age 55, in Figures 3 and 4, 
respectively. These results replicate those for the 30 variants in Ji et al. with similar mean 
effect sizes among carriers (SBP: -6.888 mmHg, p=0.02; DBP: -3.120 mmHg, p=0.11).  
 
Discussion 
 We attempted to apply the criteria from Ji et al. to ARIC exome sequencing data 
to identify putative LOF variants within the Bartter and Gitelman syndromes SLC12A3, 
SLC12A1, and KCNJ1 genes. While we failed to demonstrate the robustness of the 
methods used in Ji et al. in the ARIC exome sequencing as we did not see the BP-
lowering effect they did when applying their filtering criteria to the ARIC exome 
sequencing data, we did replicate the LOF effect of several specific rare variants analyzed 
in their study, demonstrating evidence that such variants in these genes are protective 
against essential hypertension. These results merit further discussion. Rare LOF alleles at 
SLC12A3, SLC12A1, and KCNJ1 do decrease blood pressure and hypertension risk in 
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heterozygotes in the general population but the specific alleles showing such effects are 
only a subset of all annotated deleterious alleles. 
 It is usually expected that identical computational genomic analyses should return 
similar, if not identical, results; however, many inadvertent differences can occur. First, 
there are many differences in the sequence versions of the orthologs and paralogs used in 
the two studies because many records were either updated or dropped from the NCBI 
Refseq records over the past 9 years. We had 18-42% sites conserved across all species in 
the multiple alignments, while the authors in Ji et al. state 18-24% conservation rate for 
each of the three genes. Sequence and ClustwalW software version differences, as well as 
differences in calculation methods of these values, are likely to have led to some 
discrepancies, even for SLC12A3, for which we used the same orthologs and paralogs. In 
our multiple alignments, 21 out of 28 FHS SNVs are completely conserved, of which 17 
are listed in Table 1 of Ji et al. as completely conserved in their study (the remaining four 
are listed as conserved in vertebrates in their study). Additionally, dropping sequence 
records that were obsolete by the time we conducted this study likely contributed to the 
higher percentages of conserved sites in the species studied, though these positions still 
represent a conserved set. 
The two studies also used different variant detection methods: we used exome 
sequencing whereas Ji et al. used temperature gradient capillary electrophoresis (TGCE) 
with confirmation by PCR amplification and Sanger sequencing from the original DNA 
sample. The original study stated a “high” sensitivity of detection, having identified 
known single nucleotide variants (SNVs) in FHS, buttressed by a high concordance with 
frequencies in previous studies. Follow-up studies state that the vast majority (14 out of 
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18, with conflicting results for an addition two variants) of the variants in their study 
were shown in Xenopus laevis oocytes and HEK293 cells to be LOF.110–112 We use WES 
data in this study, at high sequencing depths that are in the range of previous estimates 
deemed sufficient for detection of the vast majority of heterozygous variants.113–115 The 
WGS data used for concordance comparison indicated some discordance with the WES 
data, but are low-coverage and therefore, it is likely that variants were missed in these 
data that were called in the WES data. However, it should also be noted that WES and 
WGS data often contain both false positives and false negatives,116,117 despite a low error 
rate, for the rarest of variants. Our annotation of the 65 analyzed ARIC variants and the 
28 FHS SNVs analyzed in Ji et al. with the software programs SIFT, PANTHER, and 
PolyPhen support the predicted pathogenicity of both variant sets, and similar fractions of 
variants in both sets were present in the ExAC non-Finnish European population, 
demonstrating high concordance with their properties. However, it is not necessarily 
surprising for sequencing errors to also display this profile of pathogenicity due to the 
increased probability that rare variants are sequencing errors and that the analyzed 
variants were specifically chosen at sites preselected for their conservation among a set of 
species. 
Despite these differences, the carriers of the subset of variants from the Ji et al. 
study that were also in the ARIC WES data present similar effect sizes for SBP (10 
variants) and DBP (eight variants) as in the Ji et al. study, and nearly all passed the same 
selection criteria in ARIC. As the distributions of variants in both studies seem to show 
no distinct or study-specific patterns or differences, it remains possible that only certain 
LOF variants at mechanistically specific locations are essential for BP regulation. This 
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replication is especially notable because the FHS offspring cohort is younger in their 
visits as compared to ARIC individuals, who were minimum 45 years of age at baseline, 
and the age difference affects the proportion of individuals whose measurements 
necessitated adjustment for medication use. Further, the methods detailed in Levy et al. 
indicate that the effects reflect a longer time span of measurements, as they required 
samples to have at least 3-4 visits over at least 10 years, while our samples had a 
maximum of four visits over 12 years. These differences can affect analyses, but in this 
case the effect is still visible. Additionally, this represents a replication of the effects of 
rare variants with very low minor allele counts, which demonstrates the utility of exome 
sequencing data for study of such rare variants, though greater study is required to 
determine more appropriate filtering methods. 
 In summary, our attempt to replicate the methods in the Ji et al. study to detect 
rare and potentially LOF variants in SLC12A3, SLC12A1, and KCNJ1 reducing SBP and 
DBP in variant carriers as compared to non-carriers using WES data was overall 
unsuccessful. Although the two studies are comparable in numerous ways there are also 
pertinent differences that can lead to the discrepant outcomes. Regardless of this, we 
successfully replicated the reduction effects in SBP and DBP with a subset of variants 
from the Ji et al. study that were present in the ARIC study, which upholds the use of 
such sequencing data for the study of very rare variants and that SLC12A3, SLC12A1, and 
KCNJ1 are indeed genes protective in HTN. Additionally, this type of analysis 
demonstrates the utility of this method for analyzing specific rare variants in aggregate. 
Though hypertension is a common disease, as the particular renal salt wasting syndromes 
of interest in this study (Bartter and Gitelman) are rare, the method is applicable for 
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identifying rare LOF variants LOF in other rare diseases. Nevertheless, our study also 
supports the idea that software prediction and annotation of rare, putatively deleterious 
variants may be insufficient for detecting disease genes, and that there must be 
appropriate variant filtering methods, and subsequent functional analyses and validation 
of these variants. 
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Figure 1. Age- and sex-adjusted SBP residuals for 121 carriers of 65 variants, depicting 





































































































































































































































Figure 2. Age- and sex-adjusted DBP residuals for 62 carriers of 39 variants, depicting 
























































































































































Figure 3. Age- and sex-adjusted SBP residuals for 10 FHS variants in ARIC, depicting 
































































Figure 4. Age- and sex-adjusted DBP residuals for 8 FHS variants in ARIC, depicting 



























































Chapter 3 Tables 
 
 






















118.204 (16.487) 121.848 
(19.649) 
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122.597 (17.696) 128.491 
(22.436) 







125.916 (18.187) 133.533 
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Table 2. Whole exome (WES) versus whole genome (WGS) sequencing genotype call 
comparisons for all calls in 1,497 individuals.*  
 
 
# WES genotype calls 
0 1 2 
# WGS 
calls 
0 870,939,675 238,845 343 
1 134,332 13,030,169 33,062 
2 104 44371 9,052,661 
0, homozygous reference genotype; 1, heterozygous genotype; 2, homozygous alternate 
genotype 
 
*Comparisons of non-missing genotype calls across individuals in both datasets; the 
overall genotype concordance is 0.9995. The calculation is inclusive of homozygous 
reference calls for variants called in other samples not within this subset of 1,497 as the 






Chapter 3 Supplement 
 





Sequences of orthologs and paralogs used in this study: 
NCBI links for orthologs/paralogs may be found at http://www.ncbi.nlm.nih.gov/protein/. 
 
GenBank Protein IDs for the human are: KCNJ1 (NP_722450.1), SLC12A1 
(NP_000329.2), and SLC12A3 (NP_000330.2). 
 
Orthologs for KCNJ1 include: Rattus norvegicus (NP_058719.1), Mus musculus 
(NP_062633.1), Drosophila melanogaster (NP_651131.2), Xenopus laevis 
(AAH79788.1), Strongylocentrotus purpuratus (XP_789112.1), Takifugu rubripes 
(ABB87033.1), Danio rerio (NP_001092204.1), Bos taurus (NP_001179136.1), 
Caenorhabditis elegans (NP_509138.2). 
 
Paralogs for human KCNJ family include: KCNJ2 (NP_000882.1), KCNJ3 
(NP_002230.1), KCNJ4 (NP_004972.1), KCNJ5 (NP_000881.3), KCNJ6 
(NP_002231.1), KCNJ8 (NP_004973.1), KCNJ9 (NP_004974.2), KCNJ10 
(NP_002232.2), KCNJ11 (NP_000516.3), KCNJ12 (NP_066292.2), KCNJ13 
(NP_002233.2), KCNJ15 (NP_733933.1), KCNJ16 (NP_733938.2) 
 
Orthologs for SLC12A1 include: Tetraodon nigroviridis (CAF99849.1), Danio rerio 




Orthologs for SLC12A3 include: Oryctolagus cuniculus (AAC33139.1), 
Pseudopleuronectes americanus (AAL26926.1), Danio rerio (NP_001038545.1), Rattus 
norvegicus (NP_062218.3), Mus musculus (NP_062288.2), Bos taurus 
(NP_001193107.1), Canis lupus familiaris (XP_535292.3), Gallus gallus (XP_414059.4) 
 
Paralogs for human SLC12A family include: SLC12A2 (NP_001037.1), SLC12A4 





Table S1. ARIC variant annotation of deleterious effects using SIFT, PolyPhen-2 and PANTHER cSNP software. 
 
Gene Substitution Variant SIFT.pred PPhen.pred PANTHER.pred 
KCNJ1* R169H 11:128709633:G:A DAMAGING probably damaging probably damaging 
KCNJ1* P166S 11:128709643:C:T DAMAGING benign probably damaging 
SLC12A1 K176N 15:48512938:G:C DAMAGING probably damaging probably damaging 
SLC12A1 M188T 15:48513128:T:C DAMAGING probably damaging probably damaging 
SLC12A1 R199C 15:48513160:C:T DAMAGING probably damaging probably damaging 
SLC12A1 A232V 15:48518739:C:T DAMAGING probably damaging probably damaging 
SLC12A1 P254A 15:48521421:C:G DAMAGING probably damaging probably damaging 
SLC12A1 P254S 15:48521421:C:T DAMAGING probably damaging probably damaging 
SLC12A1 E255K 15:48521424:G:A DAMAGING probably damaging probably damaging 
SLC12A1 A265V 15:48521455:C:T DAMAGING probably damaging probably damaging 
SLC12A1 R302W 15:48522629:C:T DAMAGING probably damaging probably damaging 
SLC12A1 C461Y 15:48537031:G:A DAMAGING probably damaging probably damaging 
SLC12A1 C470S 15:48537057:T:A DAMAGING probably damaging probably damaging 
SLC12A1 A498V 15:48539146:C:T DAMAGING probably damaging probably damaging 
SLC12A1 A508T 15:48539175:G:A DAMAGING probably damaging probably damaging 
SLC12A1 V649A 15:48548011:T:C DAMAGING probably damaging probably damaging 
SLC12A1 R721G 15:48559764:C:G TOLERATED benign probably damaging 
SLC12A1 M732R 15:48559798:T:G TOLERATED benign probably damaging 
SLC12A1 D802G 15:48566770:A:G DAMAGING benign probably damaging 
SLC12A3 M233V 16:56904103:A:G DAMAGING possibly damaging probably damaging 
SLC12A3 V242M 16:56904130:G:A TOLERATED probably damaging probably damaging 
SLC12A3 R261C 16:56904577:C:T DAMAGING probably damaging probably damaging 
SLC12A3 L272P 16:56904611:T:C DAMAGING probably damaging probably damaging 
SLC12A3 K284Q 16:56904646:A:C DAMAGING probably damaging probably damaging 
SLC12A3 A356V 16:56906670:C:T DAMAGING probably damaging probably damaging 
SLC12A3 N359D 16:56906678:A:G DAMAGING probably damaging probably damaging 
SLC12A3 R399H 16:56913000:G:A DAMAGING probably damaging probably damaging 
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SLC12A3 G439S 16:56913119:G:A DAMAGING probably damaging probably damaging 
SLC12A3 A464T 16:56913508:G:A DAMAGING probably damaging probably damaging 
SLC12A3 A469T 16:56913523:G:A DAMAGING probably damaging probably damaging 
SLC12A3 A469V 16:56913524:C:T DAMAGING probably damaging probably damaging 
SLC12A3 R507C 16:56914117:C:T DAMAGING probably damaging probably damaging 
SLC12A3 I515V 16:56914141:A:G DAMAGING possibly damaging probably damaging 
SLC12A3 I522N 16:56914163:T:A DAMAGING probably damaging probably damaging 
SLC12A3 S555L 16:56916404:C:T DAMAGING probably damaging probably damaging 
SLC12A3 P556L 16:56916407:C:T TOLERATED possibly damaging probably damaging 
SLC12A3 W568R 16:56917993:T:C DAMAGING probably damaging probably damaging 
SLC12A3 M581T 16:56918033:T:C DAMAGING probably damaging probably damaging 
SLC12A3 A588E 16:56918054:C:A DAMAGING probably damaging possibly damaging 
SLC12A3 L599F 16:56918086:C:T DAMAGING probably damaging probably damaging 
SLC12A3 N611H 16:56919182:A:C DAMAGING probably damaging probably damaging 
SLC12A3 R642G 16:56919275:C:G DAMAGING probably damaging probably damaging 
SLC12A3 R642C 16:56919275:C:T DAMAGING probably damaging probably damaging 
SLC12A3 P656L 16:56920317:C:T DAMAGING probably damaging probably damaging 
SLC12A3 A714V 16:56920968:C:T DAMAGING probably damaging probably damaging 
SLC12A3 R718H 16:56920980:G:A DAMAGING probably damaging probably damaging 
SLC12A3 G729V 16:56921844:G:T DAMAGING probably damaging probably damaging 
SLC12A3 G741R 16:56921879:G:A DAMAGING probably damaging probably damaging 
SLC12A3 K743R 16:56921886:A:G DAMAGING probably damaging probably damaging 
SLC12A3 V771M 16:56924211:G:A DAMAGING benign possibly damaging 
SLC12A3 G779E 16:56924236:G:A DAMAGING probably damaging probably damaging 
SLC12A3 L859F 16:56928469:C:T DAMAGING probably damaging probably damaging 
SLC12A3 L859P 16:56928470:T:C DAMAGING probably damaging probably damaging 
SLC12A3 R861C 16:56928475:C:T TOLERATED probably damaging probably damaging 
SLC12A3 R871C 16:56928505:C:T DAMAGING probably damaging probably damaging 
SLC12A3 D907V 16:56933501:A:T DAMAGING probably damaging probably damaging 
SLC12A3 R928H 16:56936320:G:A DAMAGING probably damaging probably damaging 
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SLC12A3 K934T 16:56936338:A:C TOLERATED benign probably damaging 
SLC12A3 R967G 16:56938322:A:G DAMAGING probably damaging probably damaging 
SLC12A3 C994Y 16:56947205:G:A DAMAGING probably damaging probably damaging 
SLC12A3 R1018Q 16:56947277:G:A DAMAGING probably damaging probably damaging 
SLC12A3 V1024M 16:56947294:G:A DAMAGING probably damaging probably damaging 
SLC12A3 T1026A 16:56947300:A:G DAMAGING probably damaging probably damaging 
SLC12A3 T1026I 16:56947301:C:T DAMAGING probably damaging probably damaging 




probably damaging probably damaging 
*Although the protein sequence for NP_722450.1 (KCNJ1) was used as input to PolyPhen-2, the software annotated KCNJ1 variants 








Table S2. FHS variant annotation of deleterious effects using SIFT, PolyPhen-2 and PANTHER cSNP software. 
 
Gene Substitution Variant SIFT.pred PPhen.pred PANTHER.pred 
KCNJ1* H251Y 11:128709388:C:T DAMAGING probably damaging probably damaging 
KCNJ1* R193P 11:128709561:G:C DAMAGING probably damaging probably benign 
KCNJ1* R169H 11:128709633:G:A DAMAGING probably damaging probably damaging 
KCNJ1* P166S 11:128709643:C:T DAMAGING benign probably damaging 
SLC12A1 T235I** 15:48518748:C:T DAMAGING probably damaging probably damaging 
SLC12A1 P254A 15:48521421:C:G DAMAGING probably damaging probably damaging 
SLC12A1 R302W 15:48522629:C:T DAMAGING probably damaging probably damaging 
SLC12A1 P348L 15:48524991:C:T DAMAGING probably damaging probably damaging 
SLC12A1 N399S 15:48527182:A:G DAMAGING probably damaging probably damaging 
SLC12A1 L505V 15:48539166:C:G DAMAGING probably damaging probably damaging 
SLC12A1 P569H 15:48541793:C:A DAMAGING probably damaging probably damaging 
SLC12A1 Y1070C 15:48594991:A:G DAMAGING probably damaging probably damaging 
SLC12A1 P1083A 15:48595029:C:G DAMAGING probably damaging probably damaging 
SLC12A3 E112X 16:56901033:G:T N/A NA possibly damaging 
SLC12A3 L155F 16:56902242:C:T DAMAGING probably damaging probably damaging 
SLC12A3 S188F 16:56903698:C:T DAMAGING probably damaging probably damaging 
SLC12A3 A232T 16:56904100:G:A DAMAGING probably damaging probably damaging 
SLC12A3 R261C 16:56904577:C:T DAMAGING probably damaging probably damaging 
SLC12A3 R399L 16:56913000:G:T DAMAGING probably damaging probably damaging 
SLC12A3 G439S 16:56913119:G:A DAMAGING probably damaging probably damaging 
SLC12A3 F495L 16:56914083:C:A DAMAGING possibly damaging probably damaging 
SLC12A3 P560H 16:56917970:C:A DAMAGING probably damaging probably damaging 
SLC12A3 G613S 16:56919188:G:A DAMAGING probably damaging probably damaging 
SLC12A3 G741R 16:56921879:G:A DAMAGING probably damaging probably damaging 
SLC12A3 G779E 16:56924236:G:A DAMAGING probably damaging probably damaging 
SLC12A3 R861C 16:56928475:C:T TOLERATED probably damaging probably damaging 
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SLC12A3 R964Q 16:56938314:G:A DAMAGING possibly damaging probably damaging 
SLC12A3 G989R 16:56947189:G:A DAMAGING probably damaging possibly damaging 
*Although the protein sequence for NP_722450.1 (KCNJ1) was used as input to PolyPhen-2, the software annotated KCNJ1 variants 
in this transcript with equivalent positions in the canonical transcript NM_000220 (NP_000211.1). 
 





Table S3. ARIC variant allele frequencies in non-Finnish European individuals from the 
Exome Aggregation Consortium (ExAC). 
 
Gene Substitution Variant ExAC_AF ARIC_AF 
KCNJ1 R169H 11:128709633:G:A 1.54 x 10-5 6.72 x 10-5 
KCNJ1 P166S 11:128709643:C:T 1.08 x 10-4 1.34 x 10-4 
SLC12A1 K176N 15:48512938:G:C 1.51 x 10-5 6.72 x 10-5 
SLC12A1 M188T 15:48513128:T:C 7.49 x 10-5 6.72 x 10-5 
SLC12A1 R199C 15:48513160:C:T 1.50 x 10-5 6.72 x 10-5 
SLC12A1 A232V 15:48518739:C:T 4.51 x 10-5 6.72 x 10-5 
SLC12A1 P254A 15:48521421:C:G NA 2.69 x 10-4 
SLC12A1 P254S 15:48521421:C:T NA 6.72 x 10-5 
SLC12A1 E255K 15:48521424:G:A NA 6.72 x 10-5 
SLC12A1 A265V 15:48521455:C:T 3.39 x 10-5 6.72 x 10-5 
SLC12A1 R302W 15:48522629:C:T NA 1.34 x 10-4 
SLC12A1 C461Y 15:48537031:G:A NA 6.72 x 10-5 
SLC12A1 C470S 15:48537057:T:A NA 6.72 x 10-5 
SLC12A1 A498V 15:48539146:C:T NA 1.34 x 10-4 
SLC12A1 A508T 15:48539175:G:A 9.02 x 10-5 1.34 x 10-4 
SLC12A1 V649A 15:48548011:T:C NA 6.72 x 10-5 
SLC12A1 R721G 15:48559764:C:G NA 6.74 x 10-5 
SLC12A1 M732R 15:48559798:T:G NA 1.35 x 10-4 
SLC12A1 D802G 15:48566770:A:G 1.80 x 10-4 1.36 x 10-4 
SLC12A3 M233V 16:56904103:A:G NA 2.02 x 10-4 
SLC12A3 V242M 16:56904130:G:A 1.52 x 10-5 6.78 x 10-5 
SLC12A3 R261C 16:56904577:C:T 9.00 x 10-5 6.72 x 10-5 
SLC12A3 L272P 16:56904611:T:C NA 6.72 x 10-5 
SLC12A3 K284Q 16:56904646:A:C 4.65 x 10-5 6.73 x 10-5 
SLC12A3 A356V 16:56906670:C:T NA 6.74 x 10-5 
SLC12A3 N359D 16:56906678:A:G NA 6.75 x 10-5 
SLC12A3 R399H 16:56913000:G:A 2.04 x 10-5 6.72 x 10-5 
SLC12A3 G439S 16:56913119:G:A 4.11 x 10-4 3.36 x 10-4 
SLC12A3 A464T 16:56913508:G:A 3.02 x 10-5 1.35 x 10-4 
SLC12A3 A469T 16:56913523:G:A 2.87 x 10-4 6.73 x 10-5 
SLC12A3 A469V 16:56913524:C:T 1.21 x 10-4 2.69 x 10-4 
SLC12A3 R507C 16:56914117:C:T 2.48 x 10-4 1.35 x 10-4 
SLC12A3 I515V 16:56914141:A:G 9.34 x 10-5 6.77 x 10-5 
SLC12A3 I522N 16:56914163:T:A NA 6.83 x 10-5 
SLC12A3 S555L 16:56916404:C:T 7.49 x 10-5 6.72 x 10+ 
SLC12A3 P556L 16:56916407:C:T NA 6.72 x 10-5 
SLC12A3 W568R 16:56917993:T:C 1.50 x 10-5 1.34 x 10-4 
SLC12A3 M581T 16:56918033:T:C 2.10 x 10-4 1.34 x 10-4 
SLC12A3 A588E 16:56918054:C:A 1.50 x 10-5 6.72 x 10-5 
SLC12A3 L599F 16:56918086:C:T 1.80 x 10-4 2.69 x 10-4 
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SLC12A3 N611H 16:56919182:A:C NA 6.76 x 10-5 
SLC12A3 R642G 16:56919275:C:G NA 6.96 x 10-5 
SLC12A3 R642C 16:56919275:C:T NA 6.97 x 10-5 
SLC12A3 P656L 16:56920317:C:T 2.26 x 10-4 2.69 x 10-4 
SLC12A3 A714V 16:56920968:C:T 1.96 x 10-4 6.72 x 10-5 
SLC12A3 R718H 16:56920980:G:A 1.51 x 10-5 6.72 x 10-5 
SLC12A3 G729V 16:56921844:G:T 2.73 x 10-4 3.37 x 10-4 
SLC12A3 G741R 16:56921879:G:A 6.34 x 10-4 5.38 x 10-4 
SLC12A3 K743R 16:56921886:A:G NA 6.73 x 10-5 
SLC12A3 V771M 16:56924211:G:A NA 6.72 x 10-5 
SLC12A3 G779E 16:56924236:G:A NA 1.34 x 10-4 
SLC12A3 L859F 16:56928469:C:T NA 1.34 x 10-4 
SLC12A3 L859P 16:56928470:T:C 1.56 x 10-4 1.34 x 10-4 
SLC12A3 R861C 16:56928475:C:T 1.85 x 10-4 2.02 x 10-4 
SLC12A3 R871C 16:56928505:C:T 3.02 x 10-5 6.72 x 10-5 
SLC12A3 D907V 16:56933501:A:T NA 6.72 x 10-5 
SLC12A3 R928H 16:56936320:G:A 7.49 x 10-5 2.69 x 10-4 
SLC12A3 K934T 16:56936338:A:C 1.50 x 10-5 1.34 x 10-4 
SLC12A3 R967G 16:56938322:A:G 7.49 x 10-5 6.74 x 10-5 
SLC12A3 C994Y 16:56947205:G:A 3.15 x 10-4 7.39 x 10-4 
SLC12A3 R1018Q 16:56947277:G:A 1.50 x 10-5 6.72 x 10-5 
SLC12A3 V1024M 16:56947294:G:A 3.00 x 10-5 6.72 x 10-5 
SLC12A3 T1026A 16:56947300:A:G NA 6.72 x 10-5 
SLC12A3 T1026I 16:56947301:C:T 1.50 x 10-5 1.34 x 10-4 
SLC12A3 Q1030R 16:56947313:A:G 1.50 x 10-5 6.72 x 10-5 






Table S4. FHS SNV allele frequencies in non-Finnish European individuals from the 
Exome Aggregation Consortium (ExAC). 
 
Gene Substitution Variant ExAC_AF 
KCNJ1 H251Y 11:128709388:C:T 1.50 x 10-5 
KCNJ1 R193P 11:128709561:G:C NA 
KCNJ1 R169H 11:128709633:G:A 1.54 x 10-5 
KCNJ1 P166S 11:128709643:C:T 1.08 x 10-4 
SLC12A1 T235M 15:48518748:C:T NA 
SLC12A1 P254A 15:48521421:C:G NA 
SLC12A1 R302W 15:48522629:C:T NA 
SLC12A1 P348L 15:48524991:C:T 1.50 x 10-5 
SLC12A1 N399S 15:48527182:A:G NA 
SLC12A1 L505V 15:48539166:C:G 1.50 x 10-5 
SLC12A1 P569H 15:48541793:C:A 1.50 x 10-5 
SLC12A1 Y1070C 15:48594991:A:G NA 
SLC12A1 P1083A 15:48595029:C:G 1.50 x 10-5 
SLC12A3 E112X 16:56901033:G:T NA 
SLC12A3 L155F 16:56902242:C:T 1.59 x 10-5 
SLC12A3 S188F 16:56903698:C:T 1.50 x 10-5 
SLC12A3 A232T 16:56904100:G:A 1.50 x 10-4 
SLC12A3 R261C 16:56904577:C:T 9.00 x 10-5 
SLC12A3 R399L 16:56913000:G:T 4.07 x 10-5 
SLC12A3 G439S 16:56913119:G:A 4.11 x 10-4 
SLC12A3 F495L 16:56914083:C:A NA 
SLC12A3 P560H 16:56917970:C:A NA 
SLC12A3 G613S 16:56919188:G:A NA 
SLC12A3 G741R 16:56921879:G:A 6.34 x 10-4 
SLC12A3 G779E 16:56924236:G:A NA 
SLC12A3 R861C 16:56928475:C:T 1.85 x 10-4 
SLC12A3 R964Q 16:56938314:G:A 2.70 x 10-4 
SLC12A3 G989R 16:56947189:G:A 7.49 x 10-5 





Figure S1. Distribution of KCNJ1 variants in FHS and ARIC. SNVs unique to FHS are 







Figure S2. Distribution of SLC12A1 variants in FHS and ARIC. SNVs unique to FHS are 







Figure S3. Distribution of SLC12A3 variants in FHS and ARIC. SNVs unique to FHS are 










 Several genome-wide association studies (GWAS) have revealed associations of 
common variants at hundreds of loci with inter-individual variation in blood pressure 
(BP)12–36; however, the specific causal genes and variants at most of these loci have yet to 
be determined. Consequently, the relative roles of coding and non-coding causal variation 
affecting BP remain unknown. In addition to these loci, a set of 20 genes involved in 
kidney salt transport and related mechanisms have been studied in the context of renal 
physiology and BP, because loss-of-function protein coding defects within them have 
been previously demonstrated to result in rare monogenic BP syndromes.7–11 With respect 
to the kidney, the kidney fluid balance system118 and the systemic renin-angiotensin-
aldosterone system (RAAS)119 have also been extensively studied and established as BP 
control systems, with several genes identified as anti-hypertensive targets.41 Additionally, 
the intra-renal RAAS has been studied and implicated in hypertension.120 Thus, we must 
consider both classes of genes/loci to understand the mechanisms of BP variation, and 
determining their contributions to BP physiology. Furthermore, understanding the 
potential involvement of non-renal tissues and connecting tissue-specific information to 
blood pressure should also reveal greater specificity about the entire gamut of 
mechanisms underlying its regulation. 
In order to identify the involvement of specific genes and their networks, and to 
begin to dissect additional mechanisms underlying BP regulation, we need to identify the 
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tissues whose biology are essential to this trait. While specific BP regulation mechanisms 
centrally involving the kidney have been established, the various BP control systems, 
including the systemic RAAS, are known to involve or thought to affect numerous other 
tissues, including, but not limited to, the adrenal glands, brain, heart, and vasculature.121 
Thus, there is a need to identify non-renal tissues of interest for understanding BP 
control. At this time, the vast majority of BP GWAS loci remain to be characterized in 
terms of specific genes and variants of interest and in terms of their functional context, 
and, thus, their tissue effects are unknown. This can be performed through the evaluation 
of enrichment of GWAS loci among expression quantitative trait loci (eQTLs), as has 
been done in previous studies.122–124 However, these analyses have so far been limited to 
a few tissue sources. Consequently, their roles across diverse tissues is unknown, an 
aspect critical to identifying tissues of relevance for a given phenotype when genetic 
pleiotropy is widespread.  
 The development and expansion of public genomic resources have introduced 
multidimensional functional analyses into standard genetic analyses. The Encyclopedia of 
DNA Elements (ENCODE) Project (https://www.encodeproject.org/) has generated open 
chromatin, RNA and DNA sequencing, genotyping, and histone modification data, 
among other data types. The Genotype-Tissue Expression (GTEx) Project 
(https://www.gtexportal.org/) includes genotype and expression data across 53 tissues 
and is useful as reference transcriptome and expression quantitative trait locus (eQTL) 
dataset. As an example, and relevant to the studies described in this chapter, consider that 
standard variant annotation analysis usually occurs at the level of the genome. However, 
these public resources have enabled the development of an annotation score, deltaSVM,48 
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in which the quantitative impact of a variant on gene regulation is predicted specific to a 
tissue or cell type, based on a reference training set of regulatory regions from tissues or 
cell types of interest. 
Given the scientific need, and the availability of these resources, the primary aims 
of this chapter focused on identifying tissues of interest for BP regulation to functionally 
identify and contextualize specific causal genes and variants at some subset of the 
hundreds of known BP GWAS loci. We also aimed to extend studies of the 20 
monogenic BP syndrome genes beyond their known coding variation into their regulatory 
variation in the kidney.  
To identify tissues of interest to BP GWAS loci, we performed an eQTL 
enrichment analysis in the Kaiser Permanente Research Program on Genes, Environment 
and Health (RPGEH) Genetic Epidemiology Research on Adult Health and Aging 
(GERA)125,126 study and determined that associated variants at BP GWAS loci are 
enriched in eQTLs specific to the aorta and tibial arteries. For each artery, we next 
connected groups of proximal putative regulatory variants within and around each gene to 
both the gene’s expression and also to BP traits, inferring that the gene’s expression in a 
potentially relevant tissue affected the regulation of BP. To accomplish this, within each 
artery, we identified putative CREs, and by extension, putative CRE variants, for every 
gene, and tested these variants in aggregate for association with BP in the GERA study, 
as well as with expression in the GTEx study, in each of the arteries. We used the 
sequence kernel association test (SKAT)43 for these association analyses, with each 
variant weighted by their deltaSVM scores, to up-weight variants with greater predicted 
effects on gene regulatory activity. We supplemented the expression analyses with use of 
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the software, MetaXcan127, to identify whether the predicted expression of genes in each 
individual could be associated with BP. As all of these BP gene discovery analyses were 
novel, we first examined genes for a trait for which there is strong functional evidence (a 
positive control), such as the cardiac trait QT interval in the Atherosclerosis Risk in 
Communities (ARIC)60,61 study, and demonstrated the utility of these analyses for 
identifying genes relevant to the regulation of BP. It is expected that the QT interval is 
regulated by the heart only. Finally, we examined the effects of putative regulatory 
variation for the 20 monogenic genes in four available kidney cell types using analyses as 
described above to test for a group effect on association with BP.  
The results of these analyses suggested specific candidate genes at novel and 
previously replicated blood pressure loci regulating BP variation between individuals, 
genes that will aid in our understanding of the BP control mechanisms. We expected that 
these genes will facilitate more comprehensive analyses of gene regulatory networks 
involved in BP control.   
 
Methods 
Study participants and summary of genotypes, phenotypes, and association results 
from Hoffmann et al. Nat Genet 2017 
 The full descriptions of the studies, phenotypes, and association results are in 
Hoffmann et al.33 and are briefly recapitulated here. The Genetic Epidemiology Research 
on Adult Health and Aging (GERA) cohort, part of the Kaiser Permanente Research 
Program on Genes, Environment, and Health (RPGEH), consists of individuals from five 
populations; the majority is non-Hispanic white (EUR), with the remainder including 
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Latino, East Asians, African Americans, and South Asians. A total of 99,785 individuals 
were analyzed, of which 80,792 were EUR individuals. The populations were each 
genotyped on custom population-specific Affymetrix Axiom SNP genotyping arrays, and 
imputed to the 1000 Genomes Phase I Integrated Release Version 3 haplotype panel. 
Analyses of GERA alone, with the results of the International Consortium for Blood 
Pressure (ICBP, n=69,396) study, and with the ICBP and the UK Biobank (UKB, 
n=152,081) study identified 316 novel BP loci. Combined with the set of replicated BP 
GWAS loci available at that time, there were a total of 390 loci we considered to be of 
interest in BP regulation. Of these, 367 had minor allele frequency (MAF) > 0.001 in the 
GERA EUR study, which was used as the reference population for the eQTL analyses 
described below. 
For the purpose of several of the analyses described in this chapter, we used these 
association results, as well as summary statistics available from 80,792 GERA EUR 
individuals from the Hoffmann et al. study, and genotypes from a subset of 71,404 
GERA EUR ‘unrelated’ individuals (third degree or beyond, pruned by the KING 
software for relationship inference.)71 We converted genotypes prepared in the Hoffmann 
et al. study after imputation from IMPUTE2 genotype probabilities format to PLINK 
‘hard’ calls, setting genotypes with uncertainty greater than 0.25 to missing, and retaining 
variants with < 10% missing data, a Hardy Weinberg equilibrium test p-value < 1x10-6, 
and imputation quality score ≥ 0.3. In order to report single-variant summary statistics 
within this subset of individuals, we used the --assoc option for analysis of a quantitative 
trait (Wald test) with PLINK v1.9.69 
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We analyzed adjusted systolic (SBP) and diastolic (DBP) blood pressure in this 
study, as also described in Hoffmann et al.33 
 
ARIC genotypes, phenotypes, and association 
The Atherosclerosis Risk in Communities (ARIC) cohort is a longitudinal 
population-based study of 15,792 individuals, comprised of 11,478 European-Americans 
(EUR) and 4,266 African-Americans (AA) from four study centers: Washington County, 
MD; Forsyth County, NC; Jackson, MI; and, Minneapolis, MN.60,61 The initial 
examination occurred from 1987-1989, with participants aged between 45 and 64 years. 
Subsequent examinations occurred in 1990-1992, 1993-1995, 1996-1998, and 2011-2013, 
with the most recent visit (6) beginning in 2016. We analyzed 9,083 individuals of 
European ancestry with genotypes and QT interval phenotypes available in this study at 
baseline. The genotyping of these samples on the Affymetrix genome-wide Human SNP 
Array 6.0, quality control, and imputation to the 1000 Genomes Phase I Integrated 
Release Version 3 haplotype panel are described elsewhere.128,129 We converted 
IMPUTE2 genotype probabilities to PLINK ‘hard’ calls, setting genotypes with 
uncertainty greater than 0.25 to missing, and retaining variants with < 10% missing data, 
a Hardy Weinberg equilibrium test p-value < 1x10-6, and imputation quality score ≥ 0.3, 
(as was done for the GERA study; see above). The phenotypes were analyzed as 
previously described130 with QT residuals generated by adjusting raw QT intervals for 
resting heart rate, age, and sex. Summary statistics were generated for single variants 




GTEx genotypes and expression 
 We analyzed genotypes and expression data from the Genotype-Tissue 
Expression (GTEx) Project (https://www.gtexportal.org/) v6p for the SKAT analysis (see 
below) from the aorta, tibial artery, heart left ventricle, and heart atrial appendage tissues. 
Normalized expression was analyzed for these tissues, with the top three principal 
components, available PEER factors (15-35, depending on sample size), genotyping array 
platform, and sex used as covariates, all available from the GTEx portal. We used SNP-
gene associations from the associated * .v6p.all_snpgene_pairs.txt.gz files from the 
authors’ eQTL analyses. 
 
eQTL enrichment and DAVID analyses: Nat Genet. 201733 
We conducted an eQTL enrichment analysis and an annotation analysis using the 
GERA EUR data as the reference panel for locus definitions based on linkage 
disequilibrium (LD).  
 
The following has been reprinted from the accepted preprint of Hoffmann et al. Nat 
Genet. 201733  
eQTL enrichment analysis 
To carry out tissue-specific eQTL enrichment analysis, we used 44 tissue types 
with at least 70 samples available from the GTex project131 in addition to seven kidney 
eQTLs.132 We used 367 sentinel variants from previously reported SNPs and the three 
discovery stages presented here available in the GERA cohort with MAF>0.001. Next, 
100 sets of 367 random pseudo-sentinel variants were selected matching the MAF to the 
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original 367 (within ±0.5%). Within each set, the selection was done without 
replacement; the match for each variant was selected one at a time, and selection of the 
subsequent variant excluded all previously selected variants, as well as all variants within 
±0.5 Mb of all previously selected variants. 
Enrichment was tested at both the sentinel SNP level and locus level, 
conceptually similar to.122 At the sentinel SNP level, the number of the 367 variants that 
were also eQTLs in any of the 45 tissues was counted. At the locus level, variants in high 
LD (r2 >0.8) with any of the 367 variants were examined for overlap with eQTLs, and if 
at least one variant within the locus was also an eQTL, the locus was counted. 
Subsequently, this was repeated for each of the 100 randomly generated sets to observe if 
an enrichment of eQTLs was visible in the GWAS set. In order to assess which of the 45 
tissues were driving the enrichment, counts were also computed per tissue. For each 
tissue, an upper-tailed p-value for enrichment of the GWAS count was calculated with a 
Z-score computed using the mean and standard deviation of the null distribution for that 
tissue. 
DAVID analysis 
Annotation of genes surrounding the sentinel variants was conducted with 
DAVID 6.8 beta (non-beta was 6 years old).133,134 Genes within a ±0.5Mb window of 
each of the 390 sentinel variants were selected, as defined by GENCODE v19 GTF.135 
Subsequently, those with at least one significant eQTL in tissues identified from the 
previous enrichment analysis were included in the final list for analysis. Functional 
annotation analysis was run on the Homo sapiens background with default annotations in 
the categories of disease, functional categories, gene ontology, pathways, and protein 
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domains, as well as with default parameters, retaining terms with at least two assigned 
genes. Annotation terms meeting Benjamini-Hochberg P<0.05 (adjusting for the number 
of terms) were considered significant. 
End of reprint 
 
Partitioned heritability analyses 
 We used the stratified LD score regression method and software136 for estimating 
the heritability of the trait partitioned by genomic element using summary statistics for 
SBP and DBP from 80,792 GERA EUR individuals. The mungestats.py script was used 
to format the summary statistics as appropriate, and the baseline model with 53 categories 
which include coding, UTR, and intronic regions, in addition to various open chromatin 
and histone modification annotations as described by the authors, as well as the 1000 
Genomes Phase 3 reference files with the weights from their weights_hm3_no_hla.tgz 
file, which were provided and described by the authors on their website 
(https://github.com/bulik/ldsc/wiki/Partitioned-Heritability), were used to conduct the 
analyses. 
 
Construction of putative regulatory element maps 
 Much of the statistical analyses described here required identification of putative 
enhancers that were active in tissues of interest. Putative regulatory element maps for the 
arteries were constructed using datasets available from ENCODE considered as 
representative of the aorta, tibial artery, and certain parts of the kidney (downloaded May 
23, 2017). Open chromatin regions that were detected by either DNAse-seq or ATAC-seq 
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were taken as putative regulatory elements; for the arteries, enhancer-associated 
H3K27ac or H3K4me1 histone modifications were used to subset those open chromatin 
regions that overlapped and were taken as putative enhancers. We completed this work as 
an extension of previous work in the generation of a cardiac CRE map (Lee et al., 
unpublished). 
As there were no whole aorta open chromatin datasets, we merged five artery 
open chromatin datasets for this tissue, available among the adult tissue datasets from the 
ENCODE project. These included DNase-seq datasets from two aortic cell types (smooth 
muscle (ENCSR000EIH) and adventitia (ENCSR000EMC)) and two pulmonary artery 
cell types (endothelial cell (ENCSR000EOG) and fibroblast (ENCSR000EOH)), as well 
as one ATAC-seq dataset from whole tibial artery (ENCSR630REB). The tibial artery 
dataset was available in raw FASTQ format at the time of download, and was processed 
using the Kundaje lab protocol (https://github.com/kundajelab/atac_dnase_pipelines), 
with the exception of the BAM processing steps, including sorting, cleaning, duplicate 
marking and alignment filtering, retaining reads with quality score >30 and if properly 
paired, with samtools137 v1.3 and Picard Tools138 v2.9.2, which were completed as 
described in (https://github.com/tobiasrausch/ATACseq/blob/master/src/atac.sh). We 
used five whole, ascending, or thoracic aorta H3K27ac datasets (ENCSR069UMW, 
ENCSR015GFK, ENCSR318HUC, ENCSR519CFV, and ENCSR322TJD).  
For tibial artery, we used the tibial artery ATAC-seq dataset that was also used as 
a subset of the open chromatin regions for aorta above (ENCSR630REB), as well as one 
H3K4me1 dataset available for whole tibial artery (ENCSR233LCT). The peak calling 
for the H3K4me1 dataset was redone from the available filtered BAM file with MACS2 
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with the --broad option to call broad peaks, using the parameters q=0.05 for the narrow 
peak cutoff, and q=0.2 for the broad peak cutoff, with extension size 400 bases. 
While no whole kidney open chromatin data were available, there were four cell 
types available from the ENCODE project from adult/non-fetal data: renal cortical 
epithelial cell (ENCSR000EOK), glomerular endothelial cell (ENCSR000EOM), 
epithelial cell of the proximal tubule (ENCSR000EPW), and glomerular visceral 
epithelial cell from a 3-year-old child (ENCSR785BDQ). No histone modification data 
were used, so open chromatin regions were considered as putative regulatory regions as a 
whole category. 
 For all experiments, where replicates were available, the one with the fewer peaks 
called was used as the reference replicate with peaks overlapping the replicate within 
each experiment retained. The artery open chromatin peaks were merged with the 
bedtools v2.26 merge utility.139 To prepare the open chromatin regions for each tissue for 
training with gkm-SVM, we selected 600bp regions to represent each putative regulatory 
element. Peaks shorter than 600bp were extended 300bp from the midpoint, and peaks 
longer were subset to the 600bp region with the maximum signal over all combined 
datasets for each tissue. The five H3K27ac datasets for aorta were merged using bedtools 
merge, and the peaks from this merged set and the tibial artery H3K4me1 dataset were 
extended by 100 bases in both directions, as we considered the boundaries of histone 
modification peaks to be inexact.140,141 We retained those open chromatin regions 
overlapping a histone modification peak (after the 100bp extension) by at least 50% for 
training for the aorta and tibial arteries. Nearly all the datasets were available on genome 
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build hg38, so these analyses were carried out on this build and then lifted over to hg19 
for compatibility with downstream analyses. 
 
Generation of deltaSVM scores 
 Each set of peaks (hg19 build) for the six tissues or cell types (aorta, tibial artery, 
and each of the four kidney cell types) was used as a positive training set to build gkm-
SVM models,142 as described in other work142–144 with some modifications. The LS-
GKM145 software with the default parameter set was used for training.  Regions from 
chromosome 9 were excluded from the training and used for evaluating the adequacy of 
the trained models.  The final models were generated by averaging gkm-SVMs from 10 
independent negative training sets for each of the tissues or cell types. Subsequently, for 
each tissue or cell type, a deltaSVM score was calculated for each of 10,041,372 variants 
from the 1000 Genomes European-ancestry population, defined as the difference in gkm-
SVM scores for reference and alternate alleles for that variant, as previously described.48 
 
Gene-based testing with SKAT 
We used the sequence-kernel association test (SKAT)43 within the SKAT R 
package146 to test genes with median RPKM ≥ 0.3 in GTEx samples for the aorta (n=197) 
and tibial (n=285) arteries with their respective variant sets. For each gene, we tested all 
variants within 50Kb of the gene start or end, inclusive of the entire gene body, per 
GENCODE v19 annotations (https://www.gencodegenes.org/releases/19.html). The 
weights used were taken as the absolute value of the deltaSVM score for each variant to 
reflect its predicted impact; for comparison, we also ran SKAT using default weights 
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with beta density parameters (weights.beta=c(1,25), which up-weights rare variants as 
compared to common variants), as well as equal weights to all variants 
(weights.beta=c(1,1)). We tested association of each gene with adjusted SBP and DBP 
phenotype residuals (see above), as well as the GTEx normalized expression data with 
covariates (release v6p, https://www.gtexportal.org/), from the aorta and tibial arteries. 
We restricted our primary analyses in each of the kidney cell types to the 20 monogenic 
genes. We additionally tested tissue- or cell-type-specific groupings in the ARIC dataset 
with the adjusted QT interval phenotype using the sets for the heart and heart tissues from 
GTEx, arteries and kidney cell types, as described above. 
 
Prediction of gene expression association with blood pressure 
We used the MetaXcan127 software with prebuilt HapMap training models for the 
GTEx (https://www.gtexportal.org/) tissues aorta and tibial arteries, provided by the 
authors at http://predictdb.hakyimlab.org/, with summary statistics from 80,792 GERA 
EUR individuals for SBP and DBP. We also used the software with the provided models 
for heart left ventricle and atrial appendage, for the QT interval phenotype analysis using 
summary statistics from 9,083 ARIC EUR individuals. MetaXcan is an extension of the 
PrediXcan147 method, which predicts gene expression from genotypes and tests 
association of predicted expression with phenotypes using summary association results.  
 
Statistical significance 
Significance was determined for analysis using the Bonferroni method for 
multiple test correction to adjust for the number of genes within each analysis. We made 
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no additional adjustment for the number of tissues, in part due to the correlation of 
specific subsets (the arteries, and individual kidney cell types), and as we examined genes 
across multiple analyses, for phenotype and for expression, to note their significance. 
 
Results 
 We conducted several tissue-specific analyses to identify tissues and genes of 
interest for BP regulation in the GERA study. We initially focused on identifying tissues 
relevant to BP GWAS loci, and subsequently expanded on this by using tissue-specific 
information to analyze putative cis-regulatory variation of genes in these tissues to 
identify specific genes and variants of interest at these loci. We also studied putative 
regulatory variation of 20 monogenic genes in several kidney cell types. These analyses 
are described below. 
 
The following has been reprinted from the accepted preprint of Hoffmann et al. Nat 
Genet. 201733  
Expression Quantitative Trait Loci analysis in different tissues and enrichment 
analysis for functional elements 
We next investigated whether the previously identified and all newly identified 
loci (367 sentinel variants with MAF>0.001), co-localized with Expression Quantitative 
Trait Loci (eQTLs) in certain tissues. We used eQTLs from 44 Genotype-Tissue 
Expression (GTEx) tissues and kidney eQTLs.131,132 Across all tissues, there are 186 
significant eQTLs at the sentinel level, and 213 at the locus level. We determined for 
each tissue whether the number of eQTLs observed (either by sentinel SNP or by locus) 
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was greater than expected by chance, where expectation was derived from a random 
sampling of SNPs and loci (see Online Methods). We ranked the tissues by eQTL P 
value, both for the sentinel SNP and locus analysis. As tissues with higher numbers of 
eQTLs are generally expected to overlap SNP sets to a greater degree, it may be expected 
that enrichment is greater in the tissues with the highest number of eQTLs simply 
because of chance overlap with the GWAS set, especially when eQTLs in tissues relevant 
to the phenotype are also found in these tissues. To observe whether the enrichment 
visible for a given tissue is greater than what we expect relative to the total number of 
eQTLs it contains, we examined the relationship between P value and total eQTL count 
per tissue  (Figure 1). We observed that the aorta and tibial artery are clear outliers as 
compared to the other tissues, even accounting for total number of eQTLs in those 
tissues. 
 
Enrichment analysis for functional elements 
We subsequently investigated whether the genes near the sentinel variants are 
enriched for certain functional pathways. We included genes within ±0.5Mb of the 390 
sentinel variants with a significant eQTL in either of the two tissues identified above 
(aorta and tibial artery). We identified 2,013 genes near all 390 sentinel variants (see 
Online Methods) and tested for enrichment of functional annotations. Using DAVID 
6.8,133,134 1,480 had annotations available, producing 26 significant annotation terms 
(Benjamini-Hochberg P<0.05, Table 1), without a clear functional pathway emerging. 




Partitioned heritability of BP 
 We examined BP heritability for SBP and DBP for 80,792 GERA EUR subjects 
with stratified LD score regression (LDSC) across several functional categories136 to 
identify functional categories in which BP heritability was enriched, and found that the 
top-ranked categories of enrichment were those of enhancer-associated histone marks 
H3K27ac, H3K4me1, and the Hnisz “super-enhancer” category (Tables 2-3). This is in 
accordance with a previous study in which BP heritability was determined to be mostly 
from within DNaseI hypersensitivity sites,6 and, taken together with the results of the 
eQTL enrichment analyses, supports the study of regulatory elements in specific tissues 
of interest for BP. 
 
Tissue-specific identification of candidate genes 
With knowledge of tissues highly relevant to characterizing BP GWAS loci, our 
next aim was to test each gene’s putative cis-regulatory variation for association with 
both blood pressure and expression, in a tissue-specific context. This is expected to assist 
in identifying novel genes of interest, as well as provide tissue- or cell-type-specific 
information about known genes.  
We first constructed putative regulatory element maps for the aorta and tibial 
arteries, as well as four kidney cell types (renal cortical epithelial cell, glomerular 
endothelial cell, epithelial cell of proximal tubule, and glomerular visceral epithelial cell), 
because of the involvement of the kidney in blood pressure regulation, using data from 
the ENCODE project (Table 4). These were completed as an extension of the 
construction of a cardiac putative regulatory element map in our previous work (Lee et 
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al., unpublished). We specifically focused on identifying putative enhancers for the aorta 
and tibial arteries (see Methods). We subsequently used these maps for training with the 
software gkm-SVM, in order to generate deltaSVM functional scores for all variants from 
the 1000 Genomes European population, to be tested for association on a gene-level 
basis. The performance for each model was as follows: aorta, AUC=0.88 trained on 
61,083 peaks; tibial artery, AUC=0.84 trained on 117,994 peaks, renal cortical epithelial 
cell, AUC=0.97 trained on 108,858 peaks; glomerular endothelial cell, AUC=0.96 trained 
on 55,191 peaks; epithelial cell of proximal tubule, AUC=0.96 trained on 76,889 peaks; 
and glomerular visceral epithelial cell, AUC=0.96 trained on 70,934 peaks. A possible 
reason for the improved performance of the renal cell types is that open chromatin 
regions from individual cell types were used, which may have been optimal for training, 
whereas the mixture of cell types comprising the arteries may have affected the 
performance due to biological complexity. The magnitude of the deltaSVM score for a 
variant reflects its predicted impact on regulatory functional activity, while its sign 
reflects the prediction with respect to the reference or alternate alleles. Therefore, to 
represent the predicted impact of each variant irrespective of allele, we show the 
distributions of the absolute values of the deltaSVM scores for the arteries and kidney 
cell types in Figure 2.  
As our emphasis in this section is to connect a gene’s putative CRE variants to 
both a phenotype of interest and to its expression in relevant tissues (see Figure 3 for a 
schematic describing the BP association analyses), we first describe the overall analysis 
scheme as applied to a general phenotype of interest. We then describe how we applied 
these analyses, first to the QT interval in the ARIC study, as proof of principle to 
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demonstrate the utility of these analyses, and then to our BP traits of interest in the 
GERA study.  
We defined a gene’s “cis”-regulatory variants in this analysis as those variants 
falling in putative CREs within 50Kb of the gene’s start and end, and tested the aggregate 
effect of these CRE variants for each gene using SKAT,43 for association with the 
phenotype(s) of interest in the relevant population, which were SBP and DBP in the 
GERA study, and QT interval in the ARIC study. SKAT is a test that has generally been 
used to study groups of variants together and is useful when variants can have 
bidirectional effects; rare variants are more highly weighted than common variants by 
default. In addition to the default weights, we ran the analysis using equal weights for all 
variants. We finally used the tissue- or cell-type-specific deltaSVM scores for the 
analyzed variants as weights for a custom SKAT test; the greater an effect the variant is 
predicted to have on functional regulatory activity, the higher the score. 
We then tested these groupings with expression data from GTEx v6p in the 
tissues of interest to link variants in the genes of interest to their expression in the 
relevant tissues. The groupings tested in the GTEx data with expression were not always 
identical to the groupings tested in the GERA or ARIC studies because of differences in 
imputation quality score filtering, missingness of genotypes from genotype probabilities 
to hard call conversion, and variants present in the reference populations studied. 
However, this analysis still connects a given gene to its expression and to the phenotype 
via a highly overlapping set of putative proximal regulatory variants, and was completed 
this way to test the most complete set of variants available meeting our criteria, in each of 
the datasets. In addition to testing putative regulatory variants with gene expression in 
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GTEx, we used the recently developed MetaXcan127 software to augment the SKAT 
results and to identify any new associations by this method. This software predicts the 
association of gene expression with the phenotype given genotypes for the population of 
interest based on training from reference genotypes and expression data. 
 As mentioned earlier, we considered the cardiac trait QT interval first to 
demonstrate proof of concept for tissue-specific gene identification. The QT interval is 
the measurement between the Q and T waves in the electrical conduction system in the 
heart148 with about ~30% heritability.149–152 Two of the genes with major effects as 
estimated through a GWAS that have also been implicated and functionally validated in 
the heritability of QT interval are NOS1AP152–154 and SCN5A,154,155 and so are the focus 
for this particular analysis. We analyzed the association of the QT interval adjusted for 
heart rate, age, and sex at baseline in 9,083 ARIC EUR individuals with putative CRE 
variants in the SCN5A and NOS1AP genes using SKAT and MetaXcan; these results are 
depicted in Tables 5-6. The tissues available from GTEx that we considered to be of 
relevance for QT interval for expression analyses are the heart left ventricle and atrial 
appendage tissues; for comparison, we also show the six tissues or cell types we analyzed 
in this study for blood pressure in these tables. A heart-specific effect is visible for 
SCN5A (deltaSVM p, p.SKAT.qt.dsvm =4.86 x 10-4; equal weighting p, 
p.SKAT.qt.eq=1.65 x 10-4) and not for the arteries or kidney cell types (Table 5); a much 
larger number of variants were analyzed for heart as there are more open chromatin 
regions within and immediately surrounding the gene in the heart compared to other 
tissues. The association with expression is not visible here, however. The NOS1AP gene 
shows a strong signal across all tissue/cell types (Table 6), indicating the presence of 
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individual variants driving the signal in open chromatin regions across all of the analyzed 
tissue/cell types. However, it is interesting to note that the SKAT analysis in GTEx heart 
left ventricle tissue shows the greatest evidence for association 
(p.SKAT.GTEx.dsvm=3.85 x 10-4; p.SKAT.GTEx.eq=1.51 x 10-4), with the next 
strongest signal from tibial artery (p.SKAT.GTEx.dsvm=2.22 x 10-3; 
p.SKAT.GTEx.eq=0.012). The MetaXcan results were uninformative in this case; there 
were no models available for NOS1AP in either heart tissue or for SCN5A in heart left 
ventricle (p.MetaXcan=0.011 in heart atrial appendage). 
 Considering both sets of effects, certainly variants with detectable signals present 
in open chromatin regions specific to the relevant tissue/cell types will allow the 
detection of a tissue-specific signal, as for SCN5A. It also appears, however, that gene-
level signals may be captured by analyses in which all variants are weighted equally, and 
when local open chromatin boundaries across tissues/cell types overlap considerably, 
especially when variants with strong signals are present within these shared regions, we 
will not necessarily be able to differentiate between different tissue/cell types. Weighting 
with the tissue-specific deltaSVM scores introduces an additional tier of tissue specificity 
and is based on global open chromatin differences. While we see some of this difference 
for SCN5A with the ENCSR000EOM results (p.SKAT.qt.dsvm=0.077; 
p.SKAT.qt.eq=0.0013), it is for NOS1AP in particular that we can see that the aorta and 
ENCSR000EOK groupings are down-weighted by ~10 orders of magnitude using 
deltaSVM weights compared to using equal weights. Finally, using the default weights 
shows least concordance with the other two sets of results, indicating that for this 
analysis, rare variants are not driving the signal as compared to common variants. 
	
	 106	
We then applied these analyses to our tissues of interest for BP regulation, which 
included the aorta, tibial artery, and the four kidney cell types, in a subset of 71,404 
unrelated GERA EUR individuals. We tested 14,035 genes expressed at RPKM ≥ 0.3 in 
197 aorta GTEx samples and 13,920 genes expressed at RPKM ≥ 0.3 in 285 tibial artery 
GTEx samples for the SKAT analyses. We used summary statistics already available 
from 80,792 individuals33 to maximize the sample size for which the MetaXcan analyses 
were run, for the aorta and tibial arteries. Results for each of the arteries are presented in 
Tables 7-10. In some cases, shared variants drive the positive signal for multiple genes at 
the same locus; expression in the relevant tissue or cell type may pinpoint a specific gene. 
However, it may be noted that the genes CERS5, COX14, and RP4-605O3.4 are all 
present at the same locus in the arteries (Tables 7 and 9), but evidence of expression 
association is present for multiple of these genes; this may be indicative of proximal 
variants affecting the different genes, or pleiotropy of single variants affecting the 
expression of multiple genes. 
 While there are several genes in each analysis with interesting associations with 
BP traits, here we highlight six genes that are significant by deltaSVM-weighted SKAT 
in either of the arteries and also have strong expression support, reaching significance 
either from MetaXcan or the analogous GTEx SKAT analysis (using the same deltaSVM 
p-value Bonferroni-determined cutoff as in the phenotype SKAT analysis, with the 
majority of variants tested in the phenotype SKAT analysis also tested in the expression 
SKAT analysis). These include: NOV (tibial artery, DBP); ULK4 (aorta and tibial 
arteries, DBP); SDCCAG8 (aorta, DBP), and CLCN6 (tibial artery, SBP), reaching 
significance in the relevant MetaXcan analyses; additionally, though not significant by 
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MetaXcan but by SKAT in GTEx, are the two genes MTHFR (tibial artery, SBP) and 
C10orf32 (tibial artery, SBP). As previously mentioned, though variant sets tested for 
each gene for association with phenotype and tissue-specific expression were not always 
identical, we examined which variants were driving the signal, as displayed in Tables 11-
12 (aorta and tibial arteries, respectively). Most of these genes (NOV16, ULK426, 
CLCN6100, MTHFR13,28, C10orf3228) are present at or near previously replicated BP 
GWAS loci; SDCCAG8 was identified as part of Hoffmann et al.33 It is noteworthy that 
both CLCN6 and MTHFR are neighboring genes, but have independent expression 
support in the same tissue. 
 We also studied the genes involved in monogenic forms of hypotension or 
hypertension in four kidney cell types available from the ENCODE project: renal cortical 
epithelial cell (ENCSR000EOK), glomerular endothelial cell (ENCSR000EOM), 
epithelial cell of proximal tubule (ENCSR000EPW), and glomerular visceral epithelial 
cell (ENCSR785BDQ). As the expression data available for kidney are insufficient, we 
studied each cell type individually and carried out only SKAT analyses for these genes; 
the results are in Table 13-14. The most notable result is that of CYP17A1, which shows 
an effect (p~10-5 – 10-7) across all four cell types in the un-weighted variants analyses for 
SBP only, and more specifically, only in the glomerular endothelial cell 
(ENCSR000EOM) (p.SKAT.dsvm.ENCSR000EOM=1.26 x 10-7) in the deltaSVM-
weighted results. However, as C10orf32 is a gene of interest at the same locus based on 
the tibial artery results above, we examined and noted that the results are somewhat 
similar for this gene, though not as striking, due to variant set sharing in the SKAT 
analyses for these genes (deltaSVM p-values: ENCSR000EOK, 8 variants, p=1.33 x 10-3; 
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ENCSR000EOM, 12 variants, p=3.87 x 10-5; ENCSR000EPW, 10 variants, p=8.25 x 10-
4; ENCSR786BDQ, 9 variants, p=0.027). The breakdown of individual variants analyzed 
for these two genes is in Table 15. The variant rs3824754, with an SBP association 
p=1.40 x 10-11, appears in the groupings of both genes for all four cell types, but has the 
highest deltaSVM magnitude in the endothelial cell. Additionally, there is a set of four 
variants with SBP association p<1 x 10-4 (rs284853, rs284854, rs284855, rs284856) 
which only appear in the ENCSR000EOM groupings.  We observed that while CYP17A1 
was similarly associated with, or demonstrated evidence of association with, SBP in the 
deltaSVM and unweighted variants analysis (aorta deltaSVM p=1.12 x 10-5, 34 variants; 
tibial artery deltaSVM p=6.78 x 10-8, 15 variants, Table 9), the analysis of variants in 
GTEx (33 variants for aorta and 14 variants for tibial artery) did not reflect any 
significant association (p>0.01). Contrastingly, C10orf32 demonstrated association of 
evidence with SBP (aorta deltaSVM p=1.26 x 10-5, 17 variants; tibial artery deltaSVM 
p=6.73 x 10-8, 8 variants, Table 9) and with expression in GTEx (aorta deltaSVM p=1.22 
x 10-13, 15 variants; tibial artery deltaSVM p=1.87 x 10-14, 7 variants, Table 9). The same 
four variants unique to the ENCSR000EOM groupings above with strong associations 
with SBP are also present in the artery groupings. As is evident from Tables 11 and 12, 
three of these variants (rs284854, rs284855, rs284856) are eQTLs for C10orf32 in the 
aorta and tibial arteries; these variants do not show association with CYP17A1 expression 
in these tissues (all p>0.03 for aorta, all p>0.21 for tibial artery, from eQTL data 
available from the GTEx portal (https://www.gtexportal.org/)). This may reflect an 
endothelial-cell-specific effect for C10orf32 rather than a tissue-type effect, especially as 
this locus has been identified in several previous BP GWAS studies,26,28,156,157; it may 
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also not be very informative for the kidney, though suitable expression data for kidney 
would be required to assess this. 
 
Discussion 
 Our combined analyses identify two specific potential tissues – the aorta and tibial 
arteries – relevant to blood pressure regulation. We have also subsequently identified 
several genes with regulatory variants linking significantly to BP traits and to expression 
data, most at previously replicated BP loci. Although the involvement of the kidney is 
well established in BP regulation, given the systemic nature of hypertension, we sought 
to identify genes at any of the hundreds of BP GWAS loci in a tissue-specific manner, by 
taking advantage of the additional information provided by tissue-specificity. We 
examined groupings of multiple proximal and putatively causal variants defined around 
genes within a single tissue in order to identify specific genes of interest. 
 We identified six genes of interest using artery-specific information: NOV, ULK4, 
SDCCAG8, C10orf32, CLCN6, and MTHFR. In addition to its role in the progression of 
various cancers, the NOV gene has been identified as a player in angiogenesis158,159 and 
vascular homeostasis.160 The ULK4 gene has been previously associated with DBP,26 and 
variation in this gene has also been associated with aortic disease and acute aortic 
dissections.161 Associations of rare variants in the gene CLCN6, encoding a chloride 
channel, have been identified with BP.100 Additionally, the association of a homozygous 
variant (C677T) in its neighboring gene, MTHFR, has also been associated with BP and 
vascular disease162–165; more generally, this locus has been identified in large BP 
GWAS.13,28 The locus including C10orf32 has been identified previously28 and neighbors 
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the well-studied gene CYP17A1. Though we initially examined only the latter among 
kidney cell types because of its known role in monogenic hypertension, we note that both 
genes show BP association in endothelial contexts, but it is C10orf32 that has strong 
expression support in the arteries in our study, while CYP17A1 does not, and remains to 
be characterized.166 Finally, the gene SDCCAG8 is a centrosomal protein linked with 
nephronophthisis-related ciliopathies (OMIM: Senior-Loken Syndrome 7, 613615; 
Bardet-Biedl syndrome-16, 615993, and Airik et al.167), and is expressed in the kidney 
and lung epithelia.167  
 The MetaXcan software has supported most of these genes highlighted here and 
identified novel associations, although there were some limitations with the availability 
of the models for all genes. Additionally, our results indicated that deltaSVM weighting 
might be validly discriminatory between cell types; this is most evident with the QT 
interval genes NOS1AP and SCN5A, and is suggestive of cell-type specificity with the 
results for CYP17A1 in the kidney cell types. It may be informative moving forward to 
characterize these genes at the individual cell-type level in the arteries as well. 
 Our attempts to expand findings with respect to the 20 genes involved in 
monogenic forms of hypertension or hypotension were inconclusive. We attribute this to 
the dearth of public data available for the kidney at this time, and expect that the future 
availability of such data will resolve some of the issues in further studies. 
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Figure 1. Tissue specific expression quantitative trait loci (eQTL) analysis of 45 tissues. 
The two outlier tissues, accounting for total eQTL count, are labeled. Tissue total eQTL 
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Figure 2. Distributions of absolute value of deltaSVM scores in arteries and kidney cell 







Figure 3. Schematic of BP association analyses in this study. We test association of 
groups of variants present within open chromatin regions within 50Kb of the gene start or 
end with both the gene’s measured expression in the tissues of interest in GTEx, and with 




Chapter 4 Tables 
 
 
Table 1. DAVID enrichment analysis. 
 
Category Term Count % 
List 






UP_KEYWORDS Alternative splicing 846 57.2 1328 10581 20042 1.21 1.50 x 10-14 
UP_SEQ_FEATURE splice variant 616 41.6 1316 7761 20064 1.21 1.30 x 10-6 
UP_KEYWORDS Polymorphism 901 60.9 1328 12023 20042 1.13 1.50 x 10-7 
UP_KEYWORDS Phosphoprotein 595 40.2 1328 7493 20042 1.2 1.20 x 10-6 
UP_KEYWORDS Acetylation 301 20.3 1328 3426 20042 1.33 6.80 x 10-6 
UP_SEQ_FEATURE sequence variant 906 61.2 1316 12444 20064 1.11 9.60 x 10-5 
GOTERM_CC_DIRECT GO:0016020~membrane 181 12.2 1226 1901 17701 1.37 0.0034 
GOTERM_CC_DIRECT GO:0005813~centrosome 55 3.7 1226 416 17701 1.91 0.0018 
UP_KEYWORDS Protein transport 69 4.7 1328 606 20042 1.72 0.0013 
GOTERM_MF_DIRECT 
GO:0005515~protein 
binding 676 45.7 1150 8706 16483 1.11 0.017 
UP_KEYWORDS Golgi apparatus 84 5.7 1328 806 20042 1.57 0.0031 
UP_KEYWORDS Transit peptide 61 4.1 1328 533 20042 1.73 0.0027 
UP_KEYWORDS Cell division 47 3.2 1328 378 20042 1.88 0.0029 
GOTERM_CC_DIRECT 
GO:0005774~vacuolar 
membrane 7 0.5 1226 12 17701 8.42 0.015 
UP_KEYWORDS Nucleotide-binding 158 10.7 1328 1774 20042 1.34 0.0045 
UP_KEYWORDS Cytoplasm 373 25.2 1328 4750 20042 1.19 0.0042 
UP_KEYWORDS Proteomics identification 204 13.8 1328 2405 20042 1.28 0.0054 
KEGG_PATHWAY 
hsa04022:cGMP-PKG 
signaling pathway 26 1.8 487 162 6891 2.27 0.041 
	
	 117	
UP_KEYWORDS Cytoskeleton 105 7.1 1328 1112 20042 1.43 0.0082 
UP_KEYWORDS Transport 169 11.4 1328 1965 20042 1.3 0.01 
UP_KEYWORDS Mitochondrion 103 7 1328 1103 20042 1.41 0.013 
UP_KEYWORDS Endoplasmic reticulum 99 6.7 1328 1057 20042 1.41 0.014 
UP_KEYWORDS ATP-binding 124 8.4 1328 1384 20042 1.35 0.013 
UP_KEYWORDS Oxidoreductase 59 4 1328 571 20042 1.56 0.022 
UP_KEYWORDS Coiled coil 215 14.5 1328 2649 20042 1.22 0.023 
UP_KEYWORDS Cell cycle 64 4.3 1328 640 20042 1.51 0.026 
%, percent of total genes assigned to term; Count, number of genes in analysis assigned to term; List Total, all genes in analysis with 
category annotation; Enrichment, ((Count)/(List Total))/((Pop Hits)/(Pop Total))  
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Table 2. Partitioned heritability results from baseline model for SBP 
 
Category Prop_SNPs Prop_h2 (SE) 
Enrichment 
(SE) Enrichment_p 
H3K27ac_Hnisz.extend.500.bedL2_0 0.23 0.79 (0.05) 1.88 (0.12) 3.39 x 10-11 
Conserved_LindbladToh.extend.500.bedL2_0 0.42 0.74 (0.06) 2.23 (0.19) 1.13 x 10-9 
H3K4me1_Trynka.extend.500.bedL2_0 0.39 0.98 (0.05) 1.62 (0.09) 2.00 x 10-9 
H3K4me1_Trynka.bedL2_0 0.72 1.03 (0.10) 2.43 (0.24) 1.05 x 10-8 
SuperEnhancer_Hnisz.extend.500.bedL2_0 0.17 0.35 (0.03) 2.05 (0.17) 2.25 x 10-8 
SuperEnhancer_Hnisz.bedL2_0 0.61 0.36 (0.03) 2.17 (0.20) 2.61 x 10-8 
Repressed_Hoffman.extend.500.bedL2_0 0.33 0.47 (0.05) 0.65 (0.06) 1.64 x 10-7 
H3K9ac_Trynka.extend.500.bedL2_0 0.13 0.55 (0.06) 2.40 (0.28) 1.59 x 10-6 
H3K27ac_Hnisz.bedL2_0 0.03 0.64 (0.05) 1.64 (0.13) 2.60 x 10-6 
Conserved_LindbladToh.bedL2_0 0.26 0.38 (0.08) 14.64 (2.98) 7.71 x 10-6 
H3K4me3_Trynka.extend.500.bedL2_0 0.17 0.56 (0.07) 2.21 (0.26) 1.00 x 10-5 
H3K9ac_Trynka.bedL2_0 0.42 0.49 (0.09) 3.88 (0.68) 4.47 x 10-5 
H3K27ac_PGC2.extend.500.bedL2_0 0.34 0.60 (0.06) 1.80 (0.19) 4.75 x 10-5 
Enhancer_Hoffman.extend.500.bedL2_0 0.09 0.31 (0.06) 3.45 (0.64) 2.80 x 10-4 
Enhancer_Hoffman.bedL2_0 0.11 0.26 (0.07) 6.14 (1.56) 1.45 x 10-3 
UTR_3_UCSC.bedL2_0 0.54 0.10 (0.03) 8.76 (2.60) 2.88 x 10-3 
DHS_peaks_Trynka.bedL2_0 0.17 0.49 (0.13) 4.39 (1.18) 4.55 x 10-3 
FetalDHS_Trynka.extend.500.bedL2_0 0.13 0.56 (0.10) 1.99 (0.34) 4.63 x 10-3 
FetalDHS_Trynka.bedL2_0 0.28 0.39 (0.11) 4.61 (1.29) 5.58 x 10-3 
TFBS_ENCODE.extend.500.bedL2_0 0.04 0.61 (0.10) 1.80 (0.28) 6.16 x 10-3 
DHS_Trynka.extend.500.bedL2_0 0.08 0.76 (0.09) 1.53 (0.19) 6.40 x 10-3 
H3K27ac_PGC2.bedL2_0 0.27 0.48 (0.08) 1.79 (0.31) 0.012 
DHS_Trynka.bedL2_0 0.17 0.50 (0.13) 2.99 (0.79) 0.012 
DGF_ENCODE.extend.500.bedL2_0 0.4 0.75 (0.09) 1.40 (0.16) 0.015 
Intron_UCSC.bedL2_0 0.01 0.47 (0.04) 1.22 (0.09) 0.017 
TFBS_ENCODE.bedL2_0 0.34 0.42 (0.13) 3.22 (0.97) 0.024 
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H3K4me1_peaks_Trynka.bedL2_0 0.04 0.48 (0.14) 2.85 (0.82) 0.025 
H3K9ac_peaks_Trynka.bedL2_0 0.04 0.24 (0.09) 6.14 (2.28) 0.027 
Transcribed_Hoffman.extend.500.bedL2_0 0.01 0.63 (0.06) 0.82 (0.08) 0.028 
Intron_UCSC.extend.500.bedL2_0 0.13 0.45 (0.03) 1.15 (0.08) 0.052 
TSS_Hoffman.bedL2_0 0.01 0.09 (0.04) 5.19 (2.38) 0.081 
Coding_UCSC.bedL2_0 0.03 0.06 (0.03) 4.26 (2.29) 0.157 
PromoterFlanking_Hoffman.extend.500.bedL2_0 0.46 -0.02 (0.04) -0.67 (1.17) 0.157 
PromoterFlanking_Hoffman.bedL2_0 0.06 -0.03 (0.03) -4.18 (3.88) 0.179 
H3K4me3_Trynka.bedL2_0 0.5 0.24 (0.08) 1.78 (0.59) 0.186 
H3K4me3_peaks_Trynka.bedL2_0 0.03 0.15 (0.08) 3.56 (1.99) 0.201 
Promoter_UCSC.extend.500.bedL2_0 0.14 0.07 (0.03) 1.89 (0.73) 0.228 
Coding_UCSC.extend.500.bedL2_0 0.02 0.11 (0.04) 1.73 (0.61) 0.231 
UTR_3_UCSC.extend.500.bedL2_0 0.39 0.06 (0.03) 2.22 (1.06) 0.249 
Repressed_Hoffman.bedL2_0 0.04 0.34 (0.12) 0.73 (0.26) 0.295 
CTCF_Hoffman.extend.500.bedL2_0 0.02 0.01 (0.06) 0.18 (0.85) 0.331 
DGF_ENCODE.bedL2_0 0.76 0.26 (0.12) 1.88 (0.92) 0.339 
WeakEnhancer_Hoffman.extend.500.bedL2_0 0.02 0.12 (0.07) 1.40 (0.74) 0.590 
Enhancer_Andersson.extend.500.bedL2_0 0.07 0.00 (0.03) 0.15 (1.68) 0.614 
TSS_Hoffman.extend.500.bedL2_0 0.02 0.05 (0.04) 1.49 (1.06) 0.646 
CTCF_Hoffman.bedL2_0 0 0.05 (0.06) 2.11 (2.46) 0.652 
WeakEnhancer_Hoffman.bedL2_0 0.09 0.00 (0.05) 0.16 (2.35) 0.720 
UTR_5_UCSC.extend.500.bedL2_0 0.03 0.02 (0.03) 0.64 (1.23) 0.771 
Transcribed_Hoffman.bedL2_0 0.35 0.32 (0.11) 0.93 (0.31) 0.811 
Promoter_UCSC.bedL2_0 0.01 0.04 (0.04) 1.22 (1.32) 0.865 
Enhancer_Andersson.bedL2_0 0.03 0.00 (0.03) 0.35 (5.88) 0.911 
UTR_5_UCSC.bedL2_0 0.03 0.00 (0.02) 0.64 (3.62) 0.921 
baseL2_0 1 1.00 (0.00) 1.00 (0.00) - 




Table 3. Partitioned heritability results from baseline model for DBP 
 
Category Prop_SNPs Prop_h2 (SE) 
Enrichment 
(SE) Enrichment_p 
H3K9ac_Trynka.extend.500.bedL2_0 0.23 0.73 (0.07) 3.19 (0.29) 1.97 x 10-12 
H3K27ac_Hnisz.extend.500.bedL2_0 0.42 0.80 (0.06) 1.90 (0.14) 7.02 x 10-10 
H3K27ac_Hnisz.bedL2_0 0.39 0.76 (0.06) 1.94 (0.15) 2.13 x 10-9 
Repressed_Hoffman.extend.500.bedL2_0 0.72 0.44 (0.05) 0.61 (0.07) 1.10 x 10-8 
SuperEnhancer_Hnisz.extend.500.bedL2_0 0.17 0.36 (0.03) 2.12 (0.19) 1.76 x 10-8 
H3K4me1_Trynka.extend.500.bedL2_0 0.61 0.97 (0.06) 1.60 (0.10) 3.30 x 10-8 
Conserved_LindbladToh.extend.500.bedL2_0 0.33 0.73 (0.07) 2.21 (0.22) 6.08 x 10-8 
H3K9ac_Trynka.bedL2_0 0.13 0.59 (0.09) 4.72 (0.69) 1.31 x 10-7 
Conserved_LindbladToh.bedL2_0 0.03 0.40 (0.07) 15.58 (2.85) 2.90 x 10-7 
H3K4me3_Trynka.extend.500.bedL2_0 0.26 0.65 (0.07) 2.53 (0.29) 6.61 x 10-7 
SuperEnhancer_Hnisz.bedL2_0 0.17 0.34 (0.04) 2.05 (0.21) 9.01 x 10-7 
H3K4me1_Trynka.bedL2_0 0.42 0.98 (0.11) 2.31 (0.26) 1.36 x 10-6 
H3K27ac_PGC2.extend.500.bedL2_0 0.34 0.66 (0.07) 1.98 (0.22) 1.14 x 10-5 
Enhancer_Hoffman.extend.500.bedL2_0 0.09 0.35 (0.06) 3.91 (0.67) 2.30 x 10-5 
DHS_peaks_Trynka.bedL2_0 0.11 0.67 (0.13) 6.05 (1.20) 5.30 x 10-5 
DGF_ENCODE.extend.500.bedL2_0 0.54 0.89 (0.09) 1.65 (0.16) 1.54 x 10-4 
H3K4me1_peaks_Trynka.bedL2_0 0.17 0.71 (0.14) 4.17 (0.85) 2.50 x 10-4 
TFBS_ENCODE.bedL2_0 0.13 0.59 (0.12) 4.46 (0.94) 3.96 x 10-4 
FetalDHS_Trynka.extend.500.bedL2_0 0.28 0.62 (0.09) 2.17 (0.32) 4.17 x 10-4 
Enhancer_Hoffman.bedL2_0 0.04 0.30 (0.07) 7.16 (1.75) 4.23 x 10-4 
FetalDHS_Trynka.bedL2_0 0.08 0.52 (0.13) 6.25 (1.51) 5.62 x 10-4 
H3K27ac_PGC2.bedL2_0 0.27 0.57 (0.09) 2.11 (0.34) 1.24 x 10-3 
DHS_Trynka.bedL2_0 0.17 0.64 (0.16) 3.85 (0.94) 2.75 x 10-3 
Intron_UCSC.extend.500.bedL2_0 0.4 0.49 (0.04) 1.23 (0.09) 0.010 
Coding_UCSC.bedL2_0 0.01 0.12 (0.04) 8.40 (3.07) 0.016 
TFBS_ENCODE.extend.500.bedL2_0 0.34 0.60 (0.11) 1.74 (0.31) 0.017 
	
	 121	
H3K4me3_peaks_Trynka.bedL2_0 0.04 0.25 (0.09) 5.91 (2.08) 0.018 
H3K9ac_peaks_Trynka.bedL2_0 0.04 0.25 (0.09) 6.57 (2.35) 0.019 
UTR_3_UCSC.bedL2_0 0.01 0.08 (0.03) 6.73 (2.71) 0.034 
H3K4me3_Trynka.bedL2_0 0.13 0.32 (0.09) 2.37 (0.68) 0.040 
PromoterFlanking_Hoffman.bedL2_0 0.01 -0.06 (0.03) -7.00 (4.13) 0.054 
TSS_Hoffman.extend.500.bedL2_0 0.03 0.11 (0.04) 3.25 (1.19) 0.063 
Repressed_Hoffman.bedL2_0 0.46 0.21 (0.13) 0.47 (0.29) 0.066 
Coding_UCSC.extend.500.bedL2_0 0.06 0.15 (0.05) 2.28 (0.71) 0.068 
DHS_Trynka.extend.500.bedL2_0 0.5 0.69 (0.11) 1.39 (0.22) 0.079 
UTR_5_UCSC.extend.500.bedL2_0 0.03 0.08 (0.03) 3.13 (1.24) 0.082 
DGF_ENCODE.bedL2_0 0.14 0.36 (0.14) 2.63 (1.02) 0.108 
TSS_Hoffman.bedL2_0 0.02 0.09 (0.05) 4.95 (2.54) 0.126 
Intron_UCSC.bedL2_0 0.39 0.45 (0.04) 1.17 (0.11) 0.139 
Promoter_UCSC.extend.500.bedL2_0 0.04 0.09 (0.03) 2.30 (0.90) 0.142 
Enhancer_Andersson.extend.500.bedL2_0 0.02 0.07 (0.03) 3.49 (1.83) 0.179 
Transcribed_Hoffman.extend.500.bedL2_0 0.76 0.69 (0.06) 0.91 (0.08) 0.242 
CTCF_Hoffman.bedL2_0 0.02 0.08 (0.06) 3.56 (2.55) 0.318 
CTCF_Hoffman.extend.500.bedL2_0 0.07 0.01 (0.06) 0.14 (0.91) 0.345 
WeakEnhancer_Hoffman.bedL2_0 0.02 0.07 (0.06) 3.34 (2.81) 0.409 
Enhancer_Andersson.bedL2_0 0 0.03 (0.03) 6.06 (7.09) 0.475 
WeakEnhancer_Hoffman.extend.500.bedL2_0 0.09 0.13 (0.06) 1.47 (0.73) 0.522 
Promoter_UCSC.bedL2_0 0.03 0.05 (0.04) 1.58 (1.33) 0.663 
Transcribed_Hoffman.bedL2_0 0.35 0.32 (0.12) 0.92 (0.34) 0.824 
UTR_5_UCSC.bedL2_0 0.01 0.01 (0.02) 1.37 (4.55) 0.935 
PromoterFlanking_Hoffman.extend.500.bedL2_0 0.03 0.04 (0.04) 1.09 (1.28) 0.946 
UTR_3_UCSC.extend.500.bedL2_0 0.03 0.03 (0.03) 1.03 (1.17) 0.976 
baseL2_0 1 1.00 (0.00) 1.00 (0.00) - 




Table 4. Summary of datasets for analysis in this study. 
 
Study/Project Dataset Description Analysis 
ENCODE Project    
Artery Open Chromatin 
ENCSR000EIH aortic smooth muscle cell Aorta SKAT analyses groupings 
ENCSR000EMC aortic adventitia cell Aorta SKAT analyses groupings 
ENCSR000EOG pulmonary artery endothelial cell Aorta SKAT analyses groupings 
ENCSR000EOH pulmonary artery fibroblast Aorta SKAT analyses groupings 
ENCSR630REB 
tibial artery 
Aorta, Tibial Artery SKAT analyses 
groupings 
Histone Modification 
ENCSR519CFV aorta H3K27Ac Aorta SKAT analyses groupings 
ENCSR015GFK aorta H3K27Ac Aorta SKAT analyses groupings 
ENCSR318HUC aorta H3K27Ac Aorta SKAT analyses groupings 
ENCSR069UMW aorta H3K27Ac Aorta SKAT analyses groupings 
ENCSR322TJD aorta H3K27Ac Aorta SKAT analyses groupings 
ENCSR233LCT 
tibial artery H3K4me1 
Tibial Artery SKAT analyses 
groupings 
Kidney Open Chromatin 
ENCSR000EOK renal cortical epithelial cell Kidney SKAT analyses groupings 
ENCSR000EOM glomerular endothelial cell Kidney SKAT analyses groupings 
ENCSR000EPW proximal tubule epithelial cell Kidney SKAT analyses groupings 
ENCSR785BDQ glomerular visceral epithelial cell (3yo) Kidney SKAT analyses groupings 
GERA Genotypes, BP 
phenotype 71404 European-Ancestry individuals SKAT, BP traits 
Summary statistics 80,792 European-Ancestry individuals 
Partitioned heritability analyses, 
MetaXcan 
ARIC Genotypes, QT interval 9,083 European-Ancestry individuals SKAT, QT interval 
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Summary statistics 9,083 European-Ancestry individuals 





     Aorta 197 samples SKAT, expression (for BP) 
     Tibial Artery 285 samples SKAT, expression (for BP) 
     Heart Atrial 
Appendage 159 samples SKAT, expression (for QT) 
















def N.MetX p.MetX 
Heart 39 4.86 x 10-4 1.65 x 10-4 0.015 - - - - - - 
Heart.LV - - - - 34 0.857 0.405 0.461 - - 
Heart.AA - - - - 34 0.265 0.546 0.310 13 0.011 
Aorta_Artery - - - - - - - - - - 
Tibial_Artery 2 0.682 0.383 0.675 - - - - - - 
ENCSR000EOK 3 0.051 0.218 0.154 - - - - - - 
ENCSR000EOM 6 0.077 1.28 x 10-3 0.099 - - - - - - 
ENCSR000EPW 5 0.076 0.100 0.099 - - - - - - 
ENCSR785BDQ 3 0.215 0.335 0.204 - - - - - - 
N.qt, number of variants analyzed in SKAT analysis of QT in ARIC  
p.qt.*, p-values from SKAT analysis of QT in ARIC with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx  
p.GTEx.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results 
 p.MetX, MetaXcan p-value  
 
LV, left ventricle; AA, atrial appendage; ENCSR000EOK, renal cortical epithelial cell; ENCSR000EOM, glomerular endothelial cell; 
ENCSR000EPW, epithelial cell of proximal tubule; ENCSR785BDQ, glomerular visceral epithelial cell  
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Table 6. NOS1AP SKAT and MetaXcan results for QT interval 
 











10-4 - - - - - - 
Heart.LV - - - - 59 3.85 x 10-4 1.51 x 10-4 0.054 - - 






































10-14 0.012 - - - - - - 
N.qt, number of variants analyzed in SKAT analysis of QT in ARIC  
p.qt.*, p-values from SKAT analysis of QT in ARIC with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx  
p.GTEx.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results 
 p.MetX, MetaXcan p-value  
 
LV, left ventricle; AA, atrial appendage; ENCSR000EOK, renal cortical epithelial cell; ENCSR000EOM, glomerular endothelial cell; 













































10-3 14 0.177 0.070 0.414 4 
2.96 x 
10-9 MetaXcan 




4 0.780 3 
1.27 x 
10-7 MetaXcan 
ARHGAP42 12 0.032 
6.25 x 




3 0.112 35 
2.08 x 
10-7 MetaXcan 
TMEM133 2 0.422 0.193 0.454 2 0.167 0.202 0.170 49 
2.39 x 
10-7 MetaXcan 
IDH2 7 0.026 0.021 0.779 7 0.070 
1.19 x 10-
3 0.685 10 
1.46 x 
10-6 MetaXcan 
ATF1 4 0.064 
5.06 x 









NSF - - - - - - - - 27 
4.08 x 
10-6 MetaXcan 
N.sbp, number of variants analyzed in SKAT analysis of SBP in GERA  
p.sbp.*, p-values from SKAT analysis of BP in GERA with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx 
 p.GTex.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results  



























ATXN2 9 1.99 x 10-13 
9.77 x 
10-11 0.148 11 0.988 0.987 0.937 - - SKAT 
NOV 10 2.40 x 10-8 
1.98 x 
10-8 0.664 7 4.54 x 10-5 
4.04 x 
10-5 1 99 0.102 SKAT 
SH2B3 8 4.49 x 10-8 
3.37 x 
10-10 0.521 9 0.415 0.368 0.988 - - SKAT 
COX14 6 7.58 x 10-8 
7.49 x 
10-7 0.138 4 1.01 x 10-3 
5.97 x 
10-5 0.338 5 
2.77 x 
10-3 SKAT 
CERS5 7 7.66 x 10-8 
1.92 x 
10-6 0.138 5 0.151 0.012 0.494 - - SKAT 
RP4-
605O3.4 7 7.66 x 10-8 
1.92 x 
10-6 0.138 5 0.018 
5.11 x 
10-4 0.425 - - SKAT 
SMARCD1 5 3.12 x 10-7 
3.10 x 
10-6 0.138 4 0.353 0.243 0.308 - - SKAT 
GPD1 5 3.12 x 10-7 
3.10 x 
10-6 0.138 4 0.101 0.251 0.772 - - SKAT 




10-3 3 0.011 0.014 0.842 - - SKAT 











CSK 3 9.49 x 10-7 
8.91 x 
10-7 0.068 3 2.67 x 10-5 
2.49 x 
10-5 0.579 17 
7.93 x 
10-5 SKAT 
ULK3 2 9.93 x 10-7 
9.76 x 
10-7 0.826 3 8.35 x 10-4 
7.02 x 
10-4 0.164 9 
2.09 x 
10-4 SKAT 
SLX4IP 70 1.14 x 10-6 
7.91 x 
10-8 0.198 69 0.497 0.294 0.167 - - SKAT 
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TMEM133 2 0.308 0.369 0.305 2 0.167 0.202 0.170 49 
3.74 x 
10-7 MetaXcan 
ATF1 4 0.048 
2.56 x 







HIST1H2AE 51 0.015 
9.33 x 
10-3 0.429 22 1.82 x 10-3 
1.48 x 
10-3 0.085 13 
1.13 x 
10-6 MetaXcan 
ARHGAP42 12 0.083 
6.59 x 
10-3 0.389 13 8.36 x 10-3 
7.40 x 
10-3 0.112 35 
1.29 x 
10-6 MetaXcan 
SPATA2L 10 9.51 x 10-3 0.028 0.684 11 6.72 x 10-4 
1.03 x 
10-3 0.928 10 
7.70 x 
10-6 MetaXcan 













SDCCAG8 10 6.71 x 10-7 
1.74 x 
10-6 0.359 10 1.99 x 10-6 
2.26 x 





N.dbp, number of variants analyzed in SKAT analysis of DBP in GERA  
p.dbp.*, p-values from SKAT analysis of DBP in GERA with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx 
 p.GTex.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results  






















































































10-6 0.742 11 0.873 0.839 0.633 - - SKAT 
ATP2B1 4 0.452 0.511 0.348 4 1 0.882 0.915 6 
5.82 x 
10-12 MetaXcan 



























10-3 0.096 0.552 3 0.684 0.297 0.760 1 
3.80 x 
10-7 MetaXcan 




10-3 0.834 36 
9.70 x 
10-7 MetaXcan 
ARL17A - - - - - - - - 55 
1.28 x 
10-6 MetaXcan 
MST1 2 0.048 
8.10 x 





















































N.sbp, number of variants analyzed in SKAT analysis of SBP in GERA  
p.sbp.*, p-values from SKAT analysis of BP in GERA with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx 
 p.GTex.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results  














































































10-7 - - SKAT 
HECTD4 2 0.015 0.016 0.077 1 0.860 0.860 0.860 4 
1.46 x 
10-9 MetaXcan 
TMEM133 - - - - - - - - 37 
4.35 x 
10-8 MetaXcan 
SPATA2L 10 0.015 0.015 0.095 12 1.03 x 10-4 
3.79 x 


















5 0.130 7 4.29 x 10-5 
1.73 x 
10-5 0.273 17 
8.08 x 
10-8 MetaXcan 
ARHGAP42 19 0.021 0.028 0.092 20 4.57 x 10-7 
3.14 x 
10-7 0.208 38 
5.06 x 
10-7 MetaXcan 





CDK11A - - - - - - - - 9 
4.82 x 
10-6 MetaXcan 







8 0.731 16 6.91 x 10-6 
7.95 x 











10-3 11 3.34 x 10-13 
3.61 x 





N.dbp, number of variants analyzed in SKAT analysis of DBP in GERA  
p.dbp.*, p-values from SKAT analysis of DBP in GERA with deltasvm (dsvm), eq (equal), or default (def) weights  
N.GTEx, number of variants analyzed in SKAT analysis of expression in GTEx 
 p.GTex.*, p-values from SKAT analysis of expression in GTEx with deltasvm (dsvm), eq (equal), or default (def) weights  
N.MetX, number of variants used in MetaXcan prediction results  





Table 11. Aorta individual variants analyzed from six genes 
 















(0.07) 7.64 x 10-4 0.205 (0.08) 0.013 
CLCN6 rs2151655 0.292 -0.301 0.021 (0.07) 0.769 
-0.034 
(0.05) 0.458 -0.019 (0.05) 0.723 






(0.07) 7.60 x 10-4 0.223 (0.08) 6.85 x 10-3 
CLCN6 rs59375726 0.173 -0.258 0.059 (0.09) 0.492 
-0.013 
(0.06) 0.808 0.052 (0.07) 0.456 






(0.04) 1.04 x 10-3 -0.118 (0.05) 0.022 






(0.07) 6.78 x 10-4 0.235 (0.08) 6.38 x 10-3 






(0.07) 7.43 x 10-4 0.251 (0.08) 3.57 x 10-3 






(0.07) 7.43 x 10-4 0.251 (0.08) 3.57 x 10-3 






(0.07) 6.96 x 10-4 0.223 (0.08) 6.83 x 10-3 
CLCN6 rs55686944 0.048 -0.209 0.066 (0.15) 0.660 0.107 (0.10) 0.272 -0.030 (0.11) 0.788 
CLCN6 rs1572151 0.071 -0.346 0.225 (0.12) 0.072 0.129 (0.08) 0.111 -0.042 (0.09) 0.652 
CLCN6 rs17421511 0.168 1.143 0.082 (0.09) 0.337 0.011 (0.06) 0.848 0.031 (0.07) 0.663 
CLCN6 rs45449597 0.166 0.062 0.070 (0.09) 0.416 0.009 (0.06) 0.866 0.031 (0.07) 0.664 
CLCN6 rs45608437 0.167 -1.696 0.068 (0.09) 0.429 0.008 (0.06) 0.881 0.033 (0.07) 0.640 






(0.04) 2.86 x 10-3 -0.124 (0.05) 0.015 
CLCN6 rs17037388 0.158 -0.060 -0.496 1.46 x -0.260 4.40 x 10-6 0.261 (0.07) 2.29 x 10-4 
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(0.09) 10-8 (0.06) 






(0.07) 5.72 x 10-4 0.240 (0.09) 7.58 x 10-3 






(0.07) 5.54 x 10-4 0.240 (0.09) 7.58 x 10-3 




(0.09) 6.74 x 10-3 0.242 (0.12) 0.047 
CLCN6 rs45460391 0.002 -0.210 0.026 (0.68) 0.970 0.049 (0.44) 0.912 - - 




(0.11) 3.38 x 10-4 0.275 (0.14) 0.044 






(0.06) 2.83 x 10-6 0.250 (0.07) 7.14 x 10-4 




(0.10) 0.169 0.659 (0.14) 4.90 x 10-6 
CLCN6 rs198411 0.140 -0.364 0.048 (0.09) 0.603 
-0.027 
(0.06) 0.646 0.059 (0.07) 0.419 
CLCN6 rs198412 0.083 1.260 0.239 (0.12) 0.037 0.126 (0.07) 0.092 0.005 (0.08) 0.949 
CLCN6 rs198413 0.140 -0.479 0.050 (0.09) 0.584 
-0.029 
(0.06) 0.621 0.059 (0.07) 0.419 
CLCN6 rs198414 0.140 0.415 0.054 (0.09) 0.561 
-0.013 
(0.06) 0.829 0.059 (0.07) 0.419 
CLCN6 rs17350396 0.169 -0.675 0.072 (0.09) 0.398 0.010 (0.06) 0.863 0.021 (0.07) 0.774 
SDCCAG8 rs6662991 0.369 -0.335 0.151 (0.07) 0.025 0.176 (0.04) 5.41 x 10-5 0.311 (0.07) 1.09 x 10-5 
SDCCAG8 rs3904682 0.483 0.138 0.130 (0.06) 0.043 0.169 (0.04) 4.98 x 10-5 -0.396 (0.06) 7.53 x 10-9 
SDCCAG8 rs28599724 0.468 0.820 0.095 (0.07) 0.146 0.164 (0.04) 1.12 x 10-4 -0.378 (0.07) 6.79 x 10-8 
SDCCAG8 rs10926978 0.323 1.826 0.195 (0.07) 
4.37 x 
10-3 0.219 (0.04) 7.17 x 10-7 0.311 (0.07) 1.31 x 10-5 
SDCCAG8 rs6682448 0.323 -1.065 0.194 (0.07) 
4.56 x 
10-3 0.217 (0.04) 9.07 x 10-7 0.307 (0.07) 1.49 x 10-5 
SDCCAG8 rs10926981 0.463 -0.518 0.129 (0.06) 0.043 0.188 (0.04) 5.89 x 10-6 -0.395 (0.06) 5.21 x 10-9 
	
	 135	
SDCCAG8 rs112223723 0.033 -0.373 
-0.066 
(0.18) 0.711 0.139 (0.12) 0.229 -0.128 (0.18) 0.482 
SDCCAG8 rs3006933 0.424 0.239 
-0.092 
(0.07) 0.158 0.001 (0.04) 0.984 0.110 (0.08) 0.149 
SDCCAG8 rs113544916 0.010 0.342 0.466 (0.32) 0.146 0.158 (0.21) 0.448 - - 
SDCCAG8 rs1058305 0.258 0.669 
-0.062 
(0.07) 0.393 0.049 (0.05) 0.301 0.197 (0.08) 0.019 
NOV rs2447155 0.182 -0.133 0.117 (0.08) 0.158 
-0.229 
(0.05) 1.78 x 10-5 -0.222 (0.05) 4.08 x 10-5 
NOV rs75254116 0.018 -0.353 0.094 (0.24) 0.700 0.065 (0.16) 0.680 - - 
NOV rs115372142 0.219 -0.587 0.054 (0.08) 0.482 
-0.281 
(0.05) 1.68 x 10-8 0.230 (0.05) 3.32 x 10-5 
NOV rs16892527 0.018 0.016 0.070 (0.24) 0.772 0.036 (0.16) 0.817 - - 
NOV rs16892528 0.018 -0.582 0.070 (0.24) 0.772 0.036 (0.16) 0.817 - - 
NOV rs17791184 0.220 0.372 0.050 (0.08) 0.516 
-0.279 
(0.05) 1.94 x 10-8 0.230 (0.05) 3.51 x 10-5 
NOV rs73711267 0.238 0.613 0.057 (0.07) 0.447 
-0.261 
(0.05) 6.45 x 10-8 0.229 (0.05) 2.84 x 10-5 
NOV rs61064779 0.220 0.108 0.050 (0.08) 0.512 
-0.281 
(0.05) 1.65 x 10-8 0.230 (0.05) 3.32 x 10-5 
NOV rs144538053 0.006 -0.956 0.640 (0.43) 0.138 0.323 (0.28) 0.247 - - 
NOV rs17188373 0.220 2.089 0.047 (0.08) 0.537 
-0.281 
(0.05) 1.52 x 10-8 0.230 (0.05) 3.32 x 10-5 




10-5 0.000 (0.04) 1.000 0.372 (0.06) 6.07 x 10-10 








3 0.036 (0.09) 0.706 
C10orf32 rs17115073 0.019 0.759 0.184 (0.23) 0.427 0.194 (0.15) 0.196 0.097 (0.17) 0.573 






(0.04) 0.643 0.392 (0.06) 1.15 x 10-10 
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C10orf32 rs34102073 0.015 0.255 0.197 (0.26) 0.445 0.192 (0.17) 0.252 - - 






(0.04) 0.401 0.403 (0.06) 4.28 x 10-11 






(0.04) 0.588 0.403 (0.06) 4.28 x 10-11 






(0.04) 0.592 0.403 (0.06) 4.28 x 10-11 






(0.04) 0.875 0.371 (0.06) 6.40 x 10-10 






(0.06) 1.03 x 10-3 0.036 (0.09) 0.699 
C10orf32 rs14849 0.019 -0.297 0.217 (0.23) 0.347 0.215 (0.15) 0.148 0.103 (0.17) 0.550 
C10orf32 rs6892 0.176 0.621 0.201 (0.08) 0.017 0.072 (0.05) 0.185 0.228 (0.09) 0.012 
C10orf32 rs17523050 0.012 -0.821 0.626 (0.29) 0.032 0.205 (0.19) 0.277 - - 






(0.07) 5.39 x 10-3 -0.092 (0.12) 0.457 
C10orf32 rs12416687 0.253 -0.731 0.035 (0.07) 0.631 0.112 (0.05) 0.019 -0.695 (0.05) 3.80 x 10-26 
C10orf32 rs17881215 0.111 -0.637 
-0.041 
(0.10) 0.687 0.001 (0.07) 0.985 -0.576 (0.09) 1.87 x 10-9 




10-4 0.027 (0.04) 0.535 -0.485 (0.05) 6.22 x 10-17 




(0.25) 0.064 - - 




(0.14) 0.054 - - 




(0.06) 0.845 -0.046 (0.10) 0.651 
ULK4 rs7624877 0.026 0.226 0.167 (0.20) 0.406 0.368 (0.13) 4.73 x 10-3 0.311 (0.17) 0.064 
ULK4 rs73830585 0.150 0.944 
-0.162 
(0.09) 0.068 0.334 (0.06) 6.64 x 10-9 0.923 (0.06) 1.72 x 10-32 
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MTHFR rs6668392 0.009 -1.023 
-0.037 
(0.34) 0.912 0.205 (0.22) 0.347 - - 






(0.07) 7.64 x 10-4 0.219 (0.10) 0.028 
MTHFR rs2151655 0.292 -0.301 0.021 (0.07) 0.769 
-0.034 
(0.05) 0.458 -0.163 (0.06) 0.011 






(0.07) 7.60 x 10-4 0.233 (0.10) 0.020 
MTHFR rs59375726 0.173 -0.258 0.059 (0.09) 0.492 
-0.013 
(0.06) 0.808 0.336 (0.08) 4.59 x 10-5 






(0.04) 1.04 x 10-3 -0.226 (0.06) 2.45 x 10-4 






(0.07) 6.78 x 10-4 0.210 (0.10) 0.044 






(0.07) 7.43 x 10-4 0.213 (0.10) 0.042 






(0.07) 7.43 x 10-4 0.213 (0.10) 0.042 






(0.07) 6.96 x 10-4 0.233 (0.10) 0.020 
MTHFR rs55686944 0.048 -0.209 0.066 (0.15) 0.660 0.107 (0.10) 0.272 0.021 (0.13) 0.872 
MTHFR rs1572151 0.071 -0.346 0.225 (0.12) 0.072 0.129 (0.08) 0.111 -0.026 (0.11) 0.816 
MTHFR rs17421511 0.168 1.143 0.082 (0.09) 0.337 0.011 (0.06) 0.848 0.334 (0.08) 7.24 x 10-5 
MTHFR rs45449597 0.166 0.062 0.070 (0.09) 0.416 0.009 (0.06) 0.866 0.334 (0.08) 7.60 x 10-5 
MTHFR rs45608437 0.167 -1.696 0.068 (0.09) 0.429 0.008 (0.06) 0.881 0.335 (0.08) 7.09 x 10-5 






(0.04) 2.86 x 10-3 -0.238 (0.06) 8.22 x 10-5 






(0.06) 4.40 x 10-6 0.236 (0.09) 6.37 x 10-3 
MTHFR rs3753588 0.098 -0.852 -0.607 1.33 x -0.238 5.72 x 10-4 0.164 (0.11) 0.133 
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(0.11) 10-8 (0.07) 






(0.07) 5.54 x 10-4 0.164 (0.11) 0.133 




(0.09) 6.74 x 10-3 0.303 (0.15) 0.039 
MTHFR rs45460391 0.002 -0.210 0.026 (0.68) 0.970 0.049 (0.44) 0.912 - - 




(0.11) 3.38 x 10-4 0.373 (0.16) 0.023 






(0.06) 2.83 x 10-6 0.244 (0.09) 6.64 x 10-3 




(0.10) 0.169 0.183 (0.18) 0.308 
MTHFR rs198411 0.140 -0.364 0.048 (0.09) 0.603 
-0.027 
(0.06) 0.646 0.009 (0.09) 0.922 
MTHFR rs198412 0.083 1.260 0.239 (0.12) 0.037 0.126 (0.07) 0.092 -0.057 (0.10) 0.566 
MTHFR rs198413 0.140 -0.479 0.050 (0.09) 0.584 
-0.029 
(0.06) 0.621 0.009 (0.09) 0.922 
MTHFR rs198414 0.140 0.415 0.054 (0.09) 0.561 
-0.013 
(0.06) 0.829 0.009 (0.09) 0.922 
MTHFR rs17350396 0.169 -0.675 0.072 (0.09) 0.398 0.010 (0.06) 0.863 0.316 (0.08) 2.16 x 10-4 
SE, standard error; GTEx.slope, GTEx beta from the GTEx authors' FastQTL analyses; GTEx.p.nominal, nominal p-value from GTEx 
authors' FastQTL analyses  
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Table 12. Tibial artery individual variants analyzed from six genes 
 





















(0.06) 2.58 x 10-7 




(0.21) 0.376 - - 













(0.09) 4.88 x 10-5 










(0.06) 1.49 x 10-7 










(0.06) 1.49 x 10-7 










(0.06) 1.26 x 10-7 






(0.09) 4.88 x 10-5 

















(0.04) 4.12 x 10-4 
















CLCN6 rs17037388 0.158 0.233 -0.496 1.46 x -0.260 4.40 x 0.235 1.42 x 10-6 
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(0.09) 10-8 (0.06) 10-6 (0.05) 










(0.06) 9.46 x 10-8 










(0.06) 5.78 x 10-8 










(0.05) 4.14 x 10-8 
























(0.09) 7.75 x 10-5 


















































(0.06) 1.78 x 10-5 








(0.06) 6.40 x 10-6 
SDCCAG8 rs61833906 0.122 0.870 -0.151 0.122 -0.043 0.496 -0.064 0.467 
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(0.10) (0.06) (0.09) 






(0.10) 7.36 x 10-3 




(0.39) 0.558 - - 








(0.05) 3.84 x 10-6 








(0.04) 3.79 x 10-5 






















(0.05) 4.52 x 10-6 








(0.05) 5.94 x 10-6 








(0.05) 4.52 x 10-6 
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ULK4 rs1795313 0.489 0.589 0.014 0.831 -0.012 0.774 -0.004 0.947 
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MTHFR rs1537515 0.097 -0.389 -0.599 2.96 x -0.236 7.43 x 0.185 8.54 x 10-3 
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MTHFR rs198412 0.083 0.045 0.239 0.037 0.126 0.092 -0.082 0.236 
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(0.12) (0.07) (0.07) 




















(0.06) 7.38 x 10-7 
SE, standard error; GTEx.slope, GTEx beta from the GTEx authors' FastQTL analyses; GTEx.p.nominal, nominal p-value from GTEx 





Table 13. Kidney SBP SKAT and MetaXcan results 
 
Gene Experiment N.sbp p.sbp.dsvm p.sbp.eq p.sbp.def 
BSND ENCSR000EOK 13 0.791 0.796 0.611 
CASR ENCSR000EOK 21 0.586 0.794 0.605 
CLCNKA ENCSR000EOK 8 0.491 0.502 0.426 
CLCNKB ENCSR000EOK 9 0.521 0.382 0.454 
CUL3 ENCSR000EOK 18 0.251 0.388 0.049 
CYP11B1 ENCSR000EOK 12 0.019 0.016 1.20 x 10-3 
CYP11B2 ENCSR000EOK 10 0.013 0.014 2.91 x 10-3 
CYP17A1 ENCSR000EOK 7 0.064 1.11 x 10-6 0.018 
HSD11B2 ENCSR000EOK 4 0.121 0.104 0.248 
KCNJ1 ENCSR000EOK 13 0.993 0.958 0.789 
KCNJ5 ENCSR000EOK 11 0.548 0.742 0.982 
KLHL3 ENCSR000EOK 12 0.573 0.431 0.345 
NR3C2 ENCSR000EOK 26 0.317 0.270 0.148 
SCNN1A ENCSR000EOK 7 0.472 0.452 0.767 
SCNN1B ENCSR000EOK 7 0.049 0.310 0.479 
SCNN1G ENCSR000EOK 8 0.187 0.276 1 
SLC12A1 ENCSR000EOK 6 1 0.909 0.713 
SLC12A3 ENCSR000EOK 16 0.316 0.168 0.491 
WNK1 ENCSR000EOK 11 0.366 0.557 0.637 
WNK4 ENCSR000EOK 1 0.010 0.010 0.010 
BSND ENCSR000EOM 12 0.887 0.737 0.562 
CASR ENCSR000EOM 2 0.868 0.790 0.672 
CLCNKA ENCSR000EOM 10 0.678 0.657 0.540 
CLCNKB ENCSR000EOM 10 0.678 0.657 0.540 
CUL3 ENCSR000EOM 8 0.060 0.250 0.044 
CYP11B1 ENCSR000EOM 4 0.019 0.018 0.281 
CYP11B2 ENCSR000EOM 3 0.015 0.015 0.281 
CYP17A1 ENCSR000EOM 11 1.26 x 10-7 2.88 x 10-7 0.013 
HSD11B2 ENCSR000EOM 6 0.029 0.044 0.595 
KCNJ1 ENCSR000EOM 9 0.091 0.554 0.060 
KCNJ5 ENCSR000EOM 6 0.083 0.150 0.163 
KLHL3 ENCSR000EOM 12 0.067 0.012 0.208 
NR3C2 ENCSR000EOM 10 0.254 0.126 0.149 
SCNN1A ENCSR000EOM 5 0.518 0.572 0.727 
SCNN1B ENCSR000EOM 5 0.822 0.930 0.873 
SCNN1G ENCSR000EOM 5 0.374 0.298 0.540 
SLC12A1 ENCSR000EOM 4 0.703 0.896 0.704 
SLC12A3 ENCSR000EOM 12 0.056 0.077 0.245 
WNK1 ENCSR000EOM 7 0.153 0.158 0.864 
WNK4 ENCSR000EOM 1 0.010 0.010 0.010 
BSND ENCSR000EPW 10 0.665 0.702 0.591 
CASR ENCSR000EPW 11 0.638 0.798 0.335 
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CLCNKA ENCSR000EPW 3 0.276 0.203 0.433 
CLCNKB ENCSR000EPW 4 0.231 0.176 0.464 
CUL3 ENCSR000EPW 8 0.033 0.195 0.039 
CYP11B1 ENCSR000EPW 3 0.015 0.015 0.281 
CYP11B2 ENCSR000EPW 5 0.015 0.017 0.488 
CYP17A1 ENCSR000EPW 9 0.012 9.92 x 10-7 0.045 
HSD11B2 ENCSR000EPW 1 0.051 0.051 0.051 
KCNJ1 ENCSR000EPW 7 0.951 0.954 0.411 
KCNJ5 ENCSR000EPW 10 0.522 0.699 0.417 
KLHL3 ENCSR000EPW 8 0.395 0.525 0.428 
NR3C2 ENCSR000EPW 24 0.252 0.189 0.027 
SCNN1A ENCSR000EPW 6 0.496 0.360 0.767 
SCNN1B ENCSR000EPW 7 0.141 0.181 0.482 
SCNN1G ENCSR000EPW 6 0.725 0.565 1 
SLC12A1 ENCSR000EPW 4 1 0.896 0.704 
SLC12A3 ENCSR000EPW 13 0.163 0.116 0.358 
WNK1 ENCSR000EPW 11 0.555 0.515 0.054 
WNK4 ENCSR000EPW 1 0.010 0.010 0.010 
BSND ENCSR785BDQ 10 0.908 0.854 0.668 
CASR ENCSR785BDQ 1 0.465 0.465 0.465 
CLCNKA ENCSR785BDQ 10 0.470 0.606 0.682 
CLCNKB ENCSR785BDQ 11 0.465 0.476 0.695 
CUL3 ENCSR785BDQ 2 0.737 0.314 0.982 
CYP11B1 ENCSR785BDQ 4 0.383 0.353 0.026 
CYP11B2 ENCSR785BDQ 2 0.022 0.026 0.996 
CYP17A1 ENCSR785BDQ 12 7.24 x 10-3 3.93 x 10-5 0.020 
HSD11B2 ENCSR785BDQ 6 0.164 0.067 0.061 
KCNJ1 ENCSR785BDQ 7 0.985 0.879 0.400 
KCNJ5 ENCSR785BDQ 2 1 1 1 
KLHL3 ENCSR785BDQ 10 0.594 0.126 0.888 
NR3C2 ENCSR785BDQ 9 0.299 0.290 0.037 
SCNN1A ENCSR785BDQ 9 0.525 0.700 0.980 
SCNN1B ENCSR785BDQ 4 0.887 1 0.983 
SCNN1G ENCSR785BDQ 6 0.727 0.565 1 
SLC12A1 ENCSR785BDQ 2 0.844 0.848 0.848 
SLC12A3 ENCSR785BDQ 28 0.212 0.440 0.666 
WNK1 ENCSR785BDQ 7 0.259 0.414 0.128 
WNK4 ENCSR785BDQ - - - - 
N.sbp, number of variants analyzed in SKAT analysis of SBP in GERA  
p.sbp.*, p-values from SKAT analysis of DBP in GERA with deltasvm (dsvm), eq 
(equal), or default (def) weights  
 
ENCSR000EOK, renal cortical epithelial cell; ENCSR000EOM, glomerular endothelial 
cell; ENCSR000EPW, epithelial cell of proximal tubule; ENCSR785BDQ, glomerular 
visceral epithelial cell 
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Table 14. Kidney DBP SKAT and MetaXcan results 
 
Gene Experiment N.dbp p.dbp.dsvm p.dbp.eq p.dbp.def 
BSND ENCSR000EOK 13 0.933 0.831 0.061 
CASR ENCSR000EOK 21 0.987 0.986 0.856 
CLCNKA ENCSR000EOK 8 0.155 0.283 0.108 
CLCNKB ENCSR000EOK 9 0.159 0.410 0.137 
CUL3 ENCSR000EOK 18 0.284 0.183 0.855 
CYP11B1 ENCSR000EOK 12 0.102 0.095 0.013 
CYP11B2 ENCSR000EOK 10 0.091 0.094 0.023 
CYP17A1 ENCSR000EOK 7 0.505 0.189 0.337 
HSD11B2 ENCSR000EOK 4 0.030 0.023 0.114 
KCNJ1 ENCSR000EOK 13 0.966 0.879 0.398 
KCNJ5 ENCSR000EOK 11 0.716 0.598 0.487 
KLHL3 ENCSR000EOK 12 0.823 0.922 0.622 
NR3C2 ENCSR000EOK 26 0.731 0.766 0.104 
SCNN1A ENCSR000EOK 7 0.715 0.621 0.599 
SCNN1B ENCSR000EOK 7 3.25 x 10-4 0.012 0.053 
SCNN1G ENCSR000EOK 8 0.095 0.027 0.461 
SLC12A1 ENCSR000EOK 6 0.334 0.259 0.860 
SLC12A3 ENCSR000EOK 16 0.106 0.072 0.175 
WNK1 ENCSR000EOK 11 0.365 0.300 0.442 
WNK4 ENCSR000EOK 1 0.828 0.828 0.828 
BSND ENCSR000EOM 12 0.638 0.776 0.052 
CASR ENCSR000EOM 2 0.884 0.825 0.759 
CLCNKA ENCSR000EOM 10 0.294 0.546 0.133 
CLCNKB ENCSR000EOM 10 0.294 0.546 0.133 
CUL3 ENCSR000EOM 8 0.270 0.266 0.798 
CYP11B1 ENCSR000EOM 4 0.130 0.129 0.689 
CYP11B2 ENCSR000EOM 3 0.101 0.105 0.689 
CYP17A1 ENCSR000EOM 11 0.044 0.076 0.187 
HSD11B2 ENCSR000EOM 6 0.015 0.012 0.387 
KCNJ1 ENCSR000EOM 9 0.098 0.317 0.101 
KCNJ5 ENCSR000EOM 6 0.105 0.499 0.598 
KLHL3 ENCSR000EOM 12 0.900 0.924 0.515 
NR3C2 ENCSR000EOM 10 0.612 0.302 0.072 
SCNN1A ENCSR000EOM 5 0.783 0.709 0.547 
SCNN1B ENCSR000EOM 5 0.792 0.907 0.913 
SCNN1G ENCSR000EOM 5 0.196 0.085 0.920 
SLC12A1 ENCSR000EOM 4 0.107 0.244 0.865 
SLC12A3 ENCSR000EOM 12 7.17 x 10-3 0.044 0.234 
WNK1 ENCSR000EOM 7 0.492 0.589 1 
WNK4 ENCSR000EOM 1 0.828 0.828 0.828 
BSND ENCSR000EPW 10 0.849 0.769 0.062 
CASR ENCSR000EPW 11 0.921 0.845 0.872 
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CLCNKA ENCSR000EPW 3 0.435 0.438 0.367 
CLCNKB ENCSR000EPW 4 0.718 0.639 0.413 
CUL3 ENCSR000EPW 8 0.225 0.085 0.783 
CYP11B1 ENCSR000EPW 3 0.101 0.105 0.689 
CYP11B2 ENCSR000EPW 5 0.096 0.102 0.599 
CYP17A1 ENCSR000EPW 9 0.370 0.185 0.262 
HSD11B2 ENCSR000EPW 1 5.56 x 10-3 5.56 x 10-3 5.56 x 10-3 
KCNJ1 ENCSR000EPW 7 0.796 0.873 0.366 
KCNJ5 ENCSR000EPW 10 0.673 0.546 0.190 
KLHL3 ENCSR000EPW 8 0.819 0.867 0.448 
NR3C2 ENCSR000EPW 24 0.495 0.374 0.032 
SCNN1A ENCSR000EPW 6 0.738 0.446 0.599 
SCNN1B ENCSR000EPW 7 0.080 0.017 0.053 
SCNN1G ENCSR000EPW 6 0.631 0.061 0.297 
SLC12A1 ENCSR000EPW 4 0.403 0.244 0.865 
SLC12A3 ENCSR000EPW 13 0.024 0.050 0.217 
WNK1 ENCSR000EPW 11 0.297 0.173 0.031 
WNK4 ENCSR000EPW 1 0.828 0.828 0.828 
BSND ENCSR785BDQ 10 0.673 0.492 0.062 
CASR ENCSR785BDQ 1 0.967 0.967 0.967 
CLCNKA ENCSR785BDQ 10 0.296 0.457 0.268 
CLCNKB ENCSR785BDQ 11 0.299 0.568 0.303 
CUL3 ENCSR785BDQ 2 0.184 0.040 0.248 
CYP11B1 ENCSR785BDQ 4 0.152 0.134 2.67 x 10-3 
CYP11B2 ENCSR785BDQ 2 0.095 0.107 0.508 
CYP17A1 ENCSR785BDQ 12 0.587 0.218 0.355 
HSD11B2 ENCSR785BDQ 6 0.046 7.76 x 10-3 3.39 x 10-3 
KCNJ1 ENCSR785BDQ 7 0.957 0.795 0.128 
KCNJ5 ENCSR785BDQ 2 1 1 0.875 
KLHL3 ENCSR785BDQ 10 0.785 0.778 0.424 
NR3C2 ENCSR785BDQ 9 0.789 0.784 0.019 
SCNN1A ENCSR785BDQ 9 0.780 0.949 0.925 
SCNN1B ENCSR785BDQ 4 0.310 0.445 0.555 
SCNN1G ENCSR785BDQ 6 0.176 0.061 0.297 
SLC12A1 ENCSR785BDQ 2 0.279 0.282 0.282 
SLC12A3 ENCSR785BDQ 28 0.037 0.415 0.393 
WNK1 ENCSR785BDQ 7 0.799 0.416 0.079 
WNK4 ENCSR785BDQ - - - - 
N.dbp, number of variants analyzed in SKAT analysis of DBP in GERA  
p.dbp.*, p-values from SKAT analysis of DBP in GERA with deltasvm (dsvm), eq 
(equal), or default (def) weights  
 
ENCSR000EOK, renal cortical epithelial cell; ENCSR000EOM, glomerular endothelial 
cell; ENCSR000EPW, epithelial cell of proximal tubule; ENCSR785BDQ, glomerular 
visceral epithelial cell  
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C10orf32/
CYP17A1 
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(0.04) 0.535 - - - -0.152 
C10orf32/
CYP17A1 
SE, standard error 
ENCSR000EOK, renal cortical epithelial cell; ENCSR000EOM, glomerular endothelial cell; ENCSR000EPW, epithelial cell of 




Chapter 5: Conclusions 
 
Hypertension is a complex multigenic disease affected by many genetic as well as 
environmental factors. While the renal physiology of the genes involved in monogenic 
forms of hypertension and hypotension has been studied considerably, their contributions 
to the overall incidence of hypertension is unknown. Additionally, most of the common 
variants with small effects at hundreds of loci associated with blood pressure (BP) remain 
to be characterized at the level of genes and variants in relevant tissues. Therefore, the 
first part of this dissertation has focused on the exome, identifying rare variants in genes 
of interest (Chapters 2 and 3); the second part (Chapter 4) focused on tissues of interest 
and putative regulatory regions, identifying variants of all frequencies as well as specific 
genes, using tissue-specific information. 
 The focus of the study in Chapter 2 was to explain more of the phenotypic 
variation in BP traits and to advance blood pressure genetic findings in a population 
historically underrepresented in blood pressure genetic studies. We genotyped 15,914 
African-ancestry individuals for functionally relevant rare and low-frequency variants 
and identified rare variants in 10 genes. The major limitation in this study was that the 
array was designed primarily from sequences of European-ancestry individuals, which 
most likely contribute to the rare allele frequency of the significant results. Nevertheless, 
a literature search confirmed cardiovascular and related roles for several of these genes 




 Chapter 3 detailed a replication analysis aimed at identifying deleterious rare 
variants in three hypotension genes, SLC12A1, SLC12A3, and KCNJ1, in order to 
determine if a BP-lowering effect could be observed in a new study. If successful, that 
would give way to conducting similar analyses to identify genes in which rare variants 
are responsible for blood pressure variation in the general population. The original study 
was a targeted sequencing study in the Framingham Heart Study (FHS) offspring 
cohort,10 while the replication effort was carried out in the ARIC study with exome 
sequencing data. We observed that, while we could not replicate the effect using all 
variants meeting the original study criteria for loss-of-function variants, we did observe 
similar effects when studying only the subset of variants from the original study also 
appearing in the ARIC data. Several studies following up the FHS study provided 
biochemical evidence of loss-of-function for the FHS variants, while we did not have 
functional follow-up of any of our variants. These results suggest that variants at specific 
sites could be driving the effect; however, due to the presence of sequencing or other 
errors, we may have not been able to identify the cumulative effect of true causal variants 
due to dilution from the presence of false variants. Variants with extremely low allele 
counts are often discarded in sequencing analyses, but this study indicates that such 
effects can still be observed and be biologically relevant, and that with improved 
filtering, and eventually highly accurate sequencing, it will become possible to identify 
all such variants. Furthermore, the evidence suggests the utility of this approach in 
identifying possibly novel genes with rare loss-of-function variants associated with large 
blood pressure effects in the general population. 
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 Renal salt handling mechanisms regulating BP have been well characterized, but 
less is known about other pathways involved in BP regulation. In Chapter 4, we identified 
the aorta and tibial arteries as two tissues of interest for BP GWAS loci, and subsequently 
identified several genes and variants at GWAS loci with strong expression support in 
these tissues. We also examined the 20 monogenic BP syndrome genes in several kidney 
cell types, their suggested tissue of action, for which open chromatin data were available, 
in order to determine the contributions of regulatory variants for these genes. These 
results were largely inconclusive, in no small part due to the limited data available on 
gene regulation in the kidney. However, these analyses revealed a cell-type-specificity of 
C10orf32, residing at the same locus as the CYP17A1 gene and identified in large BP 
GWAS studies.26,28 The CYP17A1 gene has been identified as involved in a monogenic 
BP syndrome as well,168 with variants leading to 17 alpha-hydroxylase deficiency 
resulting in congenital adrenal hyperplasia, a hallmark of which is hypertension.169–171 It 
has also been assumed to be the gene of interest at the GWAS locus166 because of its 
prior functional evidence, but our results show that, while CYP17A1 is important for 
monogenic forms of hypertension, C10orf32 may be the gene playing a role in essential 
hypertension, thereby, via a different mechanism relating to the vasculature. Additionally, 
despite specific evidence ruling out CYP17A1 and supporting C10orf32 in the arteries, 
other genes at this locus must be considered for future studies even in these tissues, 
because of the not infrequent occurrence of eQTLs affecting multiple neighboring genes 
in the same tissue, as seen in Chapter 4 (such as, the MTHFR/CLCN6 and 
CERS5/COX14/RP4-605O3.4 loci). This type of analysis, however, provides a valuable 
starting place to determine genes and variants of interest that can subsequently be studied 
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in greater depth for their functional effects in putatively relevant cell types. Furthermore, 
though the results of the enrichment analysis indicate the arteries as being of interest, the 
adrenal gland is another organ known to be involved in BP regulation.172 Further study of 
this and other tissues or organs may reveal effects of genes specific to these sites of 
action. 
 An additional point of interest is the concurrent support of the ULK4 gene 
associated with DBP from two gene discovery studies in different populations (Chapters 
2 and 4). Though the Illumina HumanExome Beadchip on which the African-ancestry 
individuals were genotyped focused on rare and low-frequency coding variants as 
described in Chapter 2, a small subset of common variants represented on the chip 
replicated several previously associated common variants at this locus. Additionally, we 
found strong evidence for a low frequency coding variant supporting the gene’s 
association with DBP. The analysis in Chapter 4 provided support for the association of 
this gene to DBP in European-ancestry individuals by linking its putative regulatory 
variants to the phenotype and to its expression in arteries. 
 The studies in Chapters 2 and 3 focused primarily on identification of rare 
variants with large effects for blood pressure and hypertension, which is a common 
disease. The Chapter 3 study notably focused on specific variants involved in rare 
syndromes resulting in hypotension (Gitelman and Bartter syndromes), which extends the 
applicability of the analysis and identification of rare variants with larger effects even to 
rare diseases. The analyses in Chapter 4 included variants across the allele frequency 
spectrum, and illustrated, in conjunction with the rare variant analyses, that defining 
pathogenicity of a variant must be done both at the level of annotation in the genome, as 
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well as in the context of specific and relevant tissues and cell-types. This is an important 
and significant conclusion from this dissertation. 
More generally, because hypertension is the major risk factor for all 
cardiovascular disease,1 discovering the genetic causes of BP regulation by extension 
informs us about cardiovascular disease genetics as a whole. The importance of the large 
arteries as highlighted in Chapter 4, particularly of specific arterial cell types, needs to be 
further studied to elucidate specific mechanisms of the genes of interest to hypertension, 
and in general, cardiovascular diseases. 
Progress in our understanding of the involvement of kidney in hypertension to an 
even greater extent is essential. While kidney BP control systems, including the renin-
angiotensin-aldosterone-system (RAAS) have been established, recent evidence for “non-
classical” RAAS pathways has suggested novel players in the BP control processes and 
in kidney function.173 Furthermore, hypertension is associated with chronic kidney 
disease,1 and although the condition is referred to as “hypertension-attributed” chronic 
kidney disease or nephropathy, whether hypertension is primary or secondary to 
associated kidney disease has been often debated.174,175 Additional study to answer this 
question may also reveal additional pathways influencing BP control. 
 When the clinical utilities of gene discovery are of interest, they normally involve 
identifying novel drug targets or therapies. While numerous anti-hypertensive therapies 
have been developed2, nearly half of affected individuals remain insufficiently treated3 
and one possible reason may be the current incomplete understanding of BP genetics and 
pathways. Thus, elucidating the pathways and mechanisms in the appropriate tissues or 
organs allows the possibility of identifying an even larger range of specific therapies.   
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 A number of other scientific advances will need to be made in order to further our 
understanding of BP genetics. In addition to our findings described in Chapter 4,33 other 
recent findings analyzing BP GWAS results also implicate the endothelial/vasculature in 
BP regulation.22,36 The availability of open chromatin and expression data across a 
variety of tissues and cell types have made analyses like this possible; however, the 
paucity of kidney data has rendered such studies for BP incomplete, and its availability 
would improve assessments of contributions of different tissues to BP regulation. 
Additionally, the availability of genotypes, expression, and phenotypes for the same 
samples will allow the integration and evaluation of these variables and lead to more 
robust inferences than possible with data from different studies, as was done in Chapter 4 
with the GERA and GTEx studies. Finally, the increasing sample sizes of BP GWAS are 
expected to continue to identify even more novel loci associated with BP,176 and the 
expansion in sample sizes would allow increased power to identify variants across the 
allele frequency spectrum. 
In this dissertation, we identified rare, putatively functional protein-coding 
variants, which has suggested specific novel genes of interest; by incorporating tissue-
specific information, we not only identified additional genes, but also information about 
the relevance of their expression to BP regulation, and in some cases, the specificity of 
their expression in relation to BP regulation. Given the primary results of the studies 
detailed in this dissertation, expanding our studies in Chapter 4 to other tissues and cell 
types would be of great interest and importance. In addition to the adrenal gland, as well 
as specific arterial cell types, studying open chromatin and expression data from a variety 
of tissues and cell types would also be informative in discerning the specificity of the 
	
	 158	
phenotype. As more functional genomic data become available, analyses will evolve to 
incorporate functional information directly into gene discovery with information about 
functional context, and will facilitate the construction of tissue- or even cell-type-specific 
regulatory networks. Further, evidence may more easily be combined from analyses of 
coding variants and regulatory variants to identify specific disease genes. This is 
necessary to narrow down the inevitably large lists of candidate genes and variants we 
currently generate, for feasibility of functional testing.   
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Appendix A: MD-GEM Wolfe Street Competition Publication 
 
The publication resulting from a collaborative project funded by the Wolfe Street 
Competition (http://www.hopkinsgenetics.org/wsc/2014/) in 2014 follows. This version 
is the main text from the accepted preprint (PLOS ONE, open access publication).  
 
The citation for the full article is: 
Nandakumar P*, Tin A*, Grove ML, Ma J, Boerwinkle E, Coresh J, et al. (2017) 
MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney 
disease with hypertension. PLoS ONE 12(8): e0176734. 
https://doi.org/10.1371/journal.pone.0176734 
 
*denotes equal contributions 
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Background. In older adults (aged 70-74 years), African-Americans have 4-fold higher 
risk of developing hypertension-attributed end-stage renal disease (ESRD) than 
European-Americans. A hypothesized mechanism linking hypertension and progressive 
chronic kidney disease (CKD) is the innate immune response and inflammation. Persons 
with CKD are also more susceptible to infection. Gene expression in peripheral blood can 
provide a view of the innate immune activation profile. We aimed to identify 
differentially expressed genes, microRNAs, and pathways in peripheral blood between 
cases with CKD and high blood pressure under hypertension treatment versus controls 
without CKD and with controlled blood pressure in African Americans. 
 
Methods. Case and control pairs (N=15x2) were selected from those without diabetes 
and were matched for age, sex, body mass index, APOL1 risk allele count, and 
hypertension medication use. High blood pressure under hypertension treatment was 
defined as hypertension medication use and systolic blood pressure (SBP) ≥ 145 mmHg. 
CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2. 
Cases were selected from those with CKD and high blood pressure under hypertension 
treatment, and controls were selected from those without CKD (eGFR: 75-120 
mL/min/1.73m2 and urine albumin-to-creatinine ratio < 30mg/g) and with blood pressure 
controlled by hypertension medication use (SBP < 135 mmHg and D(diastolic)BP < 90 
mm Hg). We perform RNA sequencing of mRNA and microRNA and conducted 
differential expression and co-expression network analysis. 
 
Results. Of 347 miRNAs included in the analysis, 14 were significantly associated with 
case status (Benjamini-Hochberg adjusted p-value [BH p] < 0.05). Of these, ten were 
downregulated in cases: three of each belong to the miR-17 and miR-15 families. In co-
expression network analysis of miRNA, one module, which included 13 of the 14 
significant miRNAs, had significant association with case status. Of the 14,488 genes and 
41,739 transcripts included in the analysis, none had significant association with case 
status. Gene co-expression network analyses did not yield any significant associations for 
mRNA.   
 
Conclusion. We have identified 14 differentially expressed miRNAs in the peripheral 
blood of CKD cases with high blood pressure under hypertension treatment as compared 
to appropriate controls. Most of the significant miRNAs were downregulated and have 
critical roles in immune cell functions. Future studies are needed to replicate our findings 
and determine whether the downregulation of these miRNAs in immune cells may 








About one-third of end-stage renal disease (ESRD) in the U.S. has been attributed 
to hypertension [1,2]. In older adults, African-Americans have 4-fold higher risk of 
developing hypertension-attributed ESRD than European-Americans, and the incidence 
of hypertension-attributed ESRD increases with age [3]. A hypothesized mechanism 
linking hypertension and kidney function decline is the innate immune response and 
inflammation [4]. Inflammation biomarkers in blood have been associated with kidney 
function decline and incident hypertension [5-8]. Additionally, older adults with chronic 
kidney disease (CKD) have increased risk of infection-related hospitalization or 
bloodstream infection [9,10]. Although immune dysfunction in persons with ESRD due 
to metabolic disorder and retention of uremic solute is well established [11,12], the 
mechanisms underlying the links between immune function, hypertension, and kidney 
function in earlier stages of CKD is not well understood.  Gene expression analysis in 
peripheral blood can provide a view of the innate immune activation profile and may lead 
to insights into the pathophysiology of hypertension and CKD, and their complications.  
 Studies using immune cells have identified specific gene expression profiles of 
CKD patients versus hemodialyzed patients, and of patients with essential hypertension 
versus controls [13,14]. Recently microRNAs (miRNA) have been shown to have a 
potential role in influencing blood pressure and kidney function through modulating the 
immune response [15-17]. miRNAs are small noncoding RNAs (~22 nucleotides in 
length) with important post-transcriptional regulatory functions and are an attractive 
target of investigations.  
Given that African Americans have a strong predisposition for hypertension-
attributed kidney disease, we decided to study hypertension and kidney disease jointly in 
older African Americans. We aimed to identify differentially expressed genes and 
miRNAs in the peripheral blood to gain insights into the immune profile of hypertension 
and kidney disease. We used a matched case-control design (n=15x2) in the African 
Americans cohort of the Atherosclerosis Risk in Communities (ARIC) study [18]. We 
conducted RNA sequencing to quantify expression levels and performed differential 
expression and co-expression network analyses to identify gene expression profiles in the 





Written informed consent was obtained from all ARIC study participants, and 
approval was granted from the relevant institutional review boards (IRB) for the 
participating study centers (University of North Carolina, University of Minnesota, 
University of Mississippi Medical Center, and Johns Hopkins University). JHSPH IRB 
No. H.34.99.07.02.A1, study title “Atherosclerosis Risk in Communities (ARIC) Study - 
Morbidity/Mortality Follow-up Field Center.” This research was conducted in accordance 





 The ARIC Study is an ongoing prospective cohort study in four US communities 
[18]. A total of 15,792 participants aged 45–64 years were recruited from Forsyth 
County, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and 
Washington County, Maryland between 1987 and 1989 (Visit 1). Four follow-up 
examinations (visits 2–5) have been conducted. Blood samples preserved for RNA 
analysis using PAXgene blood tubes were available from visit 5 (2011-13).  
 Case and control pairs (N=15 pairs) were selected from those individuals without 
diabetes but on hypertension treatment and they were matched by age, sex, body mass 
index, APOL1 renal risk allele count, and hypertension medications (ACE inhibitor, 
angiotensin receptor blocker, and calcium channel blocker) to reduce heterogeneity. The 
use of hypertension medication was included in the selection criteria because a high 
proportion (>60%) of older African Americans were on hypertension treatment [19], and 
some hypertension medications have been reported to influence gene expression in 
peripheral blood [20]. In the ARIC study, hypertension medication use was determined 
by inspection of medication bottles at study visit. High blood pressure under hypertension 
treatment was defined as systolic blood pressure (SBP) ≥ 145 mmHg with hypertension 
medication use. CKD was defined as estimated glomerular filtration rate (eGFR) < 60 
mL/min/1.73m2. Cases were selected from those with CKD and high blood pressure 
under hypertension treatment. Controls were selected from those with blood pressure 
controlled by hypertensive medications (SBP < 135 mmHg and D(diastolic)BP < 90 mm 
Hg) and without CKD (eGFR: 75-120 mL/min/1.73m2 and urine albumin-to-creatinine 
ratio [UACR] < 30mg/g). The APOL1 renal risk variants are strongly associated with 
CKD progression [21], thus matching by APOL1 risk variants provided the opportunity to 
identify differential expressed genes that were independent of APOL1. The characteristics 
of the cases and controls were compared using the t-test, Kruskal-Wallis, or Fisher’s 
exact test, as appropriate.  
mRNA and miRNA library preparation, sequencing, processing, alignment, and 
quantitation methods are described in S1 Text. 
 
Surrogate variable generation 
Surrogate variables (SVs) representing unknown confounders were estimated 
using the svaseq function from the R package sva [22], with the null model absent of 
variables, and case-status as the variable of interest in the full model. SVs were included 
as covariates in models in all subsequent expression analyses as expanded upon in the 
Differential Expression Analyses Methods sections. 
 
mRNA differential expression analyses 
The mRNA analyses were conducted on genes and transcripts from a list of 
20,377 genes tagged as “protein-coding” in the GENCODE V19 annotation files. Results 
were adjusted within each analysis using the Benjamini-Hochberg [23] procedure for 
multiple testing. 
 The R package DESeq2 [24] was used to conduct gene-level analyses, with the 
null hypothesis of a zero log2-fold change. As DESeq2 incorporates normalization and 
default outlier replacement procedures, SVs were generated on DESeq2 outlier-replaced, 
normalized counts and included as covariates for these analyses. Gene-level analyses 
were carried out on14,488 genes with a normalized count ≥1 in at least 14 out of 29 
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samples (~50% as one sample failed library preparation, see Results), with a target FDR 
of alpha=0.05 used for independent filtering. SVs were generated using 10,524 genes 
with a minimum normalized count of 10 in all 29 samples.  
 Gene-level kidney-focused analyses were also conducted, in which 397 kidney-
expressed proteins from the Human Protein Atlas [25] (v14) 
(http://www.proteinatlas.org/humanproteome/kidney) were examined. Of these, 392 were 
available in our data; four were not available in the ENSEMBL GRCh37 assembly, and 
one was not in our final GTF of protein-coding genes. Genes meeting the normalized 
count threshold defined as above for expression were subset to produce the final kidney-
specific results. 
The Ballgown [26] R package was used to analyze 41,739 transcripts with 
fragments per kilobase of transcript per million mapped reads (FPKM) ≥ 0.3 in at least 14 
samples, and SVs were generated on transcripts with FPKM ≥ 0.5 in at least 26 samples 
(90%) (17,085 transcripts). 
 
miRNA differential expression analyses 
The miRNA analyses were conducted on mature miRNAs from miRBase [27] 
v20 and novel miRNAs, detected as described in S1 Text. Similar to the mRNA analyses, 
the R package DESeq2 was used for miRNA analyses with the null hypothesis of a zero 
log2-fold change, and SVs were generated on the outlier-replaced normalized counts and 
included as covariates in the model. These analyses were carried out on 347 miRNAs 
with a normalized count ≥ 1 in at least 15 out of 30 samples (50%) with target FDR of 
alpha=0.05 used for independent filtering, and SVs were generated using 270 miRNAs 
with a minimum normalized count of 3 in at least 27 samples (90%). Counts were 
summed across all precursors for each mature miRNA. Results were adjusted using the 
Benjamini-Hochberg procedure for multiple testing. We performed hierarchical 
clustering of the normalized counts of the miRNAs with nominal p-value < 0.01 to 
visualize the expression levels of these miRNAs between cases and controls.   
 
Co-expression network analysis 
 We used the Weighted Gene Co-Expression Network Analysis (WGCNA) R 
package to construct correlated signed network and tested for associations between the 
eigengene (the first principal component) of each module and case status [28]. The genes, 
transcripts, and miRNAs used for co-expression network analysis and the generation of 
surrogate variables was the same as those for differential expression analyses. The gene 
and miRNA counts were first normalized by the size factor with outlier replacement 
using DESeq2 [24]. The transcript counts were normalized to FPKM using Ballgown 
[26]. Next, the gene, transcript, or miRNA expression levels were transformed using 
natural logs after adding 1. Residuals of the log transformed expression levels were 
generated with adjustment for surrogate variables. These residuals were used as input for 
co-expression analysis. In network construction, we used bi-weight mid-correlation as a 
measure of co-expression to minimize the influence from outliers. For soft thresholding 
power, we used the first power with adjusted R square for linear fit > 0.8. The minimum 
module size was set as 25, 30, and 8 for genes, transcripts, and miRNA, respectively. The 
significant threshold for module association was defined as 0.05 divided by the number 




miRNA target prediction and gene ontology analyses 
The procedure for miRNA target prediction and gene ontology analyses of 
differentially expressed miRNAs is similar to the procedure described by the authors of 
the empiricalGO [29] software in Bleazard et al. 2015. Briefly, miRanda [30] v3.3a was 
used for miRNA target prediction with parameters free energy < −20 kcal/mol and score 
> 155 [29]. The 3’UTR sequences for target prediction were obtained from GRCh37 
ENSEMBL BioMart [31]. Subsequently, gene ontology (GO) annotations were obtained 
from GRCh37 ENSEMBL BioMart, and the empiricalGO python script was used in 
“basic” mode to produce a list of GO terms with a one-tailed permutated p-value for each 
term. The final results were subset to include only terms with a minimum size of 10, and 
the Benjamini-Hochberg multiple testing correction was applied to adjust for the number 




Study population characteristics 
 The mean age of the cases and controls was 77 years, and 67% were female. No 
significant differences were detected between cases and controls for all of the matching 
characteristics (Table 1). The cases had significantly lower eGFR (mean of 46 
min/mL/1.73m2 vs 88 min/mL/1.73m2, p < 0.0001) and higher SBP (mean of 156 mm Hg 
vs. 115 mm Hg, p < 0.0001). UACR was higher in cases (median of 13.7mg/g vs 
7.8mg/g), but the difference was not significant (p=0.13). On hypertension medications, 
none of the participants were on both angiotensin-converting-enzyme (ACE) inhibitor 
and angiotensin receptor blocker while two participants were on ACE inhibitor and beta 
blocker, and four participants were on ACE inhibitor and calcium channel blocker. These 
participants were split evenly between the case and control groups. Since gene expression 
levels were measured in whole blood, we also compared cases and controls for white 
blood cell count and percentage of lymphocyte, monocyte, and granulocyte, and did not 
observe significant differences. 
 
Table 1. Study population characteristics 
Variable Case Control p 
Selection variables    
eGFR, mL/min/m2, mean (SD) 46 (12) 88 (10) N/A 
SBP, mm Hg, mean (SD) 156 (12) 115 (33) N/A 
Matching variables    
Age, year, mean (SD) 77 (4.5) 77 (5.4) 0.97 
Female, % (n) 67 (10) 67 (10) 1.00 
BMI,  kg/m2, mean (SD) 28 (3.5) 30 (3.3) 0.09 
APOL1 high-risk, % (n) 33 (5) 33 (5) 1.00 
Hypertension medications    
    ACE inhibitor, % (n) 53.3 (8) 60 (9) 1.00 
    Angiotensin receptor blocker, % 
(n) 27 (4) 27 (4) 1.00 
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Beta blocker, % (n) 33.3 (5) 33.3 (5) 1.00 
    Calcium channel blocker, % (n) 47 (7) 60 (9) 0.71 
Blood cell type variables    
White blood cell count, 1000 per 
mm3, median (1st, 3rd quartile) 5.4 (4.1, 6.2) 4.8 (4.4, 5.9) 0.80 
Lymphocyte, %, median (1st, 3rd 
quartile) 
33.6 (29.1, 
39.0) 30.4 (27.8, 40) 0.72 












Other variables    
DBP, mm Hg, mean (SD) 76 (12) 70 (19) 0.31 
Albuminuria, median (1st, 3rd 
quartile) 13.7 (5.9, 66.7) 7.8 (5.7, 13.3) 0.13 
High sensitive C-reactive Protein,  1.4 (1.01, 6.87) 5.3 (2.5, 6.3) 0.31 
Serum creatinine, mg/dL 1.6 (0.9) 0.8 (0.1) 0.003 
Diuretic use, % (n) 73.3 (11) 64.3 (9) 0.70 
p, p-value, N/A, not applicable 
 
Sequencing and processing of mRNAs and miRNAs 
Sequencing of mRNA was successful for 29 out of 30 samples; one sample (case) 
failed library preparation. All 30 samples were successfully sequenced for miRNA. 
Quality control (QC) and mapping statistics for the 29 samples with mRNA data (depth: 
18.7M-45.1M paired-end reads) and the 30 samples with miRNA data (depth: 6.2M-
11.5M single-end reads) are listed in S1 and S2 Tables, respectively. As S1 Table 
indicates, External RNA Controls Consortium (ERCC) transcripts were poorly detected 
in one sample, but this individual was retained for analysis because the distribution of 
counts in other genomic features aligned with those of the other samples, indicating a 
possible issue with the ERCC spike-in itself. 
 
Differential expression analysis of genes, transcripts, and miRNAs 
The gene-level differential expression analysis of 14,448 protein-coding genes 
considered “expressed” (normalized count ≥ 1 in ≥50% of samples) produced no 
significant genome-wide results after Benjamini-Hochberg (BH) multiple testing 
correction (S3 Table). The relevance of the kidney to both hypertension and CKD led us 
to examine a set of 154 genes meeting our expression threshold and expressed in the 
kidney, based on data available from the Human Protein Atlas [25], which contains 
protein expression data from four kidney samples, with proteins in the glomeruli, 
proximal tubules, distal tubules and the collecting ducts. In this subset of genes, none 
were significant after BH correction. The gene with the lowest p-value was SMIM24 
(unadjusted p=5.67x10-4, BH p=0.087). 
Transcript-level analyses were conducted on 41,739 transcripts with FPKM ≥ 0.3 
in ≥ 50% of samples. After BH correction, there were no differentially expressed 
transcripts identified; results with p < 10-3 are presented in S4 Table. 
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We tested 347 miRNAs, including 12 novel miRNAs, for differential expression. 
We detected 14 significant miRNAs. Four were upregulated, and 10 were downregulated 
in the cases as compared to the controls (Table 2). The most significant miRNA was 
miR-17-5p (log2 fold change=-0.77, BH p=6.7E-4). Two other miRNAs in the miR-17 
family (miR-106a-5p, miR-106b-3p) were also significantly downregulated. The miR-15 
family has three members that were significantly downregulated in the cases (miR-15a-
5p, miR-15b-5p, and miR-16-5p). Twenty members of the miR-17 and miR-15 families 
were found in our data and all, but two, were downregulated in cases, although the 
associations of some were not significant (S5 Table). S1 Fig presents a heat map of the 
normalized count of the 32 miRNAs with nominal p-value < 0.01. 
 







Change SE p BH p 
hsa-miR-17-5p 71.97 -0.77 0.16 1.94x10-6 6.76x10-4 
hsa-miR-130a-3p 492.19 -0.60 0.15 4.31x10-5 7.47x10-3 
hsa-miR-15b-5p 215.32 -0.72 0.19 1.24x10-4 1.17x10-2 
hsa-miR-106b-3p 1425.98 -0.65 0.17 1.35x10-4 1.17x10-2 
hsa-miR-106a-5p 5.46 -1.03 0.28 2.12x10-4 1.34x10-2 
hsa-miR-16-5p 6983.54 -0.64 0.17 2.33x10-4 1.34x10-2 
hsa-miR-181a-5p 15301.70 -0.59 0.16 2.80x10-4 1.39x10-2 
hsa-miR-1285-3p 561.01 -0.44 0.13 4.92x10-4 2.14x10-2 
hsa-miR-15a-5p 430.52 -0.76 0.23 8.36x10-4 3.18x10-2 
hsa-miR-29c-5p 73.85 0.55 0.17 9.18x10-4 3.18x10-2 
hsa-miR-345-5p 715.07 0.60 0.18 1.04x10-3 3.27x10-2 
hsa-miR-142-3p 89.46 0.65 0.20 1.23x10-3 3.52x10-2 
hsa-miR-339-3p 507.26 0.36 0.11 1.32x10-3 3.52x10-2 
hsa-miR-210-3p 440.49 -0.39 0.12 1.50x10-3 3.72x10-2 
SE, standard error; p, p-value; BH p, Benjamini-Hochberg adjusted 
p-value 
 
Experimentally validated targets in humans were available for 11 of the 14 
significant miRNAs in miRTarBase [32] 6.0 (S6 Table). The number of validated target 
genes for each significant miRNA ranged from 4 (miR-1285-3p) to 134 (miR-17-5p), 
with a median of 56. Altogether 272 unique genes have experimental evidence of being 
regulated by the 11 significant miRNAs. Of these, 239 were detected in our data, and 8 
were associated with case status at p < 0.05 (S7 Table).   
 
Co-expression network analysis of genes and transcripts 
 To investigate whether patterns in gene co-expression may be related to case-
status, we conducted gene co-expression analysis. Of the 14,488 genes included in the 
analysis, 178 were assigned into four co-expression modules (S8 Table). The rest were 
pruned by WGCNA due to low correlation (< 0.3) with the eigengene in each module. 
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The association between the eigengene of the brown module (consisting of 35 genes) and 
case status was nominally significant (p=0.03, S9 Table). Of the 41,739 transcripts 
included in the analysis, no correlated modules were detected.  
 
Co-expression network analysis of miRNAs 
Of the 347 miRNA included in co-expression analysis, 182 were assigned into 
five co-expression modules with correlated miRNAs (S10 Table). The rest (n=165) were 
pruned due to low correlation with the eigengene in each module. The eigengene of the 
turquoise module (108 miRNAs) was significantly associated with case status (p=0.005, 
Table 3). The eigengene of the blue module (29 miRNAs) was nominally associated with 
case status (p=0.03). For both modules, case status was associated with lower eigengene 
values suggesting an association with lower miRNA expression in these modules. The 
turquoise module included 13 of the 14 miRNAs that were significantly downregulated in 
the cases (Table 2). 
 
Table 3. Association between the eigengene of each miRNA co-expression module 
and case status 
Module Betab SE pa Number of miRNAs 
Turquoisec -0.97 0.32 5.38x10-3 108 
Blue -0.80 0.34 2.63x10-2 29 
Green -0.06 0.37 8.63x10-1 11 
Brown 0.03 0.37 9.32x10-1 23 
Yellow -0.01 0.37 9.84x10-1 11 
SE, standard error; p, p-value;  
b Beta values are in log expression level 
units.   
c 13 out of 14 differentially expressed miRNAs (excluding hsa-miR-339-3p), belong 
to the turquoise module. 
 
Gene ontology analysis of significant miRNAs 
We then proceeded to predict target genes of the significant miRNAs using 
miRanda. The predicted targets were analyzed for enrichment of gene ontology 
annotations using empiricalGO with all predicted targets of the 347 expressed miRNAs 
as the “universe.” empiricalGO counted 5,576 targets for the 14 differentially expressed 
miRNAs from the target genes, of which 4,431 had associated GO terms. No GO terms 
with minimum size of 10 genes in our data were significant after Benjamini-Hochberg 
multiple test correction, while 25 terms had a one-tailed permutated p < 0.05 (S11 Table). 





We have identified 14 miRNAs that were significantly associated with CKD and 
high blood pressure under hypertension treatment. Ten of these miRNAs were 
downregulated in the cases, and 13 were grouped in one module in co-expression 
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network analysis. Three of the 14 miRNAs belong to the miR-17 family, and three belong 
to the miR-15 family.   
The miRNAs that were significantly associated with case status have critical roles 
in immune cell function. First, miR-17-5p, the most significantly downregulated miRNA, 
belongs to a cluster of miRNAs located in intron 3 of C13orf25 at chromosome 13 [33]. 
This cluster of miRNAs (miR-17/92) has a wide range of functions in immune cell 
development and differentiation [33]. Specifically, the miR-17 cluster has been found to 
promote T cell survival, regulate Th1 response, and interleukin 10 (IL10) production in 
regulatory T cells [34,35]. Members of two other clusters (miR-106a/363 and miR-
106b/25) of the miR-17 family were also significantly downregulated in cases. miR-106a 
on the X chromosome has been shown to downregulate IL10 expression [36], and all 
three miR-17 family members differentially expressed in our study (106a, 106b, 17-5p) 
are known to be upregulated in activated T lymphocytes [37]. Second, three members of 
the miR-15 family (miR-15a-5p, miR-15b-5p, miR-16-5p) were also significantly 
downregulated in cases. Expression of miR-15 has been found to enhance the induction 
of regulatory T cells from naïve CD4+ T cells [38]. Additionally, miR-210 suppresses 
proinflammatory cytokines in murine macrophages [39]. Finally, in considering 
experimentally verified targets of the differentially expressed miRNAs in this study, the 
BCL2, CCND1, and VEGFA genes are each targeted by five miRNAs from at least two 
miRNA families. These genes are known factors in apoptosis and cell survival, having 
previously been studied in the context of cancer pathways [40,41]. Taken together, the 
downregulation of the above miRNAs in cases suggests a lower immune activation state. 
Whether this lower activation state has implications for CKD progression or 
complications requires further investigation. 
Population-based studies have reported increased risk of infection among persons 
with early stages of CKD. In older adults (age ≥ 65 years), reduced kidney function 
(eGFR < 60 mL/min/1.73m2) is associated with increased risk of infection-related 
hospitalization or bloodstream infection [9,10]. In persons with ESRD, immune 
dysfunction due to metabolic disorder and retention of uremic solute is well established 
[11,12]. The decline in kidney function occurs in a continuum. Thus, immune 
dysfunction may play a role in earlier stages of CKD. The increased risk of infection in 
persons with earlier stages of CKD is consistent with our findings of the downregulation 
of some miRNAs that are critical for immune cell function.  
On kidney disease, the plasma levels of miR-15b were found to be 2-fold lower in 
hemodialysis patients versus non-CKD controls [42]. This result is consistent with our 
study. The associations between levels of miR-15b and miR-17 in kidney tissues and 
acute kidney injury in human and in animal models have been reported [43]. Since gene 
expression levels are highly tissue specific, it is uncertain whether studies of gene 
expression in one tissue may be generalizable to a different tissue [44-48]. 
 
Strengths and limitations 
One of the strengths of this study is its design. The cases and controls were 
carefully selected and matched for important potential confounders of gene expression, 
including hypertension medication use. In addition, we performed deep sequencing of the 
miRNA pool that allowed the discovery of novel miRNAs. However, our study has some 
limitations as well. First, the differentially expressed miRNAs need to be replicated in an 
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independent study and validated by alternate laboratory methods, such as real-time 
polymerase chain reaction. Second, gene expression levels were measured in whole blood 
and not in specific types of immune cells. Thus, although cases and controls did not differ 
in major white blood cell types, and we used surrogate variables to control for 
unmeasured confounders, we cannot exclude the possibility that the differentially 
expressed miRNAs arise from differences in the distributions of white blood cell 
subpopulations. Third, our study is a cross-sectional study. We cannot distinguish 
whether the differential expression of miRNAs might have influenced disease 
development or was a consequence of the disease condition. Fourth, in contrast to 
miRNA co-expression network analysis, mRNA co-expression network analysis did not 
detect any significant modules although one module was nominally significant. This 
suggests larger sample size may be required for mRNA differential expression analysis. 
Finally, our cases and controls were under hypertension treatment, therefore our results 
cannot be generalized to persons without hypertension. Since the majority (>60%) of 
older adults in the U.S. are hypertensive [19], our results are, however, relevant to a large 
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